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The aetiological factors in drug abuse have been reviewed. The situation relating to drug 
abuse in Hong Kong and Uganda, certain aspects of opioid pharmacology, and the principles 
of pharmacokinetics have also been reviewed. 
The present study attempted to elucidate whether or not ephedrine and phenylpropanolamine 
—both of which are common ingredients of cough and cold remedies, often in combination 
with opioids — affect the activities of morphine and codeine. This arose from observations 
of an increasing tendency towards abuse of cough and cold mixtures containing 
sympathomimetics and opioids. A mouse model was used. 
It was found that ephedrine and phenylpropanolamine had no antinociceptive effects on their 
own in the doses employed in this study, but potentiated the antinociceptive activities of both 
morphine and codeine in an apparently dose-dependent manner. 
The development of opioid physical dependence was apparently unaffected by pretreatment 
with either sympathomimetic during the induction phase. Given in the expression phase, the 
sympathomimetics significantly attenuated the withdrawal syndrome. The development of 
opioid tolerance, on the other hand, was apparently enhanced when ephedrine or 
phenylpropanolamine were administered during the induction phase; while these agents had 
no effect on opioid tolerance when given in the expression phase. 
The potentiating effects of ephedrine and phenylpropanolamine on the antinociceptive 
activities of morphine and codeine were suppressed by phentolamine but not by propranolol. 
Similarly, yohimbine, but not prazocin, abolished this potentiation. This indicated 
adrenoceptor activation as the likely explanation for the observations, which was corroborated 
using low doses of clonidine. 
The toxicity of morphine and codeine was potentiated by the sympathomimetics. During the 
chronic interactions (induction of opioid tolerance/dependence) high mortality rates were 
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noted in the sympathomimetic pretreated groups, whereas there was none observed in the 
opioids only groups. The acute lethality of morphine and codeine was similarly enhanced by 
either sympathomimetic. 
The possible modification of the pharmacokinetics of morphine and codeine in the presence 
of either sympathomimetic was also investigated. Assay of the opioids in plasma, brain and 
urine samples involved a modification of established high-performance liquid chromatography 
(HPLC) methodology. In single dose interactions it was found that neither ephedrine nor 
phenylpropanolamine significantly affected the concentration-time profiles of the opioids in 
plasma and brain. The 24 h urinary excretion of morphine, codeine and their metabolites 
were comparable in the controls and those pretreated with the sympathomimetics. 
Pharmacokinetic studies in animals that had received two days pretreatment with opioid alone 
or opioid-sympathomimetic combination similarly showed no effects attributable to ephedrine 
or phenylpropanolamine. 
It is concluded that ephedrine and phenylpropanolamine modify the activities of morphine and 
codeine in mice, through activation of aj-adrenoceptors. The effects of these 
sympathomimetics on the opioids seem to be largely pharmacodynamic with the 
pharmacokinetic profiles of morphine and codeine not significantly affected in both acute and 
chronic interactions. Combinations of various sympathomimetic agents and opioids may, 
therefore, not be as innocuous as current regulatory measures indicate. The study has shown 
that there is a pharmacological basis for the higher abuse rate of (codeine-containing) cough 
mixtures vis-a-vis codeine alone. 
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Drug abuse refers to the use, usually by self-administration, of any drug for non-medical 
purposes or in a manner deviating from the approved social patterns in a given culture. 
It is an old practice traceable almost as far back as mankind itself and certainly to the 
dawn of civilization (Laurence and Bennet, 1980; Falk and Feingold, 1987; Hollister, 
1987; laffe, 1991). Drug abuse is a diverse and dynamic entity with continually changing 
patterns and trends in different societies (UNESCO, 1982 Mello and Griffith, 1987). 
Currently, there are many stringent laws and other measures to counter certain forms of 
drug abuse in various parts of the world, some of which like Singapore, Malaysia and 
Thailand have a death penalty for drug trafficking. Over the course of time,the means of 
drug detection have become more sophisticated, and the surveillance more vigilant; and 
the dangers of drug abuse are perhaps better understood now than ever before. 
Notwithstanding the foregoing, the drug abuse trends continue upwards and there is no 
doubt that it is now a world-wide problem. 
There are many factors that operate in favour of the escalating drug abuse trends. Broadly , 
speaking, these factors may be related to the pharmacological properties of the drug, 
inherent in the individual abuser, or to socio-economic aspects. Usually it is a combination 
of all the above (Victor and Adams, 1983). 
The scope of drug abuse includes: the experimental use of a drug or drugs on one or a 
few occasions, the casual or recreational use of modest amounts of a drug for its 
pleasurable effects, the circumstantial use of a drug (or drugs) whereby certain drug 
effects are sought because they are "helpful" in the given circumstances, and compulsive 
drug use which is the most intense form of drug abuse (Jaffe, 1991). The latter may be 
characterized by drug dependence and/or tolerance. 




interactions between a living organism and a drug. It is characterized by behavioural and 
other responses that always include a compulsion to take the drug on a continuous or 
periodic basis in order to experience its psychic effects and sometimes to avoid the 
discomfort of its absence. Tolerance may or may not be present (WHO, 1964). A person 
may be dependent on more than one drug, which usually makes clinical assessment and 
management complicated (Mello and Griffith, 1987; Kreek, 1987). The factors favouring 
drug abuse are reviewed below. 
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CHAPTER 1: FACTORS IN THE AETIOLOGY OF DRUG ABUSE 
1.1. PHARMACOLOGICAL FACTORS 
There are certain pharmacological properties that determine the abuse potential of a drug. 
1.1.1. Mind-altering effects 
Many drugs of abuse have mind-altering effects, particularly euphoria, tranquillisation, 
or the abolition of unpleasant feelings like pain. The opioids, for example, produce a 
distinct syndrome of alteration in mood, thought and perception, characterized by 
relaxation, "coasting" and a sense of well-being or euphoria. This is usually described as 
pleasant by experienced users (Martin and Fraser, 1961; Haertzen, 1974; Victor and 
Adams; 1983). On the other hand, cocaine, a substance of increasing abuse importance, 
produces euphoria, excitement, a feeling of diminished fatigue and a sensation of 
increased muscular strength (Johanson and Fischman, 1989). Alcohol may produce a 
tranquillising effect, albeit a short-lived one. The nature of these subjective effects appears 
to be a principal factor in the high abuse potential of the various agents (Fraser, 1968; 
Jasinski, 1973; 1977). 
1.1.2. Satisfying ability. 
The satisfying ability of a drug is related to how well the desired effect is achieved after 
taking the drug. In part, this is governed by the onset and duration of action of the drug _ 
the faster the onset and the shorter the duration of action the greater the liability to abuse 
(Jaffe, 1991). The route of administration is also important, to the extent that it determines 
the onset of action and the efficiency of delivery of the drug (Edwards, 1982b). Routes 
favouring a fast onset and short duration of action are generally more popular among drug 
abusers, with inhalation more popular than intravenous, subcutaneous and oral routes, in 
that order (Jaffe, 1977). The route of administration may have a symbolic significance, 




Asia, and this tends to popularize such a practice (Navaratnam, 1985). 
1.1.3. Reinforcing ability 
The repeated non-medical use of drugs is a behaviour maintained by its consequences 
(Mello, 1987). Positive reinforcement (reward) strengthens the behaviour, whereas 
negative reinforcement is deterrent. Pleasure or euphoria and relief from pain or stress are 
examples of positive consequences, while pain, agitation or anxiety as consequences of . 
drug use are aversive. Reinforcement is recognizably one of the most important factors 
in the genesis and perpetuation of a drug-dependent state (Victor and Adams, 1983; Jaffe, 
1991). The reinforcing ability of a drug may be conditioned to the environment or 
circumstances of use (Falk and Feingold, 1987). By virtue of their aversive properties, 
some drugs, like chlorpromazine, are never self-administered (Jaffe, 1991). 
1.1.4 Availability 
Drug availability, per se, is an important factor in the pattern of drug abuse. In the 
laboratory setting, animals given free access to drugs develop a self-administration pattern 
similar to that observed in human users (Johanson and Schuster, 1981; Woods and 
Winger, 1987). The increased availability of opioids in the USA in the 1960s led to an 
increase in the number of opioid users; opium use is endemic in the opium producing 
areas of the "Golden Triangle" the area where the borders of Burma (Myanmar), Laos 
and Thailand meet - and the "Golden Crescent" - the intersection of the borders of Iran, 
Afghanistan and Pakistan. Meanwhile, cocaine use is es costumbre in the Andean region 
of South America where coca is grown (UNESCO, 1982). The relocation of heroin 
manufacturing laboratories to the South East Asia opium producing areas has been 
paralleled by an upsurge in the number of heroin users (Navaratnam, 1985). The easy 
availability of alcohol is partly responsible for the rampant alcohol abuse in many parts 
of Africa (UNESCO, 1982; Daynes and Msengi, 1982). The availability of some drugs 




consumption of tobacco in combination with alcohol. 
1.1.5. Tolerance and dependence 
The adaptational processes that eventually produce a grossly observable withdrawal 
syndrome apparently begin with the first dose (Kosersky et al. 1974; Eisenberg, 1982; 
Heishman et al., 1989). A single dose of a drug taken to induce euphoria or reduce 
tension may be followed by a period of rebound dysphoria or increased tension 
respectively, thereby necessitating repeated self-administration. The pharmacogenically-
induced need increases the effectiveness of a drug as a positive reinforcer and makes the 
practice of self-administration self perpetuating. Some drugs of abuse produce very 
dramatic withdrawal symptomatology after repeated use. Opioid withdrawal in man, for 
instance, is characterized by distinctly unpleasant events including yawning, rhinorrhoea, 
sweating, lacrimation, restless followed by insomnia, recurring waves of goose flesh, 
severe backache, abdominal cramps, alternating cold and hot flushes, weakness, anxiety, 
I 
lack of motivation, high irritability, nausea and vomiting, mental depression and dysphoria 
(Haertzen and Hooks, 1969). Thus in the state of physical dependence on opioids the 
desire to prevent the emergence of such symptomatology becomes another important factor 
favouring the perpetuation of drug use (Haertzen and Hooks; 1969; O'Brien, 1975; Gellert 
and Holtzman, 1979). 
Psychic dependence, usually manifest as a craving for the drug(s), is now regarded as one 
of the most important qualities in drug abuse. The psychic effects govern the initial use, 
perpetuate the self-administration and drug-seeking behaviour, and are largely responsible 
for relapses following apparent cure (Victor and Adams, 1983). Drugs that produce 
dependence -psychic or physical - are more liable to be abused. 
Tolerance, which may be pharmacokinetic due to increased elimination or metabolism or 
pharmacodynamic, due to reduced sensitivity to the drug effects, may also play an 
5 
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important role in the pattern of drug abuse. By necessitating increasingly large amounts 
to achieve the initial "high", tolerance leads to the use of more of the drug(s), thereby 
sustaining the demand. The initial drug experience may involve unpleasant effects and the 
development of tolerance to such unwanted side effects favours repeated self-
administration (Jarvik, 1979; Henningfield etal., 1983). 
The concepts of tolerance and dependence will be discussed further below, in connection 
with opioid action. 
1.2. INDIVIDUAL FACTORS 
1.2.1. Age 
Whereas all ages are susceptible to drug abuse, adolescents and young adults tend to be 
more so. In Hong Kong, for instance, over 50% of female heroin users are under 31 years 
of age (CRDA, 1982; 1991b). The picture in other parts of the world indicates a similar 
over-representation of adolescents and young adults (UNESCO, 1982; Victor and Adams, 
1983). Some forms of drug abuse, like solvent/glue sniffing, are almost entirely confined 
to the young, being rarely found among the adults (Kato, 1983; Falk and Feingold, 1987). 
In areas around the Golden Triangle recreational opium smoking and alcohol consumption 
are restricted to adult males, age is therefore important in determining such exposure. 
Many drug dependent individuals reportedly start substance abuse in adolescence or early 
adulthood (Navaratnam, 1985; CRD A, 1989). The higher susceptibility of the adolescents 
vis-a-vis the older age groups partly reflects the fact that they tend to be impressionable 
and adventurous. 
1.2.2. Gender 
Overall, there are more male drug abusers than there are female ones. In Japan, there 
were over 500,000 known amphetamine abusers by 1954 and the male: female ratio was 





males (Kato, 1983; 1985). A review of the figures from the Hong Kong Central Registry 
of Drug Abuse for the periods between 1977 and 1982, inclusive, shows that on average 
the male: female ratio was 28: 1 (CRDA, 1982). This trend remains basically unaltered 
(CRDA, 1991b). The same obtains elsewhere; Victor and Adams (1983), for instance, 
described the usual opioid addicts in the USA as young men or delinquent youths. With 
the women's liberation efforts gaining more ground in the quest for equality, these 
differences will no doubt narrow down as the more "liberated", or rather dis-inhibited, 
women develop hedonistic inclinations. 
1.2.3. Genetic factors 
Hereditary factors have been implicated in drug abuse for some time now, especially so 
in alcohol abuse. Kaij (1960) reported that the concordance rate for alcoholism was higher 
in identical twins than in fraternal ones, being 55% and 28% respectively. The incidence 
of alcoholism is about five times higher in the biological offspring of alcoholic parents 
than in those of non-alcoholics, regardless of the latter being raised by alcoholic parents 
(Goodwin et al. 1973; Goodwin, 1976; 1979). The molecular basis of such phenomena 
remains the subject of intense research efforts. Recently, alcoholism has been associated 
with an aberrant form of the dopamine D2-receptor gene (Blum et al., 1990; Cowley, 
1990). However, subsequent findings by other workers have cast doubt on this hypothesis 
(Bolos et al., 1990). How much hereditary factors contribute to other forms of drug abuse 
is even more obscure. However, to the extent that the genetic makeup affects the general 
outlook and disposition of an individual, there could be a role. 
1.2.4. Personality traits 
The individual personality disposition has a crucial bearing in the context of drug abuse. 
Whereas psychopathology is not a pre-requisite for drug abuse, there is an over-
representation of some personality disorders among drug abusers (Victor and Adams, 
1983). Monroe et al. (1971) looked at 837 opioid dependent persons and found that only 
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1% were asymptomatic of any personality disorders, the rest had characterological 
disorders (42%), emotional disturbances (29%) and thinking disorders (22%). Depressive 
disorders, anxiety and antisocial personality are more preponderate among drug abusers 
compared to the general population (Victor and Adams, 1983). Often, such disorders like 
depression may be the original reason for drug indulgence, though in the long run drug 
abuse may lead to the personality changes. 
1.2. 5. Self-motivation 
A high degree of self-motivation will restrain one from the temptation to experiment with 
a drug, thus avoiding the development of more regular drug use, or help one out of the 
drug dependent state. Robins (1974) noted that many of the USA soldiers who became 
heroin dependent during the Vietnam war were able to stop through sheer determination 
and without any special treatment ("cold turkey"). In Thailand, opium addicts who are 
highly motivated by a vow to the Buddha successfully complete their detoxification 
programmes in the hands of the priests (UNESCO, 1982; Navaratnam, 1985). The success 
of the Alcoholics Anonymous groups worldwide is one evident sign of how much self 
motivation can achieve (Robinson, 1982). It is a common observation in treatment and 
rehabilitation programmes that those who are poorly motivated tend to relapse to the 
previous habit, or even drop out, sooner than their highly motivated counterparts. 
1.2.6. Disease states 
Physical illness, especially pain, may provide the initial reason for taking a drug. This, 
for example, is the predominant reason for opium use in Thailand (UNESCO, 1982; 
Navaratnam, 1985). It is well known that many drugs of abuse are taken in the often-
mistaken belief that they are aphrodisiacs (Victor and Adams, 1983; Tabemer, 1985; 
Jaffe, 1991). Sexual dysfunction drives many to alcohol which, as put by Shakespeare of 
old, "Provokes the desire but takes away the performance" (Shakespeare, circa 1606). In 






established whereby sexual dysfunction leads to drinking, which makes the sexual 
dysfunction even worse and so leading to more drinking. A proportion of opioid addicts, 
albeit a small one, are introduced to these drugs by physicians in the course of an illness 
(Victor and Adams, 1983). 
1.2.7. Psycho-social maladjustment 
Psycho-social maladjustment tends to amplify the effects of the other factors. This may 
be a lack of self confidence, an inferiority complex, or an endeavour to be perfect 
(Edwards, 1982a). A feeling of insecurity in the presence of parents and, later on seniors 
at school or place of work, may tip one towards the non-medical use of drugs. 
Occasionally the individual may be faced with an identity crisis, in the search for escape 
from which drug use appears a plausible option. In general, those who adapt or adjust 
poorly to new situations or challenges are more vulnerable to drug abuse relative to the 
well adapting ones. 
1.3. SOCIO-ECONOMIC FACTORS 
Drug abuse is social terminology. Society defines who is to have access to which drugs 
and in what setting that is acceptable. The boundaries between acceptable drug use and 
drug abuse are, therefore, determined by the particular community (Falk and Feingold, 
1987). The nature of a particular community influences the overall environment an 
individual lives in. Socio-economic factors, therefore, play an important role in the 
escalating drug problem; and the most commonly cited ones are highlighted below. 
1.3.1. Social significance 
Some drugs of abuse are accorded special significance in certain cultural setups and this 
may thus provide the initial exposure to a drug. In many parts of Asia, opium and 




many parts of Africa, on the other hand, alcohol is a sine quo non for many a ceremony 
and it would be inconceivable to have a function worthy of the name without alcohol 
(Okot, 1966). The indulgence in such drugs, unfortunately, is not just ceremonial. 
1.3.2. Entertainment 
Many drugs are used as a form of entertainment, or for amusement and excitement. It has 
been noted that children subjected to a deficient environment at home or school search for 
escape, stimulation or expanded meaning through the use of drugs (UNESCO, 1982). 
Relief from boredom is more often cited as a cause for drug use than the search for 
expanded meaning (Leong, 1978). Many drugs with abuse potential are routinely 
associated with entertainment, for instance alcohol; and it is usual for drinkers of alcohol 
and smokers of cigarettes to partake of more alcohol and cigarettes respectively in a party 
setting. 
1.3.3. Peer group influences, social values and norms 
The behavioural effects of drugs are determined partly by the environmental context 
within which they act and peer group influence is a very important determinant in the 
sustenance of drug abuse (Falk and Feingold, 1987). Association with drug users is 
usually one of the most crucial factors in the initiation of drug abuse (Victor and Adams, 
1983; Navaratnam, 1985; Jaffe, 1991). By determining the acceptability or otherwise of 
an individual, or by according special status and approval, the peer group acts as a 
secondary reinforcer maintaining the initial drug-taking behaviour before the onset of 
pharmacogenically induced dependence. For many urban youths who may be abandoned 
or homeless, drug use provides the only acceptance into the available company of peers. 
Negative attitudes and rejection of the drug users by the rest of society increases the 
difficulties of the former in obtaining realistic gratification or alternative reinforcers, 




"addict", "junkie", or "drunkard", one's place in society is almost certainly lost. In 
constantly reminding the drug users that they are below the accepted society values and 
norms, communities end up perpetuating the drug abuse practice. 
1.3.4. Social advancement and changing lifestyles 
With the advent of modernization, rural communities have become less remote from urban 
influences. Certain practices that were previously restricted to the urban areas are now 
encountered in rural areas too (Kato, 1983; 1985; Navaratnam, 1985). The increased and 
more efficient mobility enables drugs produced in one part of the world to reach other 
parts; the consumption in the USA and western Europe of opium products produced in the 
Golden Triangle and Golden Crescent may suffice to illustrate this point. 
Increased migrations from rural to urban areas, disintegrating cultural traditions and 
rebellion against traditional values and influences, have all contributed to the current drug 
dilemma. In Africa, for instance, the extended family previously sheltered the individual 
from the daily pressures by sharing in all problems. This state of affairs is now the 
exception as there is a more individualistic approach to life. Cultural barriers continue to 
break down, partly through intermarriages across ethnic and racial boundaries, one of the 
outcomes being the possible alienation of such couples from both ends; and their offspring 
suffer a greater identity crisis with no sense of belonging to either paternal or maternal 
origins. This kind of scenario has been strongly implicated in the explosive trend towards 
alcoholism among African urban and peri-urban populations (UNESCO, 1982). 
Modem society has become more achievement-oriented, thereby bringing a lot of pressure 
to bear on the individual. Expectations of high achievement and the pursuit thereof are 
important in pushing the stress levels beyond endurance, one of the results of which could 
be to seek relief from drugs. As more and more parents pay more and more attention to 




left without the benefit of parental care and guidance. The peers then play a more decisive 
role in the activities that the children indulge in. The incidence of broken families seems 
to run in parallel with the rate of social advancement, and members of such families tend 
to be more vulnerable to drugs. There has consequently emerged a "youth culture" that 
is freer, more rebellious, less dependent on their parents, more reliant on peer groups, 
less religious and more hedonistically inclined - which is a perfect setting for drug abuse 
(Navaratnam, 1985). 
Tourism, a byproduct of social advancement, exposes many to different cultural practices. 
Better, faster, more efficient means of travel and communication enable contacts between 
parties far from one another, ensuring worldwide supply of drugs, as already alluded to. 
1.3.5. Sports • 
The use of drugs to enhance sporting performance seems to be as old as competitive 
sports itself. Mushrooms were reportedly used in the ancient Olympics (Kennedy, 1989). 
As the rewards of sporting excellence have become more lucrative, so the practice of 
"doping" has exploded. Frankle et al. (1984) cited that about 50% of weight lifters they 
surveyed were users of anabolic steroids. This seems to have been borne out by the 
positive "doping" tests at the 1990 Commonwealth Games in Auckland, New Zealand, 
where the weight lifters were the most notorious group. To date, though, the most 
spectacular of all cases of drugs in sports remains that of the Canadian sprinter Ben 
Johnson at the 1988 Olympic Games in Seoul, South Korea. Shortly after being acclaimed 
the fastest man in the world, Johnson was stripped of his gold medal, world titles and had 
to leave Seoul in disgrace after a positive steroid test. 
1.3.6. Legislation and crime 
Many drugs of abuse have been outlawed to certain degrees in various parts of the world. 
While generally having a deterrent effect (Nahas, 1990), this may also have the effect of 
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stimulating curiosity to partake of the same. When a particular substance is inaccessible, 
as a result of the proscription, there follows a change in the pattern of drug abuse in the 
particular society. The outlawing of some drugs makes them harder to get, more costly, 
and therefore more lucrative to deal in, with the overall effect being, paradoxically, an 
escalation in the use of the same said drugs. The dealers ensure controlled supply, thereby 
maximizing the pecuniary benefits. It is for this reason that there are increasingly more 
suggestions for the legalization of drugs of abuse (Edwards, 1982a; Awake, 1988; Max, 
1989). 
Crime and drug abuse are interrelated. It has been estimated that about 90% of all opioid 
dependent persons in the USA engage in some form of criminal activity, often necessary 
to obtain the daily ration, though for many of them the criminal records pre-date their 
becoming drug dependent (Victor and Adams, 1983). The reason for the crime may be 
the same for drug abuse, or the commission of the crime could have such stressful effects 
as to lead to drug use for relief. Organized crime groups like the Mafia, Triads and 
Yakuza have always been implicated in the perpetuation of drug abuse, at least by 
ensuring supply (Dubro and Kaplan, 1987). 
1.3.7. Economic / financial factors. 
At the end of 1988 it was noted by the World Press Report that with profits in excess of 
US$ 300 billion, drug dealing was the world's most booming business. The current drug 
crisis has been attributed to the money that the promoters and suppliers get out of it 
(Awake, 1988). The drug dealers have developed into a formidable force, for by using 
the monetary power they get political power and so ensure their safety. Colombia has been 
under a state of siege at the hands of the drug barons for quite some time now. Recent 
media coverage illustrated the power of the drug lords of the Golden Triangle (Television 




The price of the drug determines its affordability and therefore the level of indulgence. 
The fluctuation of the number of smokers with the price of cigarettes has been cited in 
Britain (Raw, 1982). Drugs may be the source of income, opium in the Golden Triangle 
and cocaine in the Latin Americas, to quote but a few. Clearly, calls for rooting out these 
crops cannot succeed in the absence of alternative means of sustenance. This underlies 
current international strategies of crop substitution which aims to remove the dependence 
on drug money. 
Forceful advertising of some drugs, notably tobacco and alcohol, tends to tip the balance 
in favour of the drug industry, since they have more to spend on advertising than do 
governments for campaigns against the particular products (Raw, 1982). Moreover, 
alcohol and tobacco are a source of revenue for many a government through taxation, 
making restrictions more difficult to implement (Kiyonga, 1990). Governments are often 
faced with a conflict of interest: the health of their citizens versus the often-much-needed 
revenue; the choice is almost invariably in favour of the revenues (Museveni, 1989). 
To summarize the multifaceted problem of drug abuse, Edwards (1982a) pointed out that: 
"The lab scientist will be interested in the neurochemistry and influence of the drug on 
the transmission of neural impulses, the mechanisms which underlie tolerance and the 
withdrawal state. The psychologist will focus on addiction as learnt behaviour, the drug 
experience as reinforcing and conditioning of drug taking behaviour, or on the learning 
processes which come about from the relief of withdrawal symptoms by a further dose of 
the drug. And meanwhile the sociologist will seek to understand the social determinants 
of drug taking, the peer group pressures, and the nature of the environment which 
proposes drug taking The anthropologist will point out the symbolic meaning of the 
drug and will see the rituals and functions of drug taking as rooted in the individual s 
culture. ” It is difficult to disagree with such a concise treatise. 
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CHAPTER 2; AN OVERVIEW OF THE DRUG ABUSE SITUATION IN HONG 
KONG AND UGANDA 
2.1. HONG KONG 
Hong Kong is a small British Territory, scheduled to revert to Chinese administration in 
1997. She covers a total area of 1,061 km^ with a population of about 5.6 million people. 
Considering that most of the land is covered by unusable hills, the population density is 
quite high. Hong Kong was ceded to the British in perpetuity in a treaty following one of 
the Sino-British opium wars in 1842. From its inception, therefore, Hong Kong has 
always had a major problem of drug abuse — especially of opioids (Mortimer, 1983; 
Chiu, 1983). Prohibition of trafficking and/or abuse of opium products, however, did not 
come into force until after the Second World War. The formulation of realist anti-drugs 
policies was hampered by poor coordination, lack of effective data collection and the 
resulting lack of reliable information. To address this shortfall, the Central Registry of 
Drug Abuse (CRDA) was set up in April 1972 and subsequently reorganized in September 
1976. The Central Registry is charged to: 
(i) identify the trends in the nature of addiction and the addict population in Hong Kong 
over time; . 
(ii) describe certain characteristics of the reported addict population and to contrast these 
characteristics among addicts reported from specific sources; 
(iii) provide information regarding the association of contact with certain reporting sources 
with the subsequent as well as the preceding history of addicts; and 
(iv) evaluate the effectiveness of various treatment and rehabilitation programmes; 
(CRDA, 1982; 1989; Chiu, 1983). 
The Central Registry receives, processes, analyses and reports data on drug abusers from 
law enforcement, treatment and welfare agencies, both government and voluntary 
institutions or non-governmental organizations (NGOs). Within the constraints of a 




the drug abuse trends in Hong Kong. What follows below is adopted from the various 
reports of the Central Registry. 
From September 1976 to December 1989 inclusive, the Central Registry had recorded 
62,250 persons. The number of active drug users represented 0.8% of the total population 
aged 11 years and above. The majority of the drug users were male (90.3%), with females 
being only 9.7%, but there has been noted an increasing number of females among the 
newly reported cases. In the 10 years between 1977-1987 the proportion of females in the 
newly reported cases increased from 5% in 1977 to 20.1% in 1987, and to 17.9% in 
1989. 
Another observation over the years has been a downward trend in the total number of 
newly reported cases, but an upward trend in the proportion of the young, especially those 
under 21 years of age. The under-21s were 8.3% of all newly reported cases in 1979; 
26.8% in 1982; and 38.6% in 1989. 66.8% of all newly reported cases in 1989 were aged 
16-30 years in contrast to 48.4% in 1980. The most common age of first illicit drug use 
is usually between 15 and 24 years and the proportion of those who start drug use below 
15 years has been increasing. Female drug users tend to be younger both at the time of 
initial drug use - mean age 23 years, 1980; 19.4 years, 1989 - and the mean age of newly 
reported cases - 31.4 years, 1980; 24.9 years, 1989. The corresponding values for the 
male drug user population were: mean age for initial drug use, 24.8 years in 1980 and 
23.3 years in 1989, and mean age of the newly reported cases, 38.1 years in 1980 and 
28.0 years in 1989. Overall, the mean age of newly reported cases has fallen with time, 
for instance from 37.5 years in 1980 to 27.4 years in 1989. 
The Central Registry of Drug Abuse receives reports on a number of drugs, including 
heroin, opium, morphine, methadone, cannabis, benzodiazepines, cocaine, amphetamines, 




primary drug of abuse among all persons and in the newly reported cases. There has been 
a notable downward shift in the percentage of newly reported abusers who use heroin as 
the primary drug. In 1985 93.4% used heroin as the primary drug whereas in 1989 this 
was only 60.1%. Methaqualone, another previously popular drug, has also declined in 
popularity, for instance from 20.6% in 1987 to 5.1% in 1989. The drug preferences of 
those under 21 years of age is markedly different from that of all ages taken together. In 
1989 40.5% of the under-21s reportedly used cannabis compared to 4.2% for all ages; 
51.2% used heroin compared to 93.0% for all ages. Heroin use among the young drug 
abusers (below 21 years) has been on the decline while use of cannabis has been 
increasing. Another noteworthy trend is that more and more of the drug abusers are using 
more than one drug, especially so among the young ones. 
\ 
Heroin use is by fume inhalation ("chasing the dragon"), smoking or injection. Overall, 
most of the heroin users (59%) use injection compared to inhalation (36.9%). Among the 
newly reported cases, however, inhalation is more popular, 55.4%, compared to injection, 
32.9% (CRDA, 1989). 
Other drugs including methadone, flunitrazepam, morphine, codeine, quinalbarbitone 
(Seconal), diazepam and cocaine are abused to a much smaller extent. It is particularly 
interesting to note that cocaine and the various "designer" drugs that are so popular in the 
USA and in Western Europe have not caught on in Hong Kong, at least not as yet. 
Meanwhile a new trend is that of high non-medical use of cough medicines. 
The educational attainment of the drug abusers is generally lower than the average Hong 
Kong population, though the trend over time has been towards a higher average level of 
education, partly reflecting the effects of the government policy of compulsory, free 
education at primary and early secondary level. Whereas most of the drug abusers (80%) 
have no vocational training, the majority are engaged in some lawful employment 
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(Mortimer, 1983; CRDA, 1987; 1989). 
The Golden Triangle is the main source of the opioids, smuggled in by making use of the 
free port and limited trade controls that are the hallmark of Hong Kong. Once the drugs 
are in Hong Kong, there is widespread belief that organized crime syndicates, the triads, 
play an important role in the distribution ( Dubro and Kaplan, 1987). 
Efforts to combat the drug problem in Hong Kong have been on several fronts, including: 
(i) treatment and rehabilitation, 
(ii) legislation and law enforcement, 
(iii) preventive education and publicity, and 
(iv) international cooperation in similar efforts (Mortimer, 1983). These will be looked 
at briefly in turn. 
(i)Treatment and rehabilitation are carried out by the Correctional Services Department 
through the compulsory placement programmes in the Drug Addiction Treatment Centres 
(DATC); by the voluntary inpatient programme run by the Society for the Aid and 
Rehabilitation of Drug Abusers (SARDA); and also by the voluntary outpatients 
methadone programme run by the Medical and Health Department. A drug abuser may 
be sentenced to detention in a drug treatment centre rather than a prison if the court is 
satisfied that treatment and rehabilitation are required. The SARDA has been operative 
since 1960 and is now subvented by the government but remains a non-govemmental 
organization (NGO). Services offered include detoxification, methadone replacement 
therapy, counselling and after care. A SARDA Alumni Association was formed in 1967 
by former addicts and provides self help and mutual support for SARDA dischargees. The 
voluntary outpatients methadone programme aims to free the dependent abusers from illicit 
drugs; enables them to get and keep in gainful employment; and restores their confidence 
and self respect. The medicine given to the outpatients is taken under the supervision of 
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the dispensing staff. 
(ii) Legislation which calls for the confiscation of property and the freezing of bank 
accounts of convicted drug dealers, as well as punitive prison terms, has been enacted. 
The Narcotics Bureau of the Royal Hong Kong Police and the Customs and Excise 
Department are particularly involved in the enforcement of the relevant laws. Legislation 
on drug abuse and trafficking is kept under constant review. 
(iii) Preventive education and publicity is an ongoing process aimed at keeping the drug 
abuse situation in perspective and alerting the public accordingly. Anti-drugs campaigns, 
targeting the particularly vulnerable groups, are carried out through the media - television, 
radio, newspapers- and also through posters and leaflets by various NGOs. There is a high 
public awareness of drug abuse in Hong Kong. 
(iv) On the international front, Hong Kong attends and contributes to the meetings of the 
UN Commission on Narcotics and contributes to the UN Fund for Drug Abuse Control. 
In addition, several anti-trafficking operations are carried out in collaboration with 
personnel from other countries from time to time, as the need arises (Mortimer, 1983). 
A new dimension to the problem of drug abuse in Hong Kong is the tendency towards the 
abuse of proprietary cough and cold "remedies". Chan et al. (1990) have reported on the 
dependent consumption of these remedies among youths aged 12-22 years of age. The 
most popular of the preparations abused was Phensedyl™ (M&B), containing codeine, 9 
mg, ephedrine, 3.6 mg, and promethazine, 3.2 mg, per 5 ml. These preparations are 
freely available over the counter, unlike codeine per se which is a controlled substance. 
A survey by the CRDA showed that abuse of cough medicines among students was on the 
increase between 1987 and 1990 (CRDA, 1991a), with students in the Chinese schools 
more involved than those in International schools. Overall, cough medicines were the third 
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most commonly abused substance among the students. The overall trend towards higher 
abuse of these preparations is also evident in the annual reports from the Central Registry 
(CRDA, 1990; 1991b). 
Another substance worth of note on the Hong Kong drug scene is alcohol. Alcohol is not 
subject to reporting to the Central Registry of Drug Abuse, and there is, therefore, no 
reliable source of data on alcohol consumption and abuse. There has been a consistent 
increase in the per capita consumption of alcohol in Hong Kong over the years (Singer, 
1971; 1979; Hong Kong Council on Social Services; 1983). The emerging problem of 
alcohol abuse seems to be related to abuse of other drugs. SARDA (1981) reported that 
treated heroin addicts who remained abstinent showed strong tendencies towards alcohol 
use, the males more so than the females (Lo, 1983; McPherson and MacQuarrie, 1983). 
The general awareness about alcohol-related problems is low, but there is strong 
disapproval of alcohol abuse. Alcohol-induced liver cirrhosis in the general population is 
low, and the relation between drinking and criminal offenses is apparently minimal 
(Singer, 1971; 1979; McPherson and MacQuarrie, 1983; Lo, 1983; Hong Kong Council 
on Social Services, 1983). Nevertheless, anecdotal reports from the Alcoholics 
Anonymous indicate that the problem may not be as small as is usually assumed to be the 
case (SCMP, 1990). 
In summary, the main drug problem in Hong Kong is heroin use, though cannabis is 
apparently gaining popularity especially among the young. Younger people are 
increasingly getting involved with drugs and the proportion of female abusers is 
increasing. There is a well coordinated anti-drugs front for surveillance, treatment and 
rehabilitation, law enforcement and international cooperation. More needs to be done to 





Uganda is a land locked East African country a former British colony, once described 
by Winston Churchill as "The Pearl of Africa". Despite vast natural resources, including 
fertile land where practically anything can grow, large masses of fresh water, and a good 
equatorial climate, Uganda remains generally underdeveloped. At independence in 1962, 
the social infrastructure was well laid out and the educational standard and that of other 
social services, were among the best in Africa. Over the past 30 years, unfortunately, the 
country has experienced wars, civil strife, mismanagement in all sectors, rampart 
corruption and a general decay in morals and work ethics. Uganda covers an area of 
150,400 km2 with a population of 16.6 million people. Most of the population is rural 
(89.6 %) and un- and under-employment is quite high in the urban areas (Uganda census, 
1991). 
The sum total of the traumatic experiences, coupled with a high population growth rate, 
about 3% annually, is that Uganda is now beleaguered with a lot of problems in all 
aspects of life. The cost of living has increased tremendously, yet real earnings have 
dropped due to inflation and consequently the standards of living have fallen over time. 
Families have been disrupted by war; health services are at an all-time low; corruption 
is the order of the day; and the brain drain has taken its toll as compatriots search for 
greener pastures, or at least peace of mind, elsewhere. As if that scenario was not 
frightful enough, AIDS has set in - further compounding the poor state of affairs. Given 
that background, it is not surprising that the problem of drug abuse has not received 
specific attention as yet. There is no system for surveillance or reporting of drug abuse 
and, therefore, no data exists on the extent of the problem. Presented below is an analysis 
based on anecdotal reports, indirect records and personal observations. Drugs that are 
abused to a significant extent in Uganda include alcohol, medical drugs, tobacco, 
cannabis, khat and hallucinogens. 
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One of the greatest tragedies in. contemporary Uganda is the increasing tendency towards 
alcohol abuse and alcoholism. Alcohol has always been used and accepted by the majority 
of the community for ceremonies, rituals, social gatherings or recreational purposes. 
Many factors including economic hardships, socio-moral degeneration, breakdown of the 
law enforcement mechanisms and the corruption already alluded to, have contributed to 
the high levels of alcohol use and abuse. Alcohol is freely available all over the country, 
especially the local brews, which tend to be cheap and affordable. "Western" drinks like 
beers, wines and spirits are in abundance too. In addition, there is a Uganda-made spirit, 
Uganda Waragi, obtained from enguli, a crude distillate of various sugar, molasses, 
millet or cassava preparations. At the beginning of the Uganda Waragi production, the 
population was encouraged to learn the appropriate technology for enguli brewing and 
distillation, for purposes of providing the raw materials for Waragi production. With time, 
however, enguli has become the standard, drink and is known by all sorts of names, inter 
alia: "kasese" "lira-lira", "kangala", "wesedule", "kill-me-quick", "the white stuff" and 
”the holy water." As some of the names indicate, enguli is quite potent, and yet cheap 
and readily available, all of which have attracted the cash-strapped Ugandans. The law 
prohibits the distilling of enguli without license, and requires that all of it be sold to the 
Uganda Waragi Distilleries. The reality, however, is quite to the contrary. Most people 
brew enguli to offset obvious economic need or supplement the meagre wages they are 
paid; fewer and fewer of them can afford the "exotic" drinks, and the low potency of other 
local brews vis-a-vis enguli makes the latter all the more popular. The police is virtually 
an impotent force now, incapable of stemming the widespread brewing, sale and drinking 
of enguli. Indeed, it is on record that police barracks have become leading places for the 
sale and consumption of the same! (Weekly Topic^ ^ 3rd August, 1990). It is not unusual 
to find on-duty policemen drunk. 
la Weekly Topic is the most authoritative English language 




Stagnation in the building industry, with increasing population, has created a big 
accommodation crisis in urban areas, resulting in increasing numbers of middle level 
workers, like young university graduates, being housed in slums or servants quarters and 
garages. This not only has a frustrating effect, but also exposes them to lifestyles much 
different than they expected. Inevitably, many of such young workers join the drinking 
patterns of their environment. There is an increasing number whose outlook to life is 
resigned, if not hopeless, and for these drinking appears to be a good escape. 
It may be appropriate at this point to make note of impact of AIDS on this state of affairs. 
The first reported cases of AIDS in Uganda were in 1982 in southern Uganda. There has 
been an explosive increase in the number of those afflicted, and by the end of 1991 the 
cumulative total of cases reported to the WHO was about 21,500 (Katabira and 
Goodgame, 1989; ACP, 1991). The victims have included the educated, up-market and 
generally successful in life and so the manpower shortage is worse. To dwell on the 
impact of AIDS on Uganda would be to digress, suffice it to say that many feel insecure 
as in instances where one's partner or spouse is afflicted; others have dropped out of 
school with the death of their benefactors; while others, especially the elderly, have been 
robbed of their only support. The feeling of hopelessness and grief has driven many to 
drinking (Dambisya, 1989; TASO, 1990). 
It is hard to put a numerical figure to the problem of alcohol abuse, a conservative 
estimate would be at least 30 ^ 40% of all urban dwellers are either heavy drinkers or 
overt alcoholics. The villagers tend to indulge in alcohol even more partly for lack of 
alternative activities. Alcohol-induced liver cirrhosis is on the increase, and younger 
patients are being seen with time (MOH, 1988; St. Anthony's Hosp., 1986; 1987). 
Hepatocellular carcinoma secondary to liver cirrhosis is the commonest malignancy among 
Ugandan adults (MOH, 1988). Police reports (1990) indicate that about 80% of all road 




The number of man hours lost as a result of drinking is not clear but is great enough to 
rank as the commonest cause of absenteeism and inefficiency in all sectors - civil service, 
industry and commerce (Weekly Topic, 7th June, 1990). The number of patients admitted 
in alcoholic coma in the various hospitals and other health units keeps increasing 
(Omagino, personal communication, 1990). Alcohol is the third commonest cause of death 
among Ugandan doctors (Jagwe, 1987). A recent report (Weekly Topic, 17th April, 1992) 
paints an even more grim picture. The need to properly assess, monitor and stem this 
escalating problem cannot be over stated, regrettably, though, so far only lip service has 
been paid to it. This has been the subject of a recent media report (Weekly Topic, 17th 
April, 1992). 
Misuse and abuse of medical drugs is quite rampant in Uganda. The Ugandan society is 
a highly medicated one, partly reflecting the high prevalence of ill health, but also in 
testimony to the breakdown in the health care delivery system. The standard of service 
offered in the government-run health facilities has steadily declined since 1971 and now, 
more often than not, most hospitals, health centres and dispensaries are without drugs and 
sundries, at best the supply is erratic. This led to the development of a lucrative drug 
selling business, which has been hijacked by unscrupulous get-rich-quick crooks. The 
latter are only interested in money with no regard to what is sold to whom. Those selling 
the drugs often do not know anything about their stock in trade! 
The law regulating the use and sale of drugs is quite explicit, but as is the case with 
alcohol, implementation thereof is ineffective. One can, therefore, buy a multitude of 
drugs from street vendors or mobile hawkers, ranging from antibiotics, central nervous 
system stimulants, analgesics, sedatives to, as in one frightful case, anti-neoplastic agents 
(New Vision2 2nd March, 1991). Amidst all this free availability, sedatives - the 
2 The New Vision is a government owned daily newspaper. 
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barbiturates and benzodiazepines especially _ are the most commonly abused. The extent 
of abuse is unclear. Fortunately, the narcotics morphine and pethidine have stayed strictly 
controlled and are not abused to any significant extent. Codeine is freely available, though 
scheduled as a controlled substance by law, but to date there are apparently no suggestions 
of its abuse. The great misuse and abuse of antibiotics has resulted in a physician's 
nightmare with the emergence of multi-resistant microbial strains. The problem of abuse, 
misuse and unchecked availability of drugs in Uganda was addressed by the Health Policy 
Review Commission (1988) but their recommendations remain shelved to date. There is 
urgent need for action in this connection. 
Cannabis sativum grows endemically in Uganda, under various names- njaaye, ndhaaye, 
njagga, bhanghi, to quote a few. The growing and/or consumption of cannabis is 
prohibited by law but, as already made clear, that is no deterrent. Traditionally, cannabis 
would be smoked by the very elderly in villages, an activity not condoned by the 
community. The recent trend has been the involvement of the youths. Cannabis is 
particularly popular in discotheques, video parlours and some up-market drinking places 
in the towns. Overall, the number involved is apparently small, but given the ready 
availability at no cost, this could increase (Weekly Topic, 5th July, 1991). 
Another commonly used substance is tobacco. Uganda is a tobacco growing country. For 
some parts notably the north-west, tobacco is the sole cash crop. Cigarettes are locally 
manufactured, largely by the multi-national British American Tobacco (BAT) company. 
Whereas in the western world the smoking trends are downward (Holbrook, 1983) in 
Uganda it is upwards. The tobacco industry is a critical source of the much-needed 
revenue and is backed by a powerful lobby; witness how government was recently forced 
to tone down the anti-smoking campaign (Weekly Topic, 11th November, 1990). The 
health warning on cigarette packets, introduced as late as 1989, was withdrawn in mid-




subject to any visible control. Youths in particular are taking up smoking in the absence 
of any age limit below which cigarettes may not be sold. So far only the high cost and 
poor incomes seem to be keeping smoking in check (Weekly Topic, 11th November, 
1990). Unfortunately, the hazards of smoking are masked by the more obvious, especially 
infectious diseases, making the efforts of the budding anti-tobacco group seem 
superfluous. 
Khat chewing is a relative new entrant to the Ugandan scene, introduced by Somali and 
Ethiopian immigrants and long distance truck drivers. Fresh leaves of Catha edulis, 
locally known as rmra, are chewed for their mood elevating and stimulant effects. Khat 
contains cathinone, a central nervous system stimulant with amphetamine-like effects 
(Glennon, 1987). Khat-chewing is ubiquitous among long-distance truck and commercial 
public mini-bus drivers and it would be interesting to investigate for a causal relationship 
between mira chewing and the high incidence of road traffic accidents involving long-
distance trucks and public mini-buses. In* all probability this is unlikely to be just 
coincidental. At present, there is no law against the sale or consumption of mira and mira 
selling is booming business. Recent media calls for attention to the growing popularity of 
khat have, predictably, been ignored. 
Petrol fume inhalation, probably the Ugandan delinquent's answer to glue sniffing in other 
parts of the world, is practised by displaced, homeless juveniles - the bayaye - who 
characteristically loiter around the towns. Most of the bayaye smoke cigarettes or 
cannabis, drink alcohol, or both. When no money is forthcoming for cigarettes or enguli, 
some of them soak pieces of cloth into petrol, courtesy of the car owners, and sniff at 
them. The sensation felt is supposedly one of being "charged", akin to being tipsy on 
alcohol, the results are reportedly better than those with alcohol. This practice is gaining 




adults look on amused. As far as the law is concerned, this is not illegal. 
Hallucinogen use is not widespread in Uganda, being restricted to a few quasi-religious 
practices. In the traditional setting, hallucinogens were used to get into a trance or when 
consulting an oracle, but with the advent of Christianity and Islam most of these practices 
died out. 
Heroin and cocaine are virtually unknown in Uganda. Amphetamine is not commonly 
used. Methaqualone, though available fairly easily, is not significantly abused either. 
In summary, Uganda has a big problem of drug abuse, especially alcohol abuse and 
alcoholism; with the involvement of a younger population. All sorts of drugs with abuse 
potential are within easy reach of many, and the control and regulation of the sale and 
supply of medical drugs has collapsed. This hideous state of affairs has not yet been 
specifically addressed due to the multitude of other, apparently more pressing, problems 
that have undermined the gravity of the drug abuse picture. The need to redress such a 




CHAPTER 3: SOME ASPECTS OF OPIOID PHARMACOLOGY 
The term opioid in current usage is the generic designation for all substances that bind to 
opioid receptors, and encompasses both opiates — alkaloids derived from the opium 
poppy or their synthetic derivatives — and opioid peptides which are naturally occurring 
in the body. From the pharmacological point of view, the term includes agonists, partial 
agonists and antagonists at opioid receptors (Duggan and North, 1983; Martin, 1983; Jaffe 
and Martin, 1991). 
Opium is derived from the juice of the scarified seed capsules of the opium poppy 
(Papaver somniferum). It was a major component of early medical practice, prompting 
Sydenham (1680) to write "Among the remedies which it has pleased Almighty God to 
give to man to relieve his sufferings, none is so universal and so efficacious as opium" 
(cited by Jaffe and Martin, 1991). Morphine, one of the major components of opium, was 
so-named after Morpheus - the Greek god of dreams - by Sertiiner circa 1803. Codeine, 
which occurs in smaller quantities in opium, was discovered by Robiquet in 1832. 
Morphine remains the standard against which all other opioids are compared (Jaffe and 
Martin, 1991). 
The major effects of opioid receptor agonists are analgesia, drowsiness, change in mood, 
nausea and vomiting and respiratory depression; reduced gastrointestinal motility; and 
alterations in endocrine and autonomic nervous system activity. Only the central nervous 
system (CNS) actions are subsequently reviewed. 
One important development in the understanding of opioid activity over the years has been 
that opioid action results from occupation and activation of several different opioid 
receptors. The wide-spread actions of opioids are partly a reflection of a ubiquitous 
distribution of opioid receptors. The other significant discovery has been that of the 
endogenous opioids - opio-peptides and endogenous opiates. All these have added new 
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dimensions to the understanding of opioid activity and suggest a functional role for opioids 
in many circumstances. These various aspects are briefly dealt with in turn below. 
3.1. ENDOGENOUS OPIOIDS 
3.1.1. Opioid peptides: Hughes and co-workers isolated and characterized two low 
molecular weight peptides, from bovine brain, that were able to mimic the actions of 
morphine in pharmacological test systems (Hughes, 1975; Hughes et al., 1975a; 1975b). 
These two peptides were designated enkephalins— met-enkephalin (H-Tyr-Gly-Gly-Phe-
Met-OH) and leu-enkephalin (H-Tyr-Gly-Gly-Phe-Leu-OH). The activity of the 
enkephalins on the mouse vas deferens relative to the guinea-pig ileum was instrumental 
in elucidating various opioid receptor sub-types. 
Three distinct families of endogenous opioid peptides are now known, each derived from 
a distinct precursor. Enkephalins, e.g. leu-enkephalin and met-enkephalin, are derived 
from pro-enkephalin (pro-enkephalin A); endorphins, e.g. B-endorphin, B-endorphin (1_ 
18) are derived from pro-opiomelanocortin (POMC); while the dynorphins are from 
prodynorphin (Pro-enkephalin B). Many peptides are derived from these precursors, some 
of which do not have any opioid activity (Hollt, 1986). 
In terms of affinity for opioid receptors (see 3.2, pg 33) the following rankings have been 
found (TIPS, 1992): 
Enkephalins d > > k; 
Endorphins ix > d > k 
Dynorphins k > ^ > > d. 
The distribution of pro-opiomelanocortin in the brain corresponds to areas which produce 
pain relief on electrical stimulation (Pilcher et al., 1988). Pro-dynorphin and pro-
enkephalin peptide derivatives are widely distributed throughout the central nervous 
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system, especially in areas related to pain perception, pain relief, modulation of affective 
behaviour and regulation of the autonomic nervous system and neuroendocrinological 
functions. (Jaffe and Martin, 1991). Elucidation of definitive physiological role(s) for the 
endogenous opioid peptides is as yet unresolved partly because they always occur in the 
presence of other neurotransmitters and/or neuro-humoral modulators. 
3.1.2. Endogenous opiates: Davis and Walsh (1970) suggested that alcohol evoked a 
modification in the metabolic disposition of dopamine leading to the formation of 
morphine-like alkaloids. This was postulated as a possible basis for alcohol addiction. 
Later, the existence of a morphine-like substance which was reactive against anti-morphine 
antibodies was demonstrated in mouse brain (Gintzler and Gershom, 1978). Subsequently, 
it has been shown that mammalian liver can carry out the critical steps in morphine 
biosynthesis by converting reticulin to salutaridine and morphinan, precurssors of thebaine 
(Weitz et al., 1987). These pathways are illustrated in Figure 3.1. 
Donnerer et al. (1987) found uniform distribution of morphine and codeine in rat brain, 
spinal cord and adrenal gland. Morphine concentrations were higher than those of codeine 
except in the adrenal glands where codeine was higher. A major proportion of these 
alkaloids, found in the synaptosomal fraction, was present as the sulphate conjugate 
(Donnerer et al., 1987). Morphinan synthesis in the liver suggests that morphine and 
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In a chronic pain model — the arthritic rat model — spinal cord and urinary excretion of 
(endogenous) morphine were found to be elevated but the adrenal (morphine) levels were 
unaffected (Donnerer et al., 1987). This is in line with findings of elevated levels of 
endogenous opioid peptides in the chronic arthritic rat (Millan et al., 1986). 
Taken together, these findings would suggest that endogenous opioids—peptides and 
alkaloids~are produced in response to pain. Most probably therein lies part of their 
functional role. 
3.2. OPIOID RECEPTORS 
Multiple opioid receptors were identified by physiological studies (Martin et al. 1976) and 
through biochemical methods (Lord et al., 1977). Three distinct opioid receptor types — 
mu 00 delta (8) and kappa (k)— are now well established. In addition, a putative 
receptor — epsilon (e) — has been proposed. Non-CNS bioassay systems contributed 
greatly to the identification and subsequent characterization of opioid receptor types. 
Differences in the relative potencies of enkephalins and opioid alkaloids in the guinea pig 
ileum and mouse vas deferens preparations led to the distinction between /x-receptors, for 
morphine-like alkaloids, in the guinea pig ileum, and 6-receptors, for enkephalin-sensitive 
types, in the mouse vas tteferens. Kappa-receptors were so-named for their preference for 
tetocyclazone (Martin et al., 1976; Lord et al., 1977). A sigma (a) receptor was 
originally proposed, for SFK 10047 (N-allynormetazone)-sensitive receptor (Martin et al. 
1976), but this is now known to be a phencyclidine receptor and not a true opioid one 
(Jaffe and Martin, 1991). 
The final effector pathways for /x- and 6-receptor activity are similar, namely an increase 
in K+ channel conductance leading to neuronal hyperpolarization. /c-Receptor activity, on 




neuronal activity results from stimulation of any of the opioid receptors (Haynes, 1988). 
Opioid receptors are widely distributed throughout the body. Areas with high opioid 
receptor density include the dorsal horn (spinal cord), subcortical brain regions, nucleus 
raphe magnus and locus coeruleus in the mid brain, periaqueductal grey area, 
hypothalamic and thalamic nuclei. These areas are also associated with many of the known 
effects of the opioids (Jaffe and Martin, 1991). 
Mu (/x)-receptor activation leads to analgesia, euphoria and respiratory depression. In 
addition, a high degree of tolerance and dependence develops (Chaillet et al. 1984; Jaffe 
and Martin, 1991).…Agonist activity in bioassays and binding studies correlates well with 
analgesic potency of the agents (Creese and Synder, 1975). It is thought that …agonist 
analgesic activity is exerted largely at supraspinal as opposed to spinal sites (Porreca et 
al., 1984; Jaffe and Martin, 1991). Agonists at opioid receptors are effective against all 
modes of noxious stimuli — chemical, mechanical or thermal. Most of the clinically 
available opioids are basically jii-agonists though they may activate other opioid receptors 
(Wuster et al., 1979; Takemori and Portoghese, 1987; Jiang et al., 1990). Selective 
agonists include [D-Ala? MePhe^ Gly^-ol]-enkephalin (DAMGO) sufentanyl, 
morphiceptin; while CTAP and naloxonazine are selective antagonists (TIPS, 1992). 
Two subtypes of /x-receptors — and /X2 — have been proposed, but remain unclear 
(Pasternak, 1988). It is thought that analgesia may be a /xi-receptor action while 
respiratory depression could be due to jLt2-receptor activity {vide infra). 
Kappa (/c)-receptor stimulation leads to analgesia, miosis, sedation and dysphoria. Because 
/c-agonists produce less euphoria and cause less respiratory depression, a lot of attention 
is directed towards their clinical potential of analgesia without abuse liability (Traynor, 
1989). Unfortunately, /c-agonists have the drawbacks of sedation and psychotomimetic 
effects. They do not exert a positive influence upon the mood, /c-receptor stimulation is 
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aversive and dysphoric (Shearman and Herz, 1982; Millan, 1990). -Receptors mediate 
antinociception in animals, and this was suggested to be qualitatively different from that 
of fjL- and 5-receptor stimulation, being exclusively against non-thermal stimuli (Tyers, 
1980). However, subsequent studies taking stimulus intensity into account have shown that 
/c-receptor agonists are effective against thermal stimuli as well, the discrepancy resulting 
from use of high intensity stimuli in the earlier studies (Millan, 1989; 1990). 
There is adequate evidence for a physiological role of /c-receptors in the mediation of 
antinociception under acute and chronic conditions (Millan, 1990). The substantia 
gelatinosa (of the dorsal horn) is the site for receipt and processing of primary afferent 
nociceptive information. Dynorphin-containing primary afferent fibres and neurones 
project to the brain in many species. Brain structures rich in /c-receptors and dynorphin 
include periaqueductal grey and thalamus, both of which are involved in the integration 
of ascending noxious information and are also linked to pain inhibitory pathways 
descending to the spinal cord. The cortex and limbic system, which are implicated in 
affective and emotional aspects, and the conscious awareness, of pain, are also rich in K-
receptors and dynorphin. Kappa-receptors would, therefore, appear strategically located 
for modulation of nociception at all levels of processing (Millan , 1990). 
In several species, including humans and rats, there is analgesia associated with 
pregnancy. This appears to be spinally-mediated and involves /c-receptors (Sander and 
Gintzler, 1987; Sander et al., 1989). During the third trimester of pregnancy there is an 
increase in maternal pain threshold that is opioid mediated, suggesting a spinal cord K-
system is activated in reaction to the stress of pregnancy. This could be physiologically 
relevant in other stress conditions as well (Cogan and Spinnato, 1986; Sander et al” 
1989). Ruda et al. (1987) showed that increased biosynthesis of spinal cord dynorphin 
occurs in a rat model of peripheral inflammation and hyperalgesia. Selective Ac-agonists 
include U50488, CI977 and U69593. Nor-binaltorphimine is a selective /c-antagonist 
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(TIPS, 1992). 
Delta (a)-receptors are thought to mediate both spinal and supraspinal analgesia (Porreca 
et al., 1984). In addition, 5-activity modulates the actions of jti-agonists especially 
analgesia (Vaught et al., 1982), endotoxic shock (Holaday and D'Amato, 1983; Holaday 
et al., 1986), and urinary bladder motility (Sheldon et al., 1987). Jiang et al. (1990) 
reported that 6-agonists positively modulate the potency and efficacy of ^-agonists. The 
effects of 6-receptor stimulation in man have not yet been elucidated due to lack of agents 
that cross the blood-brain barrier (Jaffe and Martin, 1991). Available selective 6-agonists 
include [D-Pen^, D-Pen^]-enkephalin (DPDPE) and [D-Ala? D-Leu]-enkephalin 
(DADLE). ICI 174864 and naltrindole are selective 6-antagonists. 
Unlike the three well-established opioid receptors, the identity of the epsilon (e)-receptor 
is still unclear. Lemaire et al. (1978) suggested that B-endorphin interacts with a B-
I endorphin specific receptor in the rat vas deferens. This finding was corroborated by 
1 others (Wuster et al., 1979; Schulz et al., 1979). Wuster et al. (1979) suggested that this 
putative receptor be called the epsilon (e) receptor. There is evidence for central e-receptor 
types (Akil et al., 1980; Goodman et al., 1983). Using a B-endorphin fragment, B-
endorphin (1-27), e-receptors have been implicated in analgesia (Nicolas et al., 1984; 
Nicolas and Li, 1985; Tseng and Li, 1986). J3-Endorphin (1-27) does not block analgesia 
produced by the agonist DAMGO but antagonizes B-endorphin-induced analgesia (Suh 
etal., 1987). 
Doubts about the existence of e-receptors are based on findings that so far only those 
agents with high intrinsic activity can activate the rat vas deferens (Gillan et al., 1981), 
that /i-receptor activity has been found in the rat vas deferens, and also that both fx- and 





Proponents of the e-receptor affirm that whereas B-endorphin may act via and d-
receptors in vitro and in vivo, it acts at a non-/x-, non-6-site in the rat vas deferens (Shook 
et al., 1988). Indeed, Shook et al. (1988) found no evidence of 5-receptors in the rat vas 
deferens. The absence of a specific/selective agonist for this putative receptor type 
remains an obstacle to the resolution of the uncertainties (Nock et al., 1990). 
3.3. OPIOID ANALGESIA. 
The most important clinical use of opioids is for relief of pain. Despite a lot of research 
into alternatives, opioids remain the most potent analgesics in use to date. Opioids produce 
analgesia selectively without affecting other sensory modalities like touch, vibration, 
vision or hearing; and are thus distinct from other central nervous system depressants — 
e.g. alcohol and barbiturates — which cloud consciousness and affect overall behaviour 
(Beecher, 1957; Sternbach, 1978). The patient's ability to tolerate pain may be markedly 
increased even when the capacity to perceive the sensation is relatively unaltered. The 
analgesic effect of opioids is largely a central nervous system (CNS) action. 
Several levels of the CNS are involved in the induction of opioid analgesia, with the 
possible involvement of various neurotransmitters and neuro-humoral modulators. It is 
apparent that afferent nerve threshold or responsiveness to noxious stimuli is not affected, 
and neither is the conduction of impulses along peripheral nerves impaired by opioids. 
However, noxious stimuli may be altered and diminished at the spinal level, the first level 
of sensory integration. Studies on stimulus-produced analgesia in man and experimental 
animals indicate that periaqueductal grey, dorsal raphe nuclei and periventricular grey 
areas of the brain are important in analgesic responses to opioids. Stimulation of these 
areas not only produces analgesia, but also shows cross-tolerance to opioids (Basbaum et 
al., 1976; Jacquet and Lajtha, 1976; Duggan and North, 1983; Gebhart et al., 1984). 




of which exerts an inhibitory influence on spinal interneurones that modulate the effects 
of incoming noxious sensory stimuli. Systemic administration of morphine leads to a 
depression of action potential discharge in dorsal horn neurones. This inhibition is 
observable whether neurones are activated by noxious stimuli applied to the skin 
(Zieglgaberger and Beyerl, 1976; Toyooka et al., 1978; Calvillo et al., 1979) or by 
electrical stimulation of unmyelinated primary afferent fibres that convey nociceptive 
information into the spinal cord (Le Bars, 1976a; 1976b; Duggan et al., 1980). 
Belcher and Ryall (1978) have suggested that the analgesic effects of morphine could be 
a result of actions at supraspinal levels and also by modifying transmission in ascending 
spinal pathways. The apparent spinal action of morphine could result from excitation of 
a descending pathway which inhibits ascending nociceptive transmission (Takagi et al. 
1955; Satoh and Takagi, 1970). It is evident from direct studies that a depression of 
nociception occurs through direct spinal actions of opioids (Grossman and Jurna, 1974; 
Kitahata et al., 1974; Le Bars, 1975; 1976a). 
Differential actions of morphine on nociceptive and non-nociceptive neurones have been 
reported (Belcher and Ryall, 1978). It was found that morphine interaction with opioid 
receptors at the spinal cord level had an excitatory effect on the non-nociceptive neurones 
while consistently inhibiting nociceptive neurone response to noxious stimuli. This 
suggests that excitation of non-nociceptive cells and/or pathways may increase their 
activity which would decrease the activity in the pain pathways — on the basis of the gate 
control theory of pain as advanced by Melzack and Wall (1965). This reciprocal excitatory 
and depressant action of morphine on different neurone types may be synergistic in pain 
reduction (Belcher and Ryall, 1978). 
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Opioid receptors in the substantia gelatinosa may also be important in mediating opioid 




1989). Further evidence suggests that morphine causes hyperpolarization and a reduction 
in action potential invasion of terminals of unmyelinated afferents thus interrupting 
synaptic transmission of nociceptive information to dorsal horn neurones (Duggan and 
North, 1983; Johnson and Fleming, 1989). 
Pain response involves perception of the noxious stimulus and the reaction of the organism 
to the perceived stimulus. The main effect of opioids appears to be in modifying the 
reaction to nociceptive stimuli, thereby making pain more bearable. 
3.4. OPIOID TOLERANCE AND DEPENDENCE 
Chronic administration of opioid drugs eventually leads to tolerance and a state of physical 
dependence (Heishman et al., 1989). These two features contribute to opioid abuse {vide 
supra). 
Tatum et al. (1929) described tolerance as a phenomenon characterized by the fact that 
more and more of the drug must be administered to produce equivalent effects. This has 
been recently paraphrased as: "A phenomenon made manifest by an escalation of the dose 
required to produce a previously obtained effect or by the decrement of the effect 
produced by a given dose of drug by continuous administration" (Stevens and Yaksh, 
1989). The basic concept is the same — gradual loss of effect with prior exposure to the 
drug. 
Drug dependence has been defined above. Physical dependence is a state of latent hyper-
excitability (Seevers and Deneau, 1963) that develops after (prolonged) exposure to 
opioids, alcohol, barbiturates and other central nervous system-acting agents. It manifests 
as specific symptoms and signs — the abstinence or withdrawal syndrome — following 
abrupt cessation of drug administration or, as in the case of opioids, after administration 




physiological function (Johnson and Fleming, 1989). 
Whereas a consensus seems emergent that tolerance to and dependence upon opioids arise 
from cellular adaptations, the underlying mechanisms for these phenomena and the 
relationships between them remain unclear (Johnson and Fleming, 1989). This is not 
surprising considering that tolerance and dependence in the intact organism may involve 
large portions of the neuraxis, with changes in several neurotransmitters and complex 
interactions (vide infra). 
Many workers assumed that opioid tolerance and physical dependence involved a common 
underlying mechanism, since both often develop concurrently on giving the drug and 
disappear in due course after cessation of the drug (Himmelsbach, 1943; Schuster 1961; 
Goldstein and Goldstein, 1968; Jaffe and Sharpless, 1968; Collier, 1980). However 
Seevers and Deneau (1963) suggested that the two are not interdependent and may have 
separate mechanisms. This line of thought has been supported by reports showing a clear 
cut dissociation of the two phenomena in vitro. Opioid dependence in isolated preparations 
is detected using naloxone, for instance naloxone evokes a powerful contraction in opioid-
dependent guinea-pig ileum not observed in a similar non opioid-dependent preparation 
(Schulz and Herz, 1976). 
It has been shown that mouse vas deferens preparations show a high degree of opioid 
tolerance but no signs of dependence. The guinea pig ileum, on the other hand, shows 
both tolerance and dependence, but dependence occurs early, rapidly reaches a maximum 
and levels off, at a time when there is almost no demonstrable tolerance. Most tolerance 
then develops without further intensification of dependence. Locus coeruleus preparations 
exhibit significant degrees of tolerance, but no detectable dependence (Wuster et al., 
1985). In their review of the above findings, Wuster et al. (1985) suggest that chronic 




dependence, which is due to receptor uncoupling; and (b) the development of dependence, 
accompanied by. a minor degree of tolerance, which are both due to compensatory 
hypersensitivity within an opioid-inhibited pathway. 
It is now generally accepted that the development of physical dependence is a continuous 
process, possibly beginning with the first exposure (Jacob et al., 1974; Kosersky et al., 
1974; Yano et al., 1979; Heishman et al., 1989). Eisenberg (1982) showed that the 
withdrawal syndrome was the same regardless of whether exposure to opioids was acute 
or chronic, and so the underlying mechanism(s) of physical dependence may be the same. 
The intensity of dependence and tolerance, however, is related to total exposure to 
physiologically effective concentrations (Goldstein and Sheehan, 1969; Goldstein and 
Schulz, 1973). 
Among the possible mechanisms involved in the development and expression of opioid 
1 tolerance and dependence are: (i)qualitative and quantitative receptor changes, (ii) 
alterations in the coupling of receptors to adenylate cyclase, (iii) changes in adenylate 
cyclase itself, and (iv) partial depolarization of neurons (Johnson and Fleming, 1989). 
Uncertainty still exists on what receptor changes, if any, characterize dependence and 
tolerance. Some studies using brain slices suggest that changes occur in opioid receptor 
affinity (Davis et al., 1975; 1979; Kitano and Takemori, 1979; Law et al., 1985b; Costa 
et al., 1985), and cooperativity (Davis et al., 1979). Davis et al. (1979) have suggested, 
on the basis of reduced affinity of binding sites for morphine in morphine-
dependent/tolerant mice, that opioid tolerance is the result of receptor alteration. Others, 
however, reported no differences in opioid receptor binding affinity (Pert and Synder, 
1973; Hitzemann et al., 1974; Klee and Streaty, 1974; Cox and Padhya, 1977; Biasing 
et al., 1979; bum et al., 1979) or in numbers (Pert and Synder, 1973; Hitzemann et al., 
1974). But like most receptors, opioid receptors can undergo up- and down-regulation 




After prolonged exposure to opioids, there occurs uncoupling of the receptors from the 
Gj protein and sequestration of the receptors away from the outer membrane — 
internalization. Internalization may eventually lead to destruction of receptors by 
lysosomal enzymes and a measurable decrease in receptor density, down-regulation 
(Blanchard et al., 1982; Wuster and Costa, 1984; Law et al., 1985a). The net result is 
desensitization to opioids, which may manifest as tolerance. In addition, the intrinsic 
activity of adenylate cyclase is increased, which could account for dependence {vide infra). 
The processes leading to desensitization and down regulation are homologous — specific 
to opioids — and may produce tolerance, but such changes would not lead to a withdrawal 
response. Increased activity of adenylate cyclase, on the other hand, is a heterologous 
change — one affecting other systems too — and could result in supersensitivity to 
stimulatory agonists (dependence) and subsensitivity to inhibitory agonists, including 
opioids, (tolerance) (Johnson and Fleming, 1989). 
Tolerance may therefore, be related to changes in the chain of events that couple 
receptor(s) to the final response (Chavkin and Goldstein, 1982; Porreca and Burks, 1983). 
It may also be the result of cellular adaptation beyond the receptor level. The latter may 
include decreased sensitivity to a number of inhibitory substances (Taylor et al. 1988) and 
increased sensitivity to excitatory substances (Johnson et al., 1978). Desensitization is a 
function of receptor occupation, while down-regulation is a function of physiological 
effect. An agonist with high efficacy could induce down-regulation in concentrations too 
small to induce desensitization. Agonist action is apparently essential for any of these 
changes to occur, antagonists do not induce desensitization (Johnson and Fleming, 1989). 
Adaptive supersensitivity has been proposed as a basic mechanism for opioid 
dependence/tolerance. Adaptive supersensitivity,or non-deviation supersensitivity, always 
involves a compensatory change in a direction opposite to that in effect. If a stimulatory 




(Trendelenburg, 1966; Fleming et al., 1973; Fleming, 1976; Fleming and Westfall, 1988). 
It is a means by which cells compensate for marked, prolonged changes in net stimulation 
received (Johnson and Fleming, 1989). Adaptive supersensitivity may be non-specific with 
chronic depression of a specific neurotransmission process leading to increased sensitivity 
to other agents without pharmacological relationship to the neurotransmitter. Several 
changes have been proposed as a basis for supersensitivity including increase in receptor 
density or spread of receptors (Colquhoum et al., 1974; McConnel and Simpson, 1976), 
changes in the activity of the Na+/K+ pump and related membrane potential changes, 
changes in adenylate cyclase or G protein coupling system, and changes related to 
calcium. Calculations based on the receptor theory, however, show that there are only 
modest changes in receptor numbers, which cannot account for the magnitude of changes 
in sensitivity that occur (Fleming and Westfall, 1988). 
Opioid activity and the mechanisms involved therein are, therefore, still unclear. The 
various factors, i.e. membrane potential changes, neurotransmitters/neurohumoral 
modulators, that have been implicated in opioid actions will be taken up below. 
3.5. FACTORS INFLUENCING OPIOID ACTIVITY. 
As is evident from the foregoing review, opioid activity involves a wide variety of 
changes in neuronal potentials and many transmitters and modulators have been 
implicated. Only the more well known ones are now discussed. 
3.5.1. Membrane potential changes 
Opioid activity involves reduced neuronal activity, through K+ and Ca2+ channel effects. 
A lot of work has been devoted to elucidating how far such changes may obtain in opioid 
tolerance and dependence. 




dependence relies largely on findings from the longitudinal muscle-myenteric plexus 
preparation of the guinea pig ileum studies. Basically, non-specific sensitivity changes are 
part of the adaptive changes that occur with chronic suppression of neurotransmission to 
a number of excitable cells (Cannon and Rosenblueth, 1949). These changes may be 
linked to alterations in resting membrane potential (Fleming et al., 1973; Fleming and 
Westfall, 1988). The morphine tolerant longitudinal muscle-myenteric plexus preparation 
shows such sensitivity changes (Johnson et al., 1978). 
The inhibition of contraction of guinea pig ileum longitudinal muscle to electrical 
stimulation by opioids appears to be partly a function of hyperpolarization. Ganglion cells 
are hyperpolarized acutely by opioids, but the membrane potentials of tolerant cells are 
not different from those of controls (Johnson and Fleming, 1989). In naive cells naloxone, 
by itself, has no effect on membrane potential, reduces the hyperpolarized state induced 
by acute opioids back to normal, and produces no action potentials. The acute addition of 
naloxone to tolerant cells, on the other hand, reduces the membrane potentials to values 
significantly less negative compared to controls, and this depolarizing effect of naloxone 
sometimes leads to the firing of action potentials (Johnson and North, 1980; Johnson and 
Fleming, 1989). 
Johnson et al. (1978) suggested that the myenteric neurones undergo an adaptive partial 
depolarization after chronic exposure to morphine thus placing the resting potential closer 
to the threshold for firing action potential. This would produce supersensitivity to 
excitatory agents (dependence) and subsensitivity to inhibitory agents (tolerance). Leedham 
et al. (1988) reported that the myenteric S-neurones are in a state of partial depolarization 
in the first few hours after removal of the ileum from morphine-tolerant animals. 
Studies on the spinal cord-dorsal root ganglion preparations have given concordant results 




morphine and 5-HT to decrease the excitability of neurones, indicating tolerance to their 
inhibitory effects. It was then suggested that withdrawal hyperexcitability not only 
indicates dependence, but is also the cause of tolerance (Grain et al., 1982). 
On the basis of the above Johnson and Fleming (1989) have proposed the following 
explanation. It is probable that the hyperpolarizing effect of opioids becomes masked by 
an adaptation in the form of a less negative resting membrane potential, a state of partial 
depolarization. The depolarized state is only evident when the hyperpolarizing effect of 
the opioids is antagonized by naloxone or the withdrawal of the opioid. The partial 
depolarization puts the neurones in a state of hyperexcitability to excitatory agents, 
whereas it produces subsensitivity to the inhibitory agents including opioids (Johnson and 
Fleming, 1989). Thus, from the perspective of adaptive membrane potential changes, 
tolerance and dependence reflect a common underlying mechanism. How far this obtains 
in the intact animal remains to be established. 
3.5.2. The role of calcium (Ca ” 
Calcium ion (Ca2+) concentration has been closely linked to opioid action. Ca^^ 
antagonizes morphine antinociception (Kakunaga et al., 1966; Harris et al., 1975b; 1976; 
Iwamoto et al., 1978; Schmidt and Way, 1980). The analgesic effects of morphine are 
reportedly potentiated by EGTA, a selective Ca^^ chelator; and also by blocking Ca^^ 
entry using lanthanum (Harris et al., 1975a; 1975b; Schmidt and Way, 1980). On the 
other hand, a single dose of morphine was shown to decrease Ca^^ levels in discrete brain 
regions (Gardens and Ross, 1975), while chronic morphine treatment produced an 
elevation of Ca2+ in synaptosomal fractions (Harris et al., 1977). 
There has been further evidence from in vitro studies. Elevation of extracellular Ca^^ 
significantly attenuated morphine potency (Jhamandas et al., 1978; Sawynok and 
Jhamandas, 1979; Illes et al., 1980; Opmeer and Van Ree, 1980). Huidobro-Toro et al. 
‘ 45 
(1981) obtained similar results using normorphine on the guinea-pig ileum. Conversely, 
decreasing extracellular levels enhanced the inhibitory effects of the jiA-agonist, 
DAMGO (Dougall and Leff, 1987). The development of tolerance to DAMGO did not 
appear to alter the anti-opioid effect of Ca^^, Ca^^ retained its ability to antagonize the 
inhibitory response to the opioid in a dose-dependent manner. Altering the Ca^^ levels did 
not, however, affect the development of morphine tolerance in guinea-pig ileum (Opmeer 
and Van Ree, 1980). 
It is known that in sympathetic nerve terminals and central nervous system noradrenergic 
fibres opioids inhibit transmitter release by reducing the availability of Ca^ "" to the 
stimulus-release coupling mechanism (Henderson and Hughes, 1974; Henderson et al., 
1979; Gather et al., 1979). Ross and Gardens (1977) proposed that Ca^^- and opioid-
receptor binding sites are in close proximity and may be functionally linked through 
subunit interactions. The intraneuronal Ca^^ pools, which regulate neurotransmitter release 
and cyclic nucleotide activity (Rubin, 1970; Wiegant, 1978) have been implicated in 
opioid tolerance (Guerrero-Munoz et al., 1980). Meanwhile, it was noted by other 
workers that elevated Ca^^ concentrations decreased opioid receptor binding (Hitzeman 
et al., 1974; Pert and Synder, 1974; Way et al., 1978). 
Electrophysiological studies have demonstrated that the hyperpolarization of myenteric S 
neurons by /x-agonists is increased when the external Ca^^ concentration is lowered, and 
decreased when the Ca^^ levels are raised (Morita and North, 1982). 
Others (Illes et al., 1980; Huidobro-Toro et al., 1981) have suggested that opioid 
inhibition of neurotransmission is, at least in part, through a reduction in the supply of 
Ca2+ to the stimulus-release coupling mechanism. Hayes and Sheehan (1986) have for 
their part suggested that the potentiation of opioid agonist effects in Ca?. levels lower than 
normal could be due to alterations in receptor-effector coupling, having observed that 
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opioid receptor ligands which had little or no significant agonism under normal conditions 
exhibit agonism when Ca . levels are lowered pointing to a change in efficacy. This 
would be in line with suggestions of decreased opioid receptor binding when the Ca^^ 
concentrations are elevated, as already alluded to above. 
However, several post-synaptic actions seem to be independent of extracellular Ca^^ 
concentrations (North, 1979). Chronic administration of morphine increases the uptake of 
Ca2+ into brain synaptosomes, and Ca2+ concentration in synaptosomal fractions is 
elevated (Harris et al., 1977; Huidobro-Toro et al., 1981). Whereas such changes may 
explain tolerance, their role in the state of hyperexcitability characteristic of the opioid 
withdrawal state is unclear. Nevertheless, to the extent that opioid actions and effects 
represent neuro-electrophysiological changes, Ca^^ concentration changes play an 
important role 
3.5.3. Adenylate cyclase — cyclic AMP system 
There has emerged much evidence underlining a role of the adenylate cyclase-cyclic AMP 
system in opioid action and effects. Cyclic AMP is frequently implicated as an 
intracellular messenger for the receptor mediated actions of opioids (Collier and Roy, 
1974; Collier, 1980; Schramm and Selinger 1984; Worley et al., 1987; Neher, 1988) 
based on biochemical evidence. 
Naito and Kuriyama (1973) reported that consecutive administrations of morphine led to 
an increase in the activity of adenylate cyclase without affecting phosphodiesterase activity 
in mouse cerebral cortex. Collier and Roy (1974) found that opioids inhibited the 
formation of cyclic AMP induced by the prostaglandins E! and Ej (PGEi and PGE2) in a 
dose-dependent, naloxone-sensitive manner. Inhibition of adenylate cyclase was then 
suggested as a basis for opioid analgesic action; while tolerance and dependence could be 




mechanism (Collier and Roy, 1974). 
The naloxone precipitated withdrawal response in rats was found to be enhanced by 
dibutyryl cyclic AMP and phosphodiesterase inhibitors, and reduced by stimulation of 
phosphodiesterase (Collier and Francis, 1975; Ho et al., 1975). Furthermore, substances 
that acutely elevated brain cyclic AMP levels induced a behavioral response similar to a 
naloxone-induced abstinence syndrome in opioid dependent animals — the quasi-morphine 
abstinence syndrome (Collier, 1974; Collier et al., 1974; 1975; Francis et al., 1975). 
Naloxone reportedly increases plasma levels of cyclic AMP in the morphine dependent 
mice (Muraki et al., 1981). 
In in vitro studies, opioids have been found to inhibit adenylate cyclase in a concentration-
dependent, naloxone-sensitive manner, correlating well with the binding affinity of 
agonists on hybrid neuroblastoma X glioma cells (Klee and Nirenberg, 1974; Sharma et 
al., 1975; 1977; Goldstein et al., 1977). 
Lampert et al. (1976) proposed that chronic opioid administration induced a compensatory 
increase in adenylate cyclase activity and increased cyclic AMP levels. After removal of 
the opioid, the ability of adenosine or PGE to elevate cyclic AMP levels was enhanced. 
Wilkening and Nirenberg (1980) took the view that the enhanced activity of adenylate 
cyclase due to chronic opioid administration may reflect a change in the proportions of 
low and high affinity forms of the enzyme, not an increase in the total amount of enzyme. 
Kuriyama (1982) and Kuriyama et al. (1983) sought to explain these events in terms of 
receptor sensitivity changes. They have suggested that morphine dependence induces an 
increased formation of cyclic AMP via activation of adenylate cyclase, as well as 
suppression of responsiveness of the cyclic AMP-generating system to added 
noradrenaline. In the abstinence syndrome, responsiveness of the cyclic AMP-generating 
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system to noradrenaline is significantly and abruptly increased (Kuriyama, 1978) due to 
three changes, viz: (a) Increased sensitivity of IVadrenergic receptors; (b) Increased 
coupling of B-adrenergic receptors and adenylate cyclase; and (c) Increased adenylate 
cyclase activity. In the final analysis, there are increased intracellular cyclic AMP levels, 
with subsequent activation of the cyclic AMP dependent protein kinase in the synapses. 
The resultant increase in phosphorylated protein in the synapses may play an important 
role in the abstinence syndrome, and/or the maintenance thereof, possibly by changing the 
functional state of the synaptic membrane (Kuriyama, 1982; Kuriyama et al., 1983). 
The increase in intrinsic activity of adenylate cyclase that occurs following chronic 
exposure to and removal of an opioid has been characterized as a heterogenous change, 
affecting actions of a number of unrelated agonists which lead either to inhibition or 
stimulation of the enzyme. This could explain the cross-dependence between opioids and 
clonidine (Lee et al., 1988). As alluded to below, there are suggestions that some of the 
actions and effects attributable to cyclic AMP changes, for instance the quasi-morphine 
abstinence syndrome, could be due to a blockade of adenosine release (Perkins and Stone, 
1980). 
3.5.4. The role of adenosine 
Release of adenosine has been postulated as one way through which spinal analgesia by 
opioids may be mediated. Both morphine and adenosine inhibit transmitter release 
(Ginsborg and Hirst, 1972; Hedquist and Fredholm, 1976) and both drug actions are 
blocked by theophylline (Sawynok and Jhamandas, 1976; Jhamandas et al., 1978). 
Conversely, dipyridamole, an inhibitor of adenosine uptake (Huang and Daly, 1974) 
potentiates the inhibition of transmitter release by both adenosine and morphine (Gintzler 
and Musachio, 1975). Analogues of adenosine have been reported to produce analgesia 
after systemic administration (Vapaatalo et al., 1975; Holmgren et al., 1983) and after 




analgesia so produced is blocked by large doses of methylxanthines, equivalent to those 
required to block morphine analgesia (Stone and Perkins, 1979; Post, 1984; De Landers 
and Hopkin, 1986; Sawynok et al., 1986; Sweeney et al., 1987). 
Aminophylline and other adenosine receptor antagonists produce hyperalgesia after 
systemic and/or intrathecal administration, and abolish the antinociceptive effects of 
morphine (Paalzow and Paalzow, 1973; Jurna, 1981; 1984; Sawynok et al., 1986). On 
the other hand, morphine reportedly releases ^H-purines from the cortex in vivo (Phillis 
et al., 1979; 1980; Jiang et al., 1980). Sweeney et al. (1987) showed that morphine 
releases endogenous adenosine from dorsal spinal cord synaptosomes, supporting the 
notion that spinal antinociception by morphine may be mediated in part by adenosine 
release. This release of adenosine (Sweeney et al, 1987) was Ca2+ dependent and was 
antagonized by naltrexone. 
Perkins and Stone (1980) proposed that the reduction of morphine analgesia by the 
methylxanthines and their ability to induce the quasi-morphine-withdrawal syndrome 
(Collier, 1974) be explained in terms of a blockade of adenosine release by morphine. 
Thus adenosine may mediate the inhibitory effects of opioids upon neuronal firing, being 
an alternative explanation to that of phosphodiesterase inhibition for some of the reported 
actions of the methylxanthines. 
On the basis of the above, Sawynok et al. (1989) have proposed a possible mechanism 
involving adenosine in morphine analgesia. Morphine activates opioid receptors on the 
small diameter primary afferent nerve terminals, leading to release of adenosine. The 
extraneuronal adenosine in turn activates A, and A? (methylxanthine-sensitive) adenosine 




3.5.5. The role of Substance P 
Von Euler and Gaddum (1931) isolated a factor from equine tissues which they designated 
substance P. It was later characterized as an eleven-unit peptide (Arg-Pro-Lys-Pro-Gln-
Gln-Phen-Phen-Gly-Leu-Met) by Chang et al. (1971). Substance P is a putative 
neurotransmitter and has been implicated in primary (sensory) afferent transmission. It is 
both a neuro-effector and a neuro-neuronal transmitter (Costa et al., 1980; Holzer and 
Lambeck, 1980; Tsou et al., 1982; Couture et al., 1985). Intrathecal administration of 
substance P produces nociceptive responses (Yashpal et al., 1982; Couture et al.,1985). 
Opioids inhibit the release of substance P both in vitro and in vivo (Gintzler and Scaliasi, 
1982; Sawynok et al., 1989). Substance P is known to release acetylcholine from 
cholinergic neurones in myenteric plexus (Yan and Youther, 1982; Costa et al., 1985) and 
also releases enkephalins in the spinal cord (Tang et al., 1983). These are indications that 
part of the analgesic effects of opioids may be mediated through inhibition of substance 
P release. 
The role of substance P in the opioid withdrawal syndrome has been underlined, 
especially, by work on guinea-pig ileum and the longitudinal muscle-myenteric plexus 
preparation. The guinea-pig ileum has been used to demonstrate acute opioid effects 
(Kosterlitz and Waterfield, 1975) and tolerance and antagonist precipitated withdrawal 
after chronic opioid treatment (Ehrenpreis et al., 1972). Schulz and Herz (1976) 
established that the naloxone-induced contraction seen in the opioid-dependent longitudinal 
muscle-myenteric plexus preparation was neurogenic. Gintzler (1980) proposed that there 
must be at least two neuronal systems at play in the manifestation of gut withdrawal 
one being cholinergic through muscarinic receptor activation and the other serotonergic, 
acting through the enteric neurons, possibly releasing substance P. Substance P would then 
be the final excitatory transmitter mediating the atropine-resistant contractile responses to 





and depletes substance P in primary sensory neurons when administered parenterally. It 
was found that capsaicin pretreatment blocked the atropine-resislant opioid withdrawal 
contracture. Using substance P antagonists, similar results were obtained, confirming that 
the non-cholinergic gut opioid withdrawal contracture is largely due to substance P release 
(Tsou et al., 1985). 
Tsou et al. (1982) further suggested that this withdrawal contracture may be due to 
hyperactivity at substance P terminals inhibited by opioids, and a sudden out-pouring of 
the neurotransmitter occurs during naloxone precipitated withdrawal. The released 
substance P then acts on both muscle and myenteric plexus neurons leading to strong 
contracture. Wang and Tsou (1989) reported that substance P is released from the opioid 
tolerant/dependent longitudinal muscle-myenteric plexus preparation during the naloxone 
precipitated withdrawal, possibly from the substance P neurons in the myenteric plexus. 
This lends further credence to the suggestion of Tsou and co-workers (1982). Chahl 
(1987) went to the extent of suggesting that substance P is the primary mediator causing . 
gut withdrawal contracture. 
There have been, however, some reports that are not consistent with a major role of 
substance P in the gut withdrawal contracture. A later report by Chahl (1988) showed that 
capsaicin sensitive primary afferent neurons of the ileum do not play an important role in 
the withdrawal response of enteric nervous system following acute opioid treatment. 
Furthermore, Bossut et al. (1988) also indicated that substance P may not, after all, be 
that crucially involved in opioid withdrawal contracture. The latter two reports suggest 
that intrinsic enteric and central neurons, but not primary afferents, play an essential role 
in the gut withdrawal response. 
There seems to be adequate data to suggest that substance P is involved in some opioid 
activities. The exact role and extent of such involvement remains to be resolved. 
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3.5,6. Gamma-aminobutyric acid (GABA) 
Gamma-aminobutyric acid (GABA) is an important inhibitory transmitter in the central 
nervous system (Roberts, 1974; Vizi, 1979); and also in the peripheral nervous systems 
(Taniyama et al., 1982a; 1982b; 1983; Tanaka, 1985; Erdo, 1985; Hills et al., 1985; 
Saito and Tanaka, 1986). Meanwhile, opioids are well known to antagonize the excitatory 
effects of some putative neuro-transmitters like acetylcholine, aspartate and glutamate 
(Bradley and Dray, 1973; Dostrovsky and Pomeranz, 1973; Satoh et al., 1974; Segal, 
1977). Not surprisingly, a lot of effort has been made to investigate the possible 
involvement of GABA in opioid activity. 
Using amino-oxyacetic acid, an inhibitor of GABA transaminase, which leads to increased 
cerebral levels of GABA (Kuriyama et al, 1966), the analgesic effects of morphine were 
found reduced in both tolerant and non-tolerant mice, while the development of tolerance 
and physical dependence were enhanced (Ho et al., 1976). In the same study, beta-
alanine, an inhibitor of GABA uptake in glial cells, had no effect on morphine 
antinociception in both tolerant and naive mice (Ho et al., 1976). Studies with muscimol 
—3-hydroxy-5-aminomethylisoxazole, a conformationally restricted analogue of GABA 
which is capable of crossing the blood brain barrier and activates brain GABA receptors 
(Krosgsgaard-Larsen et al., 1975) showed that morphine analgesia was potentiated 
(Biggio et al., 1977). Mantegazza et al. (1979), however, found that muscimol 
antagonized morphine analgesia. 
Contreras et al. (1979) reported that increasing GABA concentrations by using irreversible 
GABA-transaminase inhibitors potentiated morphine analgesia. On the other hand, 
reducing the activity of GABA using semicarbazide led to attenuation of opioid analgesia 
(Yoneda et al., 1976). Bicuculline, a well known GABA-ergic antagonist, inhibits 




Administration of morphine leads to alterations in GABA concentrations. Sherman and 
Mitchell (1974) observed an increase in brain concentrations of a naturally occurring 
metabolite of GABA, gamma hydroxybutyrate, after administration of analgesic doses of 
morphine, in a naloxone-sensitive manner in mice. Others, however, reported a reduction 
in the cortical release of GABA (and acetylcholine) following a single dose of morphine 
(Jhamandas and Sutak, 1974; Beani et al., 1979; Antonelli et al., 1986). The latter 
findings tend to agree with those of Maynert et al. (1962) who found no changes in dog 
brain levels of GABA after acute or chronic morphine treatment. Kuriyama and Yoneda 
(1978) suggested that morphine analgesia may involve mechanisms intensifying the inputs 
of GABA inhibitory neurons at the level of spinal cord and thalamus. 
Many workers have found that the efflux of GABA is reduced during the withdrawal 
stage (Jhamandas and Sutak, 1974; Casamenti et al., 1980; Crossland and Ahmed, 1984; 
Antonelli et al., 1986). At variance with this is the earlier report by Maynert et al. (1962) 
who noted no changes in GABA levels during nalorphine-induced withdrawal in the dog. 
There have been noted some changes in GABA and acetylcholine responsiveness during 
the withdrawal stage, but such changes do not run in parallel (Antonelli et al., 1986). This 
apparent discrepancy has been subsequently explained in terms of an inversion of the 
modulatory effects of noradrenergic mechanisms on GABA and acetylcholine (Beani et 
al., 1988). This concept of inversion is discussed further under acetylcholine (3.5.9). 
More suggestions for a possible mediation of opioid activity by GABA have come from 
the convulsant effects of opioids and opioid antagonists. Naloxone was reported to 
potentiate bicuculline-induced convulsions, and to attenuate the facilitation of unit activity 
induced by GABA in nucleus accumbens and tuberculum olfactorium (Breuker et al., 
1976). The latter suggested that the convulsant effects of opioids — and that of their 
structural analogues like naloxone may be the result of GABA receptor blockade or at 




depression seems to be related, to a certain degree, to increased GABA-ergic activity 
(Szdkely, 1982). 
3.5.7. The role of histamine 
It is known that morphine leads to histamine release in various tissues (Sollman and 
Pilcher, 1917; Feldberg and Paton, 1949; Nasmyth and Steward, 1949). Tanaka and Lin 
(1969) showed that cerebroventricular perfusion with morphine led to appearance of 
histamine in the ventricular perfusate. Whereas it is not clear whether or not these actions 
are naloxone-sensitive, such findings suggest a possible involvement of histamine in opioid 
action, especially with attention being focused on histamine as a central nervous system 
neurotransmitter (Haas and Bucker, 1975; Schwartz, 1975). In addition, both morphine 
and histamine increase the release of various brain hormones (Cacabelos et al., 1987). 
It is fairly well established that histamine may have a role in animals' response to painful 
stimuli (Chung et al. 1984). Histamine is a powerful secretagogue of endogenous opioids, 
probably via Hj-receptor activity (Bommer et al., 1987). Blockade of H2-receptors 
suppresses swim-induced antinociception in mice (Wong, 1987). 
Histamine has also been implicated in the chronic effects of opioids. Hui and Roberts 
(1974) showed that L-histidine, a histamine precursor, could inhibit the induction of 
physical dependence as evidenced by a significant decrease in withdrawal jumping in 
mice. Others have reported that histamine administered into the rat dorsal hippocampus 
induces the appearance of symptoms reminiscent of opioid abstinence (Click and Crane, 
1978) suggesting that part of the abstinence syndrome could be due to histaminergic 
activity. Anti-histaminergic agents, on the other hand, reportedly potentiate the euphoric 
effects of opioids (Cox et al., 1983). Cases of abuse of anti-histamines alone or in 
combination with opioids have been documented (Showalter, 1980; Su 1983; Chan et al., 





receptors and/or facilitate opioid penetration across the blood-brain barrier (Leza et al., 
1990). 
3.5.8. The role of catecholamines and serotonin (5-HT) 
There is much evidence implicating the adrenergic system/catecholamines in opioid 
activity. Studies with various adrenergic modulators showed that increasing the central 
adrenergic tone enhances opioid analgesia (Sigg et al., 1958; Dewey et al., 1970; 
Fennessy and Lee, 1970) whereas a reduction in the central adrenergic tone attenuated 
the analgesic effects (Takagi et al., 1964; Ross and Ashford, 1967; Verri et al., 1968). 
Administration of morphine and other opioids, on the other hand, has been shown to 
increase both brain and plasma levels of noradrenaline, adrenaline and dopamine (Moore 
et al., 1965; Van Loon et al., 1981; Appel and Van Loon, 1986). It has also been 
reported that opioids increase the central sympathetic outflow to the adrenal medulla and 
peripheral sympathetic nerve endings (Van Loon et al., 1981; Pfeiffer et al., 1983; 
I Feldberg and Wei, 1986). Various sympathomimetic agents, for example amphetamine 
and cocaine, are well known to potentiate the effects of opioids (Nott, 1968; Blumberg 
and Ikeda, 1978) a fact occasionally made use of in clinical practice and often by drug 
abusers (Szekely, 1982). 
Other findings indicate that opioids inhibit the activity of adrenergic neurons (Korf et al. 
1974; Andrade et al., 1983). Opioid agonists inhibit sympathetic transmission in various 
noradrenergically innervated tissues (Ledda and Mantelli, 1982; Fuder and Rothacher, 
1984) thought to be a presynaptic effect (Leslie, 1987). Furthermore, administration of 
a single dose of morphine demonstrably led to a reduction in the release and turnover of 
noradrenaline in the cortex (Montel et al., 1975; Attila and Ahtee, 1984). 
More support for the possible involvement of the adrenergic system has come from studies 
on the locus coeruleus nucleus. The locus coeruleus is basically a noradrenaline nucleus, 
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with the highest density of noradrenaline-containing neurons found in the central nervous 
system (Loizou, 1969; Redmond et al., 1976). Aghajanian (1978) reported that a single 
dose of morphine led to reduced firing from locus coeruleus neurons. Clonidine, an oir 
adrenoceptor agonist, has been shown to reduce the spontaneous firing of locus coeruleus 
neurons (Svensson et al., 1975). In addition clonidine, like morphine, leads to reduced 
stimulation-induced release of noradrenaline from peripheral and central noradrenergic 
neurons (Starke and Altman, 1973; Starke and Montel, 1973); and also to reduced 
turnover of noradrenaline in the brain (Anden et al., 1970). 
Tseng et al. (1975) showed that clonidine suppressed certain aspects of the narcotic 
withdrawal syndrome in the rat. This was subsequently found to be the case in humans 
too (Gold et al., 1978 1980; Hamburg and Tallman, 1981; Lai and Fielding, 1983). 
Attempts have been made to explain this clonidine action on the basis of the similarity in 
actions of opioids and clonidine. Both morphine and clonidine block the effects of 
electrical and pharmacological activation of the locus coeruleus in various species 
(Cedarbaum and Aghajanian, 1976; 1977; Hamburg and Tallman, 1981). Hamburg and 
Tallman (1981) proposed that chronic, but not acute, administration of morphine in rats 
results in increased binding of clonidine to Q;2-adrenoceptors in the brain. It was thought 
that this increase in binding was due to enhanced numbers of a2-adrenergic binding sites 
but no change in their affinity. Others (Vicentini et al., 1982; 1983; Plishka and Neale, 
1984), however, found no changes in both numbers and affinity — based on studies in 
other tissues. 
The naloxone precipitated withdrawal syndrome causes a prompt increase in the activity 
of locus coeruleus neurons in vivo, which is opposed by clonidine (Aghajanian, 1978). 
Stimulation of locus coeruleus evokes responses similar to the naloxone-precipitated 
withdrawal syndrome (Antonelli et al., 1986) suggesting that activation of locus coeruleus 
neurons may contribute to the overall picture of opioid withdrawal. As proposed by Lai 
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and Fielding (1983) during opioid withdrawal the locus coeruleus is dis-inhibited and 
many physiological effects mediated by locus coeruleus hyperactivity are provoked. Either 
clonidine or large doses of opioids would reinstate the neuronal inhibition and so abolish 
the withdrawal symptoms (Lai and Fielding, 1983). 
It has been shown that there is a co-existence of ofj-adrenoceptors and opioid recognition 
sites on the same neurons (UnnerstaU et al., 1981; Surprenant and North, 1985; Ramme 
et al., 1986; Aghajanian and Wang, 1986). These receptors seem to activate common 
transducing mechanisms (Matsui and Yamamoto, 1984; Aghajanian and Wang, 1986; 
Holting and Starke, 1986; Jackischi et al., 1986; Dunlap et al., 1987). 
Dopamine has also been implicated in opioid activity. Acute administration of morphine 
increases the synthesis and turnover of dopamine in the striatum (Persson, 1979). 
Morphine mimics several effects produced by apomorphine, a dopamine agonist. 
Apomorphine has been reported to potentiate morphine antinociception (Szekely, 1982). 
Morphine may modify the activity of dopaminergic receptors, probably the presynaptic 
ones, through activation of opioid receptors which regulate DOPA accumulation, the 
dopamine-rich striatum is also rich in opioid receptors (Persson, 1979). Chronic opioid 
use leads to supersensitivity of dopaminergic receptors and many of the changes seen 
during withdrawal may be directly attributable to this supersensitivity (Lai and Fielding, 
1983). Attempts to use various dopaminergic blocking agents in the opioid withdrawal 
syndrome have not, however, l)een successful so far (Lai and Fielding, 1983). 
Studies on self-administration of morphine have provided more support for the role of 
catecholamines in opioid activity. Even laboratory animals can self-administer morphine 
directly into the brain, suggesting that the positive reinforcing properties of morphine may 
be mediated directly by central mechanisms (Amit et al., 1976; Belluzzi and Stein, 1977). 




1974; Click et al., 1975; Linseman, 1976); of the medial forebrain bundle (Click and 
Charap, 1973; Click, 1974); and of the hypothalamus (Amit et al., 1976; Kerr and 
Pozuelo, 1971). 
Destruction of catecholaminergic neurons using the neurotoxin 6-hydroxy dopamine (6-
OHDA) was reported to lead to an attenuation of morphine consumption in rats (Meade 
and Amit, 1974). Pretreatment with a-methyl tyrosine, a catecholamine synthesis 
inhibitor, effectively disrupts the effects of morphine (Pozuelo and Kerr, 1972). Self 
administration of morphine and amphetamine was reportedly suppressed by pretreatment 
with a-methyl tyrosine (Davis and Smith, 1972; 1973; Click et al., 1973). Grosz (1972) 
noted that the euphoric effects of self-administered heroin are lost in human subjects 
treated with propranolol, a B-adrenergic blocking agent. 
Meanwhile, Pozuelo and de Ybarra (1977) reported that treatment of human addicts with 
i a-methyl tyrosine led to reduced craving for morphine, supporting earlier suggestions that 
noradrenaline itself may subserve the reinforcing properties of morphine (Grosz, 1972). 
Treatment with fusaric acid, a dopamine hydroxylase inhibitor, also attenuated the craving 
for morphine (Pozuelo and de Ybarra, 1977). These findings were further supported by 
Brown et al. (1978) who observed that when central noradrenaline levels were depleted 
in rats by pretreatment with a dopamine-B-hydroxylase inhibitor, preference for morphine 
consumption was significantly attenuated, further implicating noradrenaline as having a 
role in the positive reinforcing properties of morphine. To the extent that positive 
reinforcement is a crucial factor in the abuse of opioids {vide supra), the catecholamines 
appear to play a very important role. 
A lot of experimental evidence relates opioid analgesia to serotonin (5-hydroxytryptamine, 
5-HT). Opioid analgesia is inhibited by 5-HT depletion or by destruction of brain regions 




tryptaminergic pathways abolishes analgesia due to stimulation of the periaqueductal grey; 
while stimulation of the periaqueductal grey increases the turnover of 5-HT in the higher 
brain levels (Beaumont and Hughes, 1979). Furthermore, spinal transmission of 
nociceptive impulses is reduced by activating descending 5-HT-containing fibres (Basbaum 
et al., 1976; Fields et al., 1977; Guilbaud et al., 1977). Many of these fibres terminate 
in the substantia gelatinosa of spinal cord (Dahlstrom and Fuxe, 1965; Basbaum et al., 
1976), an area which is also rich in opioid receptors (Duggan et al., 1976; 1977). 
Like morphine, 5-HT was found to reduce excitation evoked by noxious stimulation in 
dorsal horn neurones, suggesting that 5-HT may be a mediator of raphe-spinal actions 
(Belcher et al., 1978). Excitation of nociceptive neurones by noxious stimuli was 
consistently inhibited, whereas spontaneous activity and non-noxious excitation of both 
non-nociceptive and nociceptive neurones were often facilitated by 5-HT. These 
differential actions of 5-HT were reminiscent of those due to iontophoretically 
administered morphine on spinal neurones (Belcher and Ryall, 1978). Based on the gate 
control theory of pain (Melzack and Wall, 1965), Belcher et al (1978) have suggested the 
possibility that the descending 5-HT system not only selectively inhibits transmission from 
nociceptive afferent fibres, but also excites non-nociceptive cells which may gate the 
transmission of. nociceptive information to the higher centres. From this standpoint, 
nociceptive fibre inhibition is a presynaptic action, whereas excitation of the non-
nociceptive ones is a postsynaptic action (Belcher et al, 1978). 
On the basis that iontophoretically applied 5-HT in the spinal cord reduces discharge of 
nociceptive neurones, and also that intrathecally administered 5-HT dose-dependently led 
to analgesia (mimicking the effects produced by activation of descending systems due to 
opioid action on the periaqueductal grey), Yaksh (1979) studied the effects of 
methysergide on the antinociceptive effects of morphine on the periaqueductal grey. It was 
found that methysergide, a 5-HT antagonist, reversibly antagonized morphine 
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antinociception, suggesting that part of the action of morphine may be due to activation 
of descending serotonergic system(s). Yaksh (1979) therefore proposed that the 
antinociceptive effects of periaqueductal grey morphine may be due to action on the 
descending systems modifying sensory processing, and a supraspinal mechanism which 
functions to alter the animal's behavioral response to noxious stimulation independently 
of changes produced in the spinal pathway of nociceptive information. This may involve 
various monoamines, including 5-HT (Yaksh, 1979). 
More recently, 5-HT has been linked to the reinforcing properties of several -drugs of 
abuse (Oakley et al., 1988; Costall et al., 1988; Carboni et al., 1988). Blockade of S-HTj 
receptors was found to reduce the rewarding properties of morphine (Carboni et al., 
1988) strongly suggesting the possible involvement of 5-HT3 receptors in opioid abuse. 
While providing new possibilities to the approach on drug abuse, there are, however, 
apparently no data on the use of 5-HT3 blockers in clinical practice, as yet. 
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The possible involvement of B-adrenergic mechanisms in opioid activity has been reviewed 
under adenylate cyclase-cyclic AMP (3.5.3). It is thus apparent that the catecholamines 
and serotonin may have some role in acute opioid effects, the abstinence stage and the 
maintenance of self-administration behaviour, all of which are important determinants in 
drug abuse. 
3.5.9. Acetylcholine 
Paton (1957) and Schaumann (1957) showed that morphine impairs the release of 
acetylcholine from electrically stimulated guinea pig ileum. It was later shown that release 
of acetylcholine from other preparations including the neuromuscular junction in frog 
sartorius and rat diaphragm muscles (Fredrickson and Pinsky, 1975) were similarly 
inhibited. It is also known that morphine depresses the central nervous system release of 




Thus several lines of research suggest a possible involvement of cholinergic mechanisms 
in opioid action. 
In the longitudinal muscle-myenteric plexus preparation, on electrical stimulation 
contractions of the longitudinal muscle are due to excitation of neurones in the myenteric 
plexus and subsequent release of acetylcholine. Inhibition of intestinal contraction by 
opioids is thought to be partly due to action on cholinergic neurones, rather than directly 
on the muscle layers; for contractions due to direct acetylcholine application are unaffected 
by morphine (Kosterlitz and Robinson, 1958). Meanwhile, contraction invoked by 
‘ indirectly acting agonists like 5-HT, nicotine and neurotensin are inhibited by morphine 
(Schaumann, 1955; Gaddum and Picarelli, 1957; Kosterlitz and Robinson, 1958; 
Huidobro-Toro et al., 1984). 
Inhibition of electrically evoked contractions of the longitudinal muscle therefore appears 
to result from a depression of acetylcholine release from the myenteric plexus (Paton 
1957; Cox and Weinstock, 1966; Kennedy and West, 1967; Vizi et al., 1984). Two 
possible mechanisms have been proposed for this inhibition of acetylcholine from motor 
neurones. The first suggests a direct action on the release itself, whereby there is reduced 
acetylcholine liberated by each action potential in the presence of opioids (Paton, 1957; 
Schaumann, 1957). The other considers that opioids may also reduce the number of action 
potentials that propagate to sites of transmitter release (Satoh et al., 1973; Karras and 
North, 1981; Johnson and Fleming, 1989). Agonists active at both fi- and k-receptors are 
effective in depressing cholinergic transmission (Hutchinson et al., 1975; Goldstein et al. 
1979; Ward etal., 1986). 
Many studies have documented an increase in brain acetylcholine content following opioid 
administration in a number of species. A single dose of morphine reportedly leads to an 
increase in brain acetylcholine content within 30 minutes in naive mice (Giarman and 
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Pepeu, 1962; Hano et al., 1964) and also in the rat (Datta et al., 1971). However, 
morphine was found ineffective in altering acetylcholine content in tolerant mice, and had 
no effect on cholinesterase (Hano et al., 1964). Crossland and Slater (1968) reported that 
this effect of morphine was due to an increase in the bound, vis-a-vis the free, form, 
giving a net increase in total content. This was in line with earlier suggestions that 
increase in acetylcholine content was a reflection of decreased release (Paton, 1957; 
Schaumann, 1957). Maynet (1967) for their part, reported that production and destruction 
of acetylcholine were unaffected by morphine. Zsilla et al. (1976; 1977) have, however, 
reported that activation of opioid receptors leads to reduced acetylcholine metabolism. The 
turnover rate of acetylcholine was reduced in the hippocampus and cortex but not in the 
striatum (Zsilla et al., 1977) despite the latter being abundant in opioid receptors 
(Persson, 1979). 
Opioids have been shown to depress resting release of acetylcholine from cerebral cortex 
(Beleslin and Polack, 1965; Jhamandas et al., 1971; Labrecque and Domino, 1974). 
Similarly, acetylcholine release evoked by K+ depolarization or electrical stimulation is 
blocked by morphine (Yaksh and Yamamura, 1977); further supported by findings that 
opioids exert a potent anti-release action on the cholinergic system (Domino and Wilson, 
1973). A decrease in the release of acetylcholine at cholinergic synapses in the brain or 
peripheral neurones may be central to the actions produced by morphine and other 
opioids. 
Chronic treatment with morphine was reported to have no effect on acetylcholine levels, 
probably suggesting that tolerance develops to this effect (Large and Milton, 1970). 
During withdrawal, on the other hand, acetylcholine levels are elevated (Large and 
Milton, 1970; Labrecque and Domino, 1974; Antonelli et al., 1986). This increased 





Supersensitivity to acetylcholine has been implicated in the production of morphine 
tolerance in dog intestine (Shoham and Weinstock, 1974). Paton (1963) suggested that 
during morphine withdrawal, the (morphine) restraint on acetylcholine release is removed, 
either by abrupt cessation of morphine administration or by an antagonist, resulting in an 
excessive release of acetylcholine from brain structures. This, occurring in the presence 
of supersensitivity to acetylcholine that possibly develops at the cholinergic receptors 
during opioid dependence as a result of impaired acetylcholine release, could be the basis 
for enhanced cholinergic activity during morphine withdrawal. This line of argument was 
lent more credence by reports suggesting that anti-cholinergic agents may ameliorate the 
abstinence syndrome (Ramkhen, 1968). Furthermore, chlorpromazine, which has 
anticholinergic activity, was recommended for the treatment of the same (Friedgood and 
Ripstein, 1955; Zelson, 1970). Muscarinic blockers can suppress some manifestations of 
the withdrawal syndrome (Collier et al., 1972; Jhamandas and Dickinson, 1973). 
Prolonged treatment with opioids appears to induce a reversal of the modulatory effects 
of the noradrenergic signals on the cholinergic and GABA-ergic system (Beani et al., 
1988). In the acute setting, acetylcholine is inhibited directly through oja-adrenoceptor 
activity, whereas in the tolerant state acetylcholine is induced through a adrenoceptors • 
This is the phenomenon of inversion, and seems to depend on slow adaptive changes in 
the receiving mechanisms of target neurones (Beani et al., 1988). The exact contribution 
of this mechanism to the overall dependent/tolerant state, or at the withdrawal stage is 
unclear. 
In conclusion, much work has implicated cholinergic mechanism in the acute and chronic 
effects of opioids both in peripheral structures and in the central nervous system. That 
none of them adequately explains the overall effects of opioids is testimony to the complex 
nature of such actions. For instance, anti-cholinergic agents have not been successful in 
the treatment of the abstinence syndrome. 
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CHAPTER 4. BASIC PRINCIPLES OF PHARMACOKINETICS 
Pharmacokinetics is the study of the time course of drug (and metabolite) levels in 
different fluids, tissues and excreta of the body, and of the mathematical relationships 
required to develop models to interpret such data (Curry, 1980). In essence, 
pharmacokinetics is concerned with the rates of transfer processes associated with the 
absorption, distribution, metabolism and excretion of drugs in the body. 
A fundamental premise in the application of pharmacokinetic concepts in the 
understanding or interpretation of pharmacological activity of drugs is that there is a 
relationship between the pharmacological response to a drug and the concentration of the 
drug, for instance, in blood (Curry, 1980; Gibaldi and Perrier, 1982). Pharmacokinetics 
uses the techniques of compartmental analysis in explaining pharmacokinetic data. 
Compartments are areas of drug distribution defined in terms of the molecules which (and 
how easily they) penetrate them. . 
1 
A one-compartment model depicts the body as a single homogeneous unit. It is useful in 
the pharmacokinetic analysis of blood, serum or plasma concentrations and urinary 
excretion data for drugs which rapidly distribute between plasma and other body tissues. 
The basic assumption here is that any changes that occur in the plasma quantitatively 
reflect changes occurring in other tissue drug levels. 
In reality many drugs are distributed in the body in a multi-compartmental way, being 
preferentially concentrated, for instance, in organs with high blood flow, fat deposits, or 
in relatively inaccessible tissues like bone and teeth depending on the properties of the 
particular drug. In considering a multi-compartment model, it is assumed that a drug is 
transported from one compartment to another with first order kinetics. 
Following a bolus intravenous dose the plasma drug concentration rapidly equilibrates with 
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that in the various tissues until a distribution equilibrium is obtained. Subsequent decline 
in plasma concentration is governed by the loss of drug from the body through metabolism 
or excretion, the elimination phase (Figure 4.1). 
T \ Diettibution phase _ 
log Cone, of \ ^ 
drug \ 




The pharmacokinetics of some drugs may be adequately explained by a one-compartment 
model; assuming homogeneous distribution throughout the tissues and body fluids. Others 
show one distribution phase and are assumed to follow two-compartment model kinetics; 
yet others may have two distribution phases and thus follow kinetics of a three-
compartment open model. 
Non-compartmental methods may also be used for the kinetics of absorption and 
elimination. They indicate the extent of distribution but with little insight on the rate or 
processes of drug distribution. They are model-independent and more restrictive than the 
compartmental ones. 
There are two primary pharmacokinetic parameters: clearance and volume of distribution. 






versus time curve, are secondary and governed by clearance and volume of distribution. 
Clearance refers to the irreversible elimination of a drug from the body through excretion 
of unchanged drug, e.g. in urine, gut contents or through expired air, or the metabolic 
conversion of the drug into different chemical compounds usually in the liver, but may 
also occur at other sites (Curry, 1980; Gibaldi and Perrier, 1982; Birkett, 1988a). 
Clearance is the volume of blood or plasma cleared of drug per unit time and can be 
viewed in terms of a particular organ, hence hepatic clearance, renal clearance or lung 
clearance. Total body clearance is the sum of all the different clearances occurring for a 
given drug. Clearance is independent of the type of pharmacokinetic model used. 
Within a range of concentrations, for instance the therapeutic drug levels, clearance for 
many drugs follows first order kinetics with a constant fraction of plasma being cleared 
of the drug per unit time, in contrast to zero order kinetics which would mean a constant 
amount of drug is cleared per unit time. 
Clearance after a single bolus dose may be determined by considering the dose and the 
area under the concentration versus time curve (AUG): 
Clearance = Dose 
• (1 h \ m l min 1) AUC (1) 
Clearance determines the maintenance dose rate, given by: 
Maintenance dose rate = Steady state concentration X Clearance (2) 
(mgh-i) (mgl-i) (Ih-i) 
Equation 2 may be modified to give another mathematical definition of clearance: 
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Clearance = maintenance dose rate (mg h') (3) 
(1 h'*) steady state concentration (mg 1” 
For a given dose rate, the blood concentration is inversely proportional to clearance, i.e. 
if clearance is reduced by half the concentration doubles (Birkett, 1988a). 
Volume of distribution refers to the volume of fluid in which an administered dose of 
a drug would be distributed if the entire body content of the drug were evenly distributed 
at the concentration measured in plasma (or blood). It is not a real volume but simply 
relates the concentration of the drug in plasma to the total amount of drug in the body 
(Birkett, 1988b). Volume of distribution is determined by physico-chemical properties of 
the drug and its binding characteristics to body tissues and plasma proteins. 
Mathematically: 
Volume of distribution = Dose (4) 
Plasma concentration (at time 0) j- . 
This assumes the body to be a single compartment. The plasma concentration is taken as 
that at time 0 (C before the onset of elimination processes. C may be obtained by 
extrapolation of the plasma concentration versus time curve (Figure 4.2). 
Decline in plasma concentration is usually exponential and a plot of logio (drug 
concentration) versus time gives a straight line. Extrapolation of the line to time 0 gives 
Co, the theoretical concentration at time 0 when all the drug is in the body. Then: 
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Figure 4.2. 
Clinically, volume of distribution is used to calculate the loading dose in designing a 
dosage regimen to achieve a steady state concentration fast enough. Loading dose, desired 
steady state concentration and volume of distribution are related by the equation: 
Loading dose = Volume of distribution X Steady state concentration (6) 
(mg) (1) (mg 1-1) 
The loading dose is given to fill up the volume of distribution, as it were (Birkett, 1988b; 
Benet et al., 1991). 
Elimination half life (t.^ ) is the time taken for the amount of drug in the body or the 
plasma concentration to fall by half. Elimination of the drug is usually an exponential 
process, a constant proportion of the drug in the body is eliminated per unit time (Birkett, 
1988c). Elimination half life is a secondary pharmacokinetic parameter determined by both 
clearance and volume of distribution. It is given by the equation: 
Elimination half life = 0.693 X Volume of distribution (7) 
Clearance 
Where 0.693 is the natural logarithm of two. 
From equation 7, it is clear that the greater the volume of distribution and the lower the 
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clearance, the higher the tVi. Conversely, lower volume of distribution and higher 
clearance lead to lower t,^ . Basically, a decrease in elimination activity (clearance) means 
that the time taken to eliminate the drug is increased. The larger the volume of 
distribution, the more the drug is concentrated in the tissues compared with the blood, 
thus less drug is exposed to (hepatic or renal) clearance and so less drug will be 
eliminated. If volume of distribution is small most of the drug is in the blood and 
accessible to the elimination processes (Klotz et al., 1975). 
Half life is a poor index of drug elimination but provides a good approximation for the 
duration of action after a single dose, the time required to achieve a steady state 
concentration and dosing frequency. The longer the t,,: the longer plasma concentrations 
will stay within the effective range. It usually takes about four half lives to reach steady 
state concentrations. If a drug is given more frequently than every half life the fluctuations 
in concentration are small. Alternatively, slow-release preparations may be used to mimic 
j a constant rate infusion. In the latter instance fluctuations in plasma concentration are 
determined by the slow absorption rate rather than the elimination rate (Birkett, 1988c; 
Benet et al., 1991). 
Elimination half life may be estimated from a semilogarithmic plot of plasma 
concentration versus time (Figure 4.2) as the time between one drug concentration and 
another half the reference one. 
The total area under the (plasma) concentration-time curve (AUC) describes the 
concentration of drug in systemic circulation as a function of time from time zero to 
infinity. AUC is closely related to clearance. The intensity and duration of 
pharmacological response is a function of the concentration and persistence of the drug 




AUC is usually calculated using the trapezoid rule. The plasma concentration versus time 
curve is depicted as a series of straight lines, thereby enabling the area under the curve 
to be divided into a number of trapezoids. The area of each trapezoid is calculated and the 
sum of all the areas of the trapezoids yields an estimate of the true AUC (Curry, 1980). 
AUC is particularly useful in determining the bioavailability of oral preparations. 
For orally administered drugs, absorption, first pass clearance and bioavailability are very 
important considerations. Absorption is the extent to which intact drug is absorbed from 
the gut lumen into portal circulation. Many factors influence absorption, including 
physico-chemical properties of drug, special dosage forms, gastric emptying rate, 
intestinal motility and drug interactions within the gut lumen. 
I Having been absorbed, the drugs are subjected to first pass clearance which is the extent 
to which a drug is removed by the liver during its first passage in the portal blood through 
the liver to the systemic circulation. This gives rise to the concept of bioavailability which 
is the fraction of the dose which reaches the systemic circulation as intact drug. 
Bioavailability is considered relative to an equivalent intravenous dose by comparing the 
AUCs of the drug after an intravenous and oral dose, given on separate occasions. This 
is represented as: 
Bioavailability = AUC (oral) X 100. (8) 
AUC (IV) 
The relevant pharmacokinetic principles (Curry, 1980; Gibaldi and Perrier, 1982; Birkett, 
1988a; 1988b; 1988c; Benet et al., 1991) were used in the work described in Chapters 10 
and 11. 
71 
i CHAPTER 5; THE PRESENT INVESTIGATION. 
I 
There is a growing trend towards abuse of cough and cold preparations, especially among 
I 
teenagers in Hong Kong (Chan et al., 1990; CRDA, 1991a). The most popularly abused 
I 
: mixtures contain ephedrine and codeine, notably Phensedyl™ (codeine 9mg, ephedrine 7.2 
'I 
f mg and promethazine 3.2 mg/5ml) (M&B). Reports from elsewhere show that there is 
V 
higher non-medical use of codeine compounds (i.e. codeine in combination with other 
• drugs) than of codeine alone. This is accompanied by higher mortality and morbidity from 
I 
codeine compounds relative to codeine per se (Tennant, 1983; Kreek, 1987). 
A possible explanation for these observations could be the easier availability of codeine 
compounds, since in most countries they are available over the counter. But in view of 
the well known low addictive and abuse liability of codeine the possibility that its activity 
j may be modified in the presence of other agents needs to be borne in mind too. 
In spite of the widespread use of codeine in combination with other agents, especially 
sympathomimetics, there have apparently been no studies addressed to their possible 
interactions. Ephedrine and phenylpropanolamine are widely used and the chances that 
either agent could be taken by someone on opioids, e.g. opioid abuser with a cold or 
cough, are high. Nevertheless, there is a paucity of information on interactions between 
ephedrine or phenylpropanolamine and any other opioids. 
It was, therefore, felt worthwhile to investigate the possible interactions between these 
commonly used sympathomimetics (ephedrine and phenylpropanolamine) and the opioids 
codeine and morphine. Broadly speaking, the study aimed to establish whether or not any 
modification of opioid action occurs in combination with the sympathomimetics. 
Codeine and morphine were used each in combination with either ephedrine or 
phenylpropanolamine. The chemical structures of these drugs are shown in Figure 5.1. 
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Morphine is the prototype of the opioids and is a standard against which others are 
compared (see beginning of Chapter 3). It was proposed to study: 
A. The effect of ephedrine and phenylpropanolamine on the antinociceptive activities of 
morphine and codeine. 
B. The effect of ephedrine and phenylpropanolamine on opioid dependence and tolerance. 
C. The role of adrenoceptors in the modification of opioid activity by the 
sympathomimetics. 
D. The effect of ephedrine and phenylpropanolamine on the lethal toxicity of morphine 
and codeine. 
E. The effect of ephedrine and phenylpropanolamine on plasma and brain disposition of 
morphine and codeine after single dose treatment. 
F. The effect of ephedrine and phenylpropanolamine on the 24 h urinary elimination of 
codeine and morphine after single dose treatment. 
G. The effect of ephedrine and phenylpropanolamine on the disposition of morphine and 
codeine at "steady state". 
GENERAL ASPECTS OF THE METHODOLOGY. 
Drugs: Morphine sulphate and codeine phosphate (Macfarlan Smith Ltd., Edinburgh, 
UK), phenylpropanolamine hydrochloride (Sigma, St. Louis, MO, USA) and ephedrine 
hydrochloride (May and Baker, Essex, UK) were used throughout the investigation. Drugs 
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FIGURE 5 . 1 . CHEMICAL STRUCTURES OF CODEINE, MORPHINE, 
EPHEDRINE AND PHENYLPROPANOLAMINE. 
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i , 
I concentrations that the requisite doses were given in a volume of 10 ml kg 
subcutaneously (SC) or intraperitoneally (IP) as applicable. All doses refer to the weight 
I of the salts used. 
I 
f Ephedrine and phenylpropanolamine were administered in doses of 5, 10 or 20 mg kg 
IP, 10 min before a subcutaneous dose of the relevant opioid. The sympathomimetic 
} 
dosage was based on that previously used by Dewey et al. (1970). A lower dose level of 
* 2.5 mg kg-i consistently showed no effect. Preliminary studies showed no difference when 
the pretreatment was given 10 20 or 30 min earlier, the 10 min interval was subsequently 
used for convenience. Other drugs are mentioned under the relevant chapters. 
Animals: The mouse model was used. Male ICR mice, 4 - 5 weeks old, weighing 30 - 35 
g were used for all the experiments/Animals were from the University Animal House 
where they were kept in air-conditioned rooms with temperature at 20 2°C and 
humidity at 70%. They were kept in cages of 20 in a mouse battery, with free access to 
standard laboratory diet and tap water. A 12 h light/dark cycle was maintained with light 
.i. 
j from 6.00 am to 6.00 pm. Each mouse was used only once. 
Male mice were preferred due to the often-unreliable sensitivity changes in female mice 
(related to the short oestrogen cycle) which could complicate the interpretation of results. 
The age and weight ranges were kept within such narrow limits in order to minimize the 
influence of age- or weight-related response changes. 
i 
I 
I The presentation: Every attempt has been made to present the results in chapters that are 
complete in themselves. For this reason, most aspects of the methodology have been 
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PHAPTER 6z EFFECTS OF EPHKDRTNE AND PHENYLPROPANOT.AMINE ON 
THE ANTTNOCICEPTTVE ACTIVTTTES OF MORPHINE AND CODEINE 
6.1. INTRODUCTION 
The most important clinical use of morphine and codeine is for pain relief. Consequently, 
many studies have been directed towards the elucidation of the mechanisms of pain and 
analgesia, with the possible development of agents devoid of the drawbacks of tolerance 
and dependence. To date, however, opioids remain the mainstay of pain management 
(Chan et al., 1976; Chan and Edwards, 1978; Chan et al., 1985; Zimmerman et al., 
1985; Cramond, 1991; Famell, 1991). 
In the laboratory animal models of pain it is not possible to test for analgesia in toto as 
the animals cannot tell the investigator whether or not they feel pain. Available 
methodologies, therefore, test for modification of animal responses to nociceptive stimuli. 
The essence of these tests is that untreated animals respond to noxious/nociceptive stimuli 
in a certain way, which is modified in the presence of an analgesic or antinociceptive 
agent. The difference between the treated and untreated animals should be indicative of 
the antinociceptive activity of such an agent. 
Adrenergic mechanisms have been implicated in the mediation of various opioid actions, 
including analgesia, as already alluded to. In general, lowering the central adrenergic tone 
leads to attenuation of, while elevating the central adrenergic tone enhances, opioid 
antinociception (Fennessy and Lee, 1970; vide supra). Dewey et al. (1970), however, 
reported that ephedrine, 10 mg kg had no effect on morphine antinociception in mice 
using the tail flick and phenylquinone tests. There are apparently no other reports on the 
interactions between ephedrine and opioids. Similarly, there is a paucity of information 
on interactions between opioids and phenylpropanolamine. 





I ephedrine and phenylpropanolamine in combination with opioids — as substances of abuse 
I (Chan et al, 1990; CRDA, 1990; SCMP, 1991) the possible influence of ephedrine and 
i 
I phenylpropanolamine on the antinociceptive activities of morphine and codeine was 
addressed in this study. As a starting point, this had some inherent advantages. Morphine 
I and codeine are basically jLi-opioid receptor agonists. The euphoriant effects of opioids, 
which are critical in determining the abuse liability thereof, are also largely attributable 
to opioid receptor activity. Any modification of antinociceptive activity of these opioids 
by ephedrine or phenylpropanolamine could be indicative of possible changes in mood-
altering effects. Furthermore, indices of antinociception can be fairly well-standardized 
and, therefore, objectively interpreted. 
.1 
I 
\ Ephedrine and phenylpropanolamine are known to have central nervous system effects 
qualitatively similar to, though quantitatively less than, amphetamine (Dietz et al., 1985). 
Amphetamine, cocaine and other central nervous system stimulants are known to 
potentiate the analgesic and euphoriant effects of morphine. All these considerations were 
taken into account and formed a basis for this investigation. 
I f 
6.2. METHODS 
6.2.1 Antinociceptive assays 
i Pain has been defined by the International Association for the Study of Pain (AISP) as an 
j. unpleasant sensory and emotional experience associated with actual or potential tissue 
i: 
•i 
I damage, or described in such terms (Tempest, 1990; Farnell, 1991). As already stated, 
laboratory animals are unable to tell us whether or not they are feeling pain. Therefore, 
i I 
measures of pain and their response to supposedly painful stimuli can only be indirect and 
operationally defined. Nevertheless, bearing in mind such limitations, nociception and pain 
may be used interchangeably, as may antinociception and analgesia (Millan, 1990). 
Several nociceptive stimuli are used for antinociceptive screening. These are commonly 




I • . 
I The abdominal constriction test relies on a chemical stimulus. The noxious (pain-
I 
I • . 
i, producing) substance is injected into the peritoneum leading to a characteristic writhing 
response. This is usually after administration of the analgesic agent (Blumberg et al., 
I 1965). Bradykinin, acetylcholine bromide, phenylquinone or acetic acid may be used as 
i the nociceptive agent. Bentley et al. (1981) described a modification to this procedure 
i 
i whereby the analgesic is introduced intraperitoneally during the peak intensity of 
I 
abdominal constriction. When acetylcholine is the nociceptive agent in the Bentley 
modification, the analgesic is mixed with acetylcholine prior to administration (Bentley 
et al, 1981 1983). The abdominal constriction test is a very sensitive assay,especially as 
modified by Bentley et al (1981) easy to carry out and quite fast (Collier et al, 1968). It 
is, however, non-specific and can be depressed by a variety of agents acting at different 
sites (Okun et al., 1963; Henderson and Forsath, 1959). The mechanisms involved in the 
abdominal constriction test are apparently complex and may be mediated at several levels, 
including local action on peritoneal receptors (Bentley et al, 1977; 1981; 1983). It is 
usually not possible to screen the animals prior to the test. 
i . 
I There are two well established variations of mechanical stimuli-based assays. Pain may 
I be produced through tissue deformation by application of pressure, usually to the tail of 
j 
j the test animal. The root of the tail is gripped with artery forceps or clip until a response 
I is observed (Haffner, 1929). Untreated animals attempt to dislodge the clip, or bite at it 
or squeak. There may be a difference between .the struggle response and vocalization. 
There are three components of the response: a motor response which may be spinally-
I 
j mediated, vocalization mediated in the medulla oblongata and vocalization after-discharge 
mediated by structures involved in the emotional aspects of pain reaction the 
hypothalamus, thalamus and rhinencephalon, for instance. Treatment with analgesic agents 





r. intensity of the painful stimulation is neither quantified nor adequately controlled. That 
coupled with the complex nature of the response renders the method unfavourable. 
i 4 • 
: In the inflamed paw test (Randall and Selitto, 1957), a hypertonic solution, e.g. sodium 
s 
^ carrageenin (Carrano et al., 1975), is injected into the hind paw of the test animal. After 
ft . 
some time (usually about 45 min) the animal foot is placed between two plastic-grooved 
I discs which are compressed by air pressure. Pressure is gradually increased until an end 
I 
I point at which vocalization or biting of the apparatus is observed. This pressure is 
recorded via a transducer on a calibrated recorder. Analgesic treatment increases the 
tolerable pressure. Ferreira et al. (1978) described a modification to this assay whereby 
constant pressure is applied to the inflammed foot, latency of response is then recorded. 
j I j 
Electrical stimulation is also used to produce pain. It is generally used in larger animals 
as, for instance, in the tooth pulp test in cats or rabbits. A time lag is required between 
implantation of the leads and the test. While this is an easy stimulus to apply, it is the 
most difficult to control (Beecher, 1957). It is quite laborious and less favourable. 
I I 
t 
i Behavioral methods of antinociceptive testing rely on nociceptive stimuli that can be 
graded from sub-threshold to a level which becomes aversive. The test animal is able to 
reduce the stimulus intensity to a non-aversive level by an appropriate behavioral 
response, such as pressing a lever. The intensity is then gradually increased until the 
threshold is reached once more, and the cycle is then repeated (Wong, 1976). Analgesics 
make the threshold levels higher. 
The use of thermal stimuli to induce pain has been common for some time now. There 
are two major thermal antinociceptive tests. The hot-plate test (Woolfe and MacDonald, 
1944) relies on a thermal stimulus to the foot. The test animal is placed on a hot plate 
maintained at a constant temperature. The time taken for the animal to lick its hind paw 
80 
is regarded as the nociceptive response since most animals usually lick their front paws. 
After treatment with an analgesic agent the latency between placement on the hot plate and 
licking the paw is increased. This response is mainly mediated supraspinally and is not 
specific for opioids. Its sensitivity is fairly low (Bentley et al., 1983). 
I 
I 
I The tail-flick method (D'Armour and Smith, 1941) relies on the application of radiant heat 
I onto the tail tip of the test animal. In essence, untreated animals flick/withdraw the tail 
I 
I after a short time (usually 5 s) and treatment with antinociceptive agents prolongs this tail-
flick latency. A schematic diagram of the tail-flick test apparatus is shown in Figure 6.1. 
A direct current battery is placed in series with alternating current mains. The mains 
charge the battery which in turn supplies the lamp. Light rays from the lamp are 
•j condensed by a converging lens and focused onto a platform at a spot corresponding to 
,| the mouse (or rat) tail tip. The animal is placed in a holder with adjustable slits, and the 
tail secured through a grove which loosely holds it in place. The tail tip occludes a 
photocell below the platform. When the light is turned on, a timer is automatically 
activated. When the animal flicks its tail the light focuses onto the photocell which 
I automatically breaks the circuit, cuts off the light and stops the timer. The time is noted 
as the tail-flick latency. The rheostat enables the light intensity to be adjusted to the 
desirable levels, should this be called for. Prior to treatment the animals can be screened 
to exclude those that do not respond within a certain time, the occurrence of false 
positives can thus be minimized. The tail flick test is highly specific for opioids. It is a 
spinally mediated reflex (Harris et al, 1969) and gives a good correlation between 
experimentally measured antinociceptive activity and clinically observed relative potencies 
of analgesics (Harris et al., 1969; Szekely, 1982). A modification of the tail flick method 
is the tail-emersion test. A water bath, maintained at constant temperature, is used as the 
noxious stimulus. The temperature can be regulated and there need not be any permanent 
tissue damage which often occurs in the radiant heat method. As for the latter, change in 
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FIG. 6.-1 SCHEMATIC DIAGRAM OF THE TAIL FLICK APPARATUS 
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1 
I In this investigation: the tail-flick method of D'Armour and Smith (1941) was used. 
\ Modifications were made such that a screening cut-off time of 5 s was used, animals 
: showing no tail withdrawal reaction within 5 s were excluded form the study, to avoid 
the effects of tissue damage. During the test, 10 s was the cut-off time taken to correspond 
.fft i 
\ to 100% analgesia, beyond 10 s tissue damage abolished any further reaction. Saline 
I 
treatment was repeatedly shown to have no effect on the base line tail flick reaction time, 
I 
nevertheless saline controls were used for all experiments taking into account the 
I possibility of day to day variations in antinociceptive responses. To minimize the effects 
I 
of diumal variations in the responses, all experiments were done between 9.00 am and 
12.30 pm. After screening, the animals were randomly assigned to the various test groups. 
Percentage analgesia per group was calculated as: 
Test group mean - saline control mean X 100 (%) 
10 - saline control mean 
6.2.2 Drugs: Ephedrine and phenylpropanolamine were administered IP 10 min before the 
j 
1 opioid (SC) throughout the experiments described (see pg 75). 
6.2.3 Statistical data analysis 
Data from single dose experiments were analyzed and compared by means of the unpaired 
(2-tailed) Student's r-test. The level of significance was P< 0.05. Dose-response curves, 
ED50 values and their 95% confidence limits were calculated using linear regression 
analysis. The curves were tested for parallelism using the parallel line assay method 
(Colquhuon, 1971). The ED50 value of morphine or codeine, after various pretreatments, 
was considered significantly different from the control value if it fell outside the 95% 
confidence limits of the latter, and also if the control ED50 lay outside the 95 % confidence 
limits of the experimental ED50. Three logarithmically spaced (x 2) dose levels, and at 






6.3.1. Determination of the test times for morphine and codeine 
:: Preliminary tests were carried out to establish the time response profile of morphine and 
codeine after subcutaneous administration. Two dose levels of each drug were used viz: 
I 
I 5 mg kg-i and 8 mg kg i for morphine, and 40 mg kg] and 80 mg kg i for codeine. 
I 
Sample size for each group was 15 animals. Tail flick tests were carried out at different 
* times. The results are shown in Figures 6.2 (morphine) and 6.3 (codeine). The peak 
I antinociceptive effects of morphine occurred at 30 min (Figure 6.2) while for codeine this 
•f J 
was at 15 min (Fig 6.3). These respective times were adopted for all subsequent studies. 
6.3.2. Effects of IP ephedrine and phenylpropanolamine on the tail-flick response 
j Ephedrine and phenylpropanolamine (5, 10 and 20 mg kg"^  ) were administered alone to 
determine whether they affected the tail-flick reaction time on their own. The results are 
shown in Table 6.1. The mean response times of mice injected with the sympathomimetics 
were not significantly different from those of the saline controls. At these dose levels, 
ephedrine and phenylpropanolamine did not affect the base-line reaction time. 
} i 
6.3.3. Effects of IP ephedrine and phenylpropanolamine on the antinociceptive activities 
of SC morphine and codeine 
The effects of a single dose of ephedrine and phenylpropanolamine (10 mg kg-\ IP) on 
the antinociceptive activity of a single dose of morphine (5 mg kg SC) and codeine (60 
mg kg-\ SC) are shown in Table 6.2. Ephedrine and phenylpropanolamine significantly 
potentiated the antinociceptive effects of the opioids. The doses of morphine and codeine 
were approximate to the ED50 values of the respective drugs (vide infra). The peak effects 
of morphine and codeine still occurred at 30 min and 15 min, respectively. 
5 The effects of varying doses of ephedrine and phenylpropanolamine on the antinociceptive 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































I in Table 6.3. Ephedrine dose-dependently potentiated the antinociceptive activity of 
I morphine (5 mg kg i). In the case of phenylpropanolamine with morphine, the dose-
response relationship was not as obvious as for ephedrine with morphine (Table 6.3a). 
Codeine (60 mg kg ” antinociception, on the other hand, was enhanced by both ephedrine 
and phenylpropanolamine in a dose dependent manner (Table 6.3b). 
I Varying dose levels of sympathomimetics were studied against varying opioid levels to 
i . 
give the effects of ephedrine and phenylpropanolamine on the ED50 values of morphine 
and codeine. The results are presented in Table 6.4. The ED50 of morphine after 
subcutaneous administration was determined to be 4.74 (4.58-4.90) mg kg Pretreatment 
with ephedrine or phenylpropanolamine caused a parallel shift in the dose-response curves 
of morphine to the left. Ephedrine dose-dependently enhanced morphine antinociception, 
with the ED50 values in the (ephedrine) pretreated groups being significantly different from 
the saline pretreated controls. Phenylpropanolamine also enhanced morphine 
antinociception, though the dose-response relationship was not as clear-cut as for 
j 
ephedrine. The ED50 of morphine in animals pretreated with phenylpropanolamine 10 mg 
kg-i was not different from that of those pretreated with phenylpropanolamine 20 mg kg i 
(Table 6.4a), but was higher than that in the phenylpropanolamine 5 mg kg'K 
Codeine ED5 was determined to be 56.43 (54.35-58.59) mg kg i. Both ephedrine and 
phenylpropanolamine caused a parallel shift in the dose-response curve(s) of codeine. 
Ephedrine dose-dependently potentiated codeine antinociception, evident from significant 
decreases in the ED50 values in the groups pretreated with ephedrine. Though pretreatment 
with phenylpropanolamine at dose levels 5 and 10 mg kg ! significantly enhanced codeine 
antinociception, there was no difference between the ED50 values of these two groups. 
When the pretreatment dose of phenylpropanolamine was increased to 20 mg kg'\ there 
was further enhancement of codeine antinociceptive activity, shown by a further decrease 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































I 6.4. DISCUSSION 
..i 
J The experiments described show that IP ephedrine and phenylpropanolamine, at the doses 
^ studied — 5, 10, 20 mg kg"^—possess no apparent antinociceptive activity as measured 
1 
I by the tail flick test. However, these two drugs potentiate the antinociceptive activities of 
I 
I both codeine and morphine. Such findings are at variance with those reported by Dewey 
et al. (1970) who only used one dose level of ephedrine, but are in line with the general 
t observations based on other sympathomimetics as reviewed by Szekely (1982). 
I . 
K 
Ephedrine and phenylpropanolamine both have a direct action on adrenoceptors, as well 
as an indirect action through the release of noradrenaline (Hoffman and Lefkowitz, 1991). 
Administration of morphine and other opioids has been shown to increase both plasma and 
brain levels of catecholamines (Rethy et al., 1971; Smith et al., 1972; Van Loon et al., 
1981; Appel and Van Loon, 1986). In addition, opioids have been demonstrated to 
increase the central sympathetic outflow to the adrenal medulla and peripheral sympathetic 
nerve endings (Van Loon et al., 1981; Pfeiffer et al., 1983; Feldberg and Wei, 1986). It 
has been previously suggested that increasing the central adrenergic tone potentiates, 
whereas depletion of the catecholamines attenuates, morphine analgesia (Dewey et al., 
i 
j 1970; Fennessy and Lee, 1970). The balance of possibilities in the interactions reported 
above are in favour of a likely increase in central adrenergic tone. This could be one way 
in which ephedrine and phenylpropanolamine potentiate morphine and codeine 
antinociception. 
On the other hand, in vitro studies show that administration of opioid agonists results in 
an inhibition of sympathetic transmission in various tissues (Ledda and Mantelli, 1982; 
Fuder and Rothacher, 1984). Furthermore, there has been demonstrated a co-existence of 
aj-adrenoceptors and opioid recognition sites on the same neurones. These two receptor 
types appear to occur closely together and seem to activate common transmission 




I Aghajanian and Wang, 1986; Jackischi et al., 1986). All these studies demonstrate 
1 . . 
I interaction(s) between noradrenergic mechanisms and opioids. The findings reported in 
1 
I this chapter suggest that opioid antinociception could be linked to the release of 
I ‘ “ 
f catecholamines and/or activation of adrenoceptors, 
i ‘ 
! 
i In all cases the opioid and opioid + sympathomimetic log dose-response curves did not 
I 
deviate significantly from parallelism. Despite various pretreatments, the peak 
I . 
antinociceptive effects of morphine and codeine still occurred at 30 min and 15 min 
respectively; indicating that the observed enhancement of opioid activity is unlikely to be 
greatly due to pharmacokinetic changes. 
The low addictive and abuse potential of codeine vis-a-vis morphine is a well-documented 
fact, so much so that in most countries codeine-containing preparations are freely available 
over the counter. Despite the widespread use of codeine (and other opioids) in 
combination with sympathomimetic agents, investigation of their interactions has received 
I 
relatively little attention. The high abuse rate of cough and cold mixtures containing, inter 
I alia, codeine and ephedrine (Chan et al, 1990) has already been alluded to. The finding 
that the acute antinociceptive action of morphine and codeine are potentiated by the 
sympathomimetics may be a clue to the high abuse rate of these mixtures. It is 
conceivable that the mixtures are more reinforcing than codeine alone and, consequently, 
more liable to be abused after all both effects are largely attributed to /x-opioid receptor 
activation. The positive side of such findings is, of course, the possibility that opioids and 
sympathomimetics could be used together in clinical practice to produce analgesia with 
minimal activation of either opioid receptors or adrenergic mechanisms, using smaller 
doses. This could potentially result in fewer toxic effects of the opioids, for instance 
f 
I respiratory depression and addiction, and of the sympathomimetics for instance 
i 
cardiovascular activation (Monasky et al., 1990). On such a basis, epidural clonidine has 
been used successfully in combination with opioids in the management of cancer pain 
93 




I These results presented a number of questions. One was whether the effects of these 
i . 
t sympathomimetics occur only in the acute as opposed to the chronic setting. If the latter 
I were to be the case, it would be of interest to establish the effects of these 
I 
I sympathomimetics on tolerance and/or dependence. Since ephedrine and 
I phenylpropanolamine are non-specific in their action, the adrenoceptors involved in their 
I . 
potentiation of morphine and codeine antinociception are worthwhile investigating. 
Toxicity, including deaths, from cough mixtures has been cited in anecdotal media reports 
(South China Morning Post, February 28th, 1991). The possible influence of the 
sympathomimetics on opioid toxicity would also need to be addressed. The possible effect 
of ephedrine and phenylpropanolamine on the disposition of morphine and codeine as a 
likely explanation for the modification of opioid activity similarly requires investigation. 














I ‘ / 
CHAPTER 7; EFFECTS OF EPHEDRINE AND PHENYLPROPANOLAMINE ON 
I OPIOID TOLERANCE AND DEPENDENCE 
I 7.1. INTRODUCTION 
I Chronic administration of opioids eventually leads to the development of tolerance and 
I physical dependence. The processes that lead to these phenomena probably begin with the 
I first dose (Heishman et al., 1989) and are subject to influence by a variety of factors, 
I including adrenergic mechanisms as reviewed" above. 
In the foregoing chapter it has been shown that ephedrine and phenylpropanolamine 
enhance the acute antinociceptive effects of morphine and codeine. It can be speculated 
on that basis that the reinforcing ability of the sympathomimetic-opioid mixture could be 
greater than for a single agent alone and, therefore, more liable to be abused. The long 
term effects of the drugs abused are equally important. It was thus pertinent that the 
effects of ephedrine and phenylpropanolamine on morphine and codeine 
tolerance/dependence be investigated. 
I \ 
Opioid tolerance and physical dependence is viewed in terms of two distinct phases, the 
induction and withdrawal phases (Collier et al., 1972). The induction phase is the period 
of drug administration whereas the withdrawal phase begins with the termination of drug 
administration or administration of an antagonist. It has been suggested that a 
neurotransmitter may play quite different or even opposite roles in these two phases. Both 
OL- and J3-adrenergic mechanisms may have an effect on the different phases of opioid 
tolerance/dependence (vide supra). 
7.2. METHODS 
7.2.1. Animals, drugs and antinociceptive assay as in Chapter 6. In addition, naloxone 
hydrochloride (Dupont) was used. The dose regimens are detailed below. 
95 
I 7.2.2. Induction of opioid tolerance and dependence 
I There are a number of methods for the induction of opioid tolerance and dependence. In 
^ essence, the drug is given for a (long) period of time. This may be through repeated 
I 
injections in increasing doses over a number of days, a single sustained-release injection 
or pellet implantation. 
I 
I In the sustained-release injection method, a "depot" preparation is made by suspending the 
drug in an emulsifying agent and light liquid paraffin. Dependence may be induced in 
animals by a single injection, with observable withdrawal signs 24 hours later (Collier et 
al, 1972). Animals so-treated, however, tend to look very sick and high mortality rates 
are not uncommon. 
Pellet implantation was introduced by Maggiolo and Huidobro (1961) with subsequent 
modifications by several workers (Way et al., 1969; Gibson and Tingstad, 1970). 
Basically, the pellet consists of morphine base (75 mg), microcrystalline cellulose (75 
i 
mg), fused silicon dioxide (0.75 mg) and calcium stearate (1.5 mg). The pellet is 
implanted usually into the dorsal aspect of the animal and removed after a time, 
determined suitable for the particular study, and the animal tested for dependence and 
tolerance. This method has gained popularity with many workers. 
Repeated injections may be tedious and withdrawal symptoms can occur between the doses 
(Buckett, 1964). Nonetheless, in this study this was the method used. It was preferred as 
it enabled the administration of known, well-controlled doses of sympathomimetics and 
opioids in a systematic manner throughout the investigation. This method of repeated, 
intermittent administration also closely resembles the drug (self-) administration in human 
drug abusers. Whereas no simple dose-response relationship exists for the production of 
tolerance and physical dependence (Laska and Fennessy, 1976), the degree of 
tolerance/dependence is dependent on the dose and time of receptor exposure to the drug 
96 
I (Stevens and Yaksh, 1989). The repeated injections offered the possibility of limiting 
I response variations that could be attributed to differences in per capita drug amounts, 
I . 
I which can occur with sustained-release or pellet implantation techniques. Morphine 
•f 
tolerance/dependence was induced using a three-day graded dose regime of twice daily 
injections (Table 7.1), while for codeine tolerance/dependence a four-day course was 
I 
I adopted (Table 7.2). 
I 
The animals were assessed for both tolerance and physical dependence, as described by 
Way et al. (1969) on day four and five for morphine and codeine, respectively. 
To study the effects of the sympathomimetics on the induction of opioid 
tolerance/dependence, a fixed dose (5, 10 or 20 mg kg-1) of ephedrine or 
phenylpropanolamine was administered intraperitoneally 10 minutes before the appropriate 
(subcutaneous) dose of morphine or codeine throughout the induction period. 
5 j 
For control purposes, a number of experiments were carried out in which only ephedrine 
j 
or phenylpropanolamine was administered for three days, to investigate the effects on 
morphine activity, or four days for the effects on codeine activity. These animals were 
then assessed for morphine and codeine, respectively, dependence and tolerance. 
7.2.3. Assessment of opioid tolerance and physical dependence 
The animals were assessed for both tolerance and physical dependence (Way et al. 1969). 
Tolerance is a phenomenon made manifest by an escalation of the dose required to 
produce a previously obtained effect or by the decrement of the effect produced by a given 
dose of a drug. Tolerance does not develop to all effects and in any case not at the same 
rate. In this investigation, tolerance to the antinociceptive effects of morphine and codeine 
was assessed. The tail flick method (D'Armour and Smith, 1941) was used, as described 




Table 7.1 Induction of morphine tolerance and dependence (All doses administered 
subcutaneously) 
D A Y 
1 2 3 4 
AM 30 mg kg-i 60 mg kg"^  120 mg kg ! 
ASSESSMENT 
PM 45 mg kg-i 90 mg kg i 120 mg kg-i 
Table 7.2 Induction of codeine tolerance and dependence (All doses administered 
subcutaneously) 
i 




1 2 3 4 5 
AM 75 mg kg-i 100 mg kg i 120 mg kg i 150 mg kg i 
Assessment 





and an increase in the ED^q values (Kalant et al., 1971; Fernandes et al., 1977). The 
tolerance index was calculated as the ratio of ED^q in tolerant mice to ED5Q in naive 
mice (Way et al., 1969; Martin and Sloan, 1977). 
Physical dependence in mice consists of many signs including teeth chattering, 
I piloerection, sweating, diarrhoea, ejaculation, wet dog shakes, loss of body weight and 
an irresistible urge to jump. Obviously, not all these features are easy to objectively assess 
or quantify. In this investigation, physical dependence was assessed on the basis of loss 
of body weight, wet dog shakes and jumping. The withdrawal syndrome was precipitated 
by a naloxone challenge (Wei et al, 1973; Kameii and Ueki, 1974). 
Weight loss occurs in dependent mice in the induction and withdrawal phases. In the 
induction phase, this may be due to reduced food intake as a result of general depression 
and reduced motivation, decreased intestinal motility and secretions, daily withdrawal 
j syndrome preceding the next injection or adrenal exhaustion due to the repeated stressor 
effect of multiple opioid injections (Szekely, 1982). This loss of weight is further 
accentuated by naloxone challenge. The latter could be due to loss of body fluids, e.g. 
through diarrhoea and sweating, and sympathetic hyperactivity. 
The wet dog shake is a reflex activity, akin to shivering in man, aimed at conserving heat. 
Jumping responses which are observed in mice following a naloxone challenge manifest 
as an irresistible urge to jump off a platform and show a good correlation with the 
physical dependence capacity of these agents in man (Saelens et al., 1971). For that 
reason, Saelens et al. (1971) suggested that this sign could suffice as a screening test to 
estimate the physical dependence capacity of unknown compounds. The withdrawal 
syndrome is time-dependent, and a function of the doses of both agonists and antagonists 
I 
(Jacob et al., 1974; Kosersky et al., 1974). 
99 
I 
The time schedules for assessment of codeine and morphine tolerance/physical dependence 
are shown in Figure 7.3. The mice were screened to exclude those that were not 
responsive to the tail-flick test within 5 seconds. Codeine or morphine was then given at 
0 min and the antinociceptive tests carried out at the respective times for peak effects of 
codeine or morphine activity. These remained unchanged at 15 min and 30 min, 
respectively, after chronic treatment with sympathomimetics or induction of 
tolerance/dependence. Naloxone was administered intraperitoneally 30 min after the 
antinociceptive assay, i.e. 45 min after acute codeine and 1 h after acute morphine. 
Preliminary studies showed that the acute opioid dose did not affect the test for 
dependence, in agreement with Way et al. (1969). The animals were labelled and weighed 
shortly before naloxone injection and then re-weighed 3 h later. Following the 
administration of naloxone the mice were observed for 15 min on an elevated platform (42 
cm long, 28 cm wide and 60 cm high) for the occurrence of wet dog shakes and 
withdrawal jumping. They were observed in groups of 7 or 8 and thereafter kept in well 
ventilated cages without access to food or water for the remaining part of the three hours. 
To assess the intensity of wet dog shakes, a cut-off point of 5 wet dog shakes per animal 
in 15 min was used, preliminary observations had indicated that those mice having 5 or 
more wet dog shakes tended to have them incessantly. The intensity of the wet dog shakes 
was calculated as: 
Group mean X 100 (%) 
5 
The percentage weight loss per animal was obtained from the equation: 
Original weight - weight 3 h later X 100 (%) 
Original weight 


















































































































































































































































































































































































































































































































































































I considered positive for this sign. The mice were returned to the platform after each jump 
and a cut-off point of 3 jumps per animal in 15 min was adopted as those that had 3 or 
I more jumps would hardly stay on the platform. The intensity of jumping was calculated 
as: 
Group mean X 100 (%) 
3 
In the final analysis, the overall magnitude of the withdrawal syndrome was considered 
on the basis of all three parameters, since the occurrence of one sign may mask that of 
others (Okamoto et al, 1976). 
7.2.4. Effects of acute (IP sympathomimetics on the expression of opioid tolerance and 
physical dependence 
Only mice that received opioids but no sympathomimetics during the induction phase were 
used for this purpose. An acute dose of ephedrine or phenylpropanolamine was given 
i intraperitoneally 10 min before the acute opioid dose (SC) during the assessment for 
tolerance and dependence, as elaborated above. A few groups were given the 
sympathomimetic 10 min (SC) before naloxone challenge (IP), to offset the effects of the 
time lag between sympathomimetic administration and naloxone challenge. 
7.2.5. Statistical data analysis 
Dose response curves, ED50 values and their 95 % confidence limits were calculated using 
linear regression, as in the previous chapter. Data on weight loss and the intensity wet 
dog shakes and jumping were compared using the unpaired Student's t-test. The level of 
significance was P < 0.05. 





7 Effects of chronic ephedrine or phenylpropanolamine pretre^tment on the 
I antinociceptive activities of morphine and codeine 
j Following chronic pretreatment with the sympathomimetics alone the antinociceptive 
effects of morphine and codeine were significantly attenuated (Table 7.3). Pretreatment 
I with saline for 3 or 4 days, on the other hand, did not affect the antinociceptive effects 
j of morphine or codeine, respectively (Table 7.3). No withdrawal signs were observed in 
I this group of mice on naloxone challenge. 
7 Rffects of cbrnnic ephedrine. and phenvlprnpanolamine on the induction of opioid 
tolerance: A three-day graded dose course of morphine led to the development of 
tolerance with a tolerance index of 4.7 (Table 7.4a). Concurrent administration of 
ephedrine or phenylpropanolamine (5, 10 mg kg ^ during the induction phase resulted 
in significantly higher levels of tolerance, while concurrent administration of saline did 
j not affect tolerance development (Table 7.4a). Concurrent administration of ephedrine or 
phenylpropanolamine 20 mg kg"^  over the induction period was invariably fatal. 
A four-day graded dose course of codeine led to the development of codeine tolerance 
with a tolerance index of 2.8 (Table 7.4b). Concurrent administration of saline did not 
affect the development of codeine tolerance. Addition of ephedrine 5 mg kg'' over the 
induction period produced a higher level of tolerance, but this was not significantly 
different from that of the saline-codeine group. Higher ephedrine dose levels (10 20 mg 
kg-i) during the induction phase were invariably fatal. Phenylpropanolamine 5 mg kg i 
concurrently administered during the induction of codeine tolerance led to a significantly 
higher level of tolerance. Phenylpropanolamine 10 mg kg"^  had apparently no effect on the 
development of tolerance (Table 7.4b). The latter group, however, had high mortality 
rates over the four-day treatment period (Table 7.11). Concurrent administration of 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































I and phenylpropanolamine (2.5 mg kg ” which showed no effect in the acute interaction 
) studies, was tried out in preliminary studies and showed no effect on the development of 
1 
opioid tolerance/physical dependence. 
I 7.3.3. Effects of repeated (IP) doses of ephedrine and phenylpropanolamine on the 
induction of opioid dependence 
I 
The results of the effects of the sympathomimetics on the development of morphine 
I dependence are shown in Table 7.5. A three-day morphine course led to the development 
of morphine dependence evidenced by the dose-dependent occurrence of withdrawal signs 
on administration of naloxone. Concurrent administration of either sympathomimetic 
apparently had little or no effect on the development of dependence. The loss of weight 
was significantly lower at the highest naloxone dose level (10 mg kg-” in all test groups, 
relative to the corresponding control. In these cases, however, the weight loss at naloxone 
10 mg kg-i was consistently significantly higher than that of the respective saline control 
j group. Furthermore, the other withdrawal signs were essentially the same, except for the 
I ephedrine 5 mg kg i group at naloxone 5 mg kg"^  which exhibited less intense wet dog 
shakes. Preliminary experiments showed that concurrent administration of saline during 
the induction period did not affect the development of morphine dependence. 
Results of the effects of the sympathomimetics on the induction of codeine dependence are 
shown in Table 7.6. A four-day course of codeine led to the development of detectable 
dependence. When ephedrine 5 mg kg'^  was given in the induction period the subsequent 
withdrawal signs indicated less weight loss at naloxone dose levels 2.5 and 5 (mg kg'^), 
with less intense wet dog shakes at naloxone 10 mg kg i. In all cases, though, only one 
of the features was affected. With phenylpropanolamine 5 mg kg-1, the loss of weight was 
I less at naloxone dose level 2.5 mg kg'\ whereas the intensity of wet dog shakes was 
j _ 
higher in the same group. Concurrent administration of phenylpropanolamine 10 mg kg"^  


























































































































































































































































































































































































































































































































































































































































































































I less intense wet dog shakes at naloxone dose levels 5 and 10 mg kg The combination 
I of codeine with the sympathomimetics was associated with high mortality rates during the 




I Considering all the withdrawal features (Okamoto et al. 1976) the sympathomimetics did 
J not significantly affect the development of opioid dependence. 
I … 
I 7.3.4. Effects of acute ephedrine and phenylpropanolamine on the expression of opioid 
tolerance: The results of the administration of ephedrine or phenylpropanolamine 10 min 
before the acute opioid dose during the assessment for tolerance are shown in Table 7.7. 
Morphine tolerance was not significantly affected by acute pretreatment with either 
sympathomimetic at these dose levels (Table 7.7a), except at phenylpropanolamine 20 mg 
kg-i where the apparent tolerance was significantly less than for the control group. 
Acute pretreatment with phenylpropanolamine 5 mg kg"^  10 min before acute codeine in 
the assessment of codeine tolerance had no effect. At ephedrine 5 mg kg i and 10 mg kg i 
of either agent, the degree of tolerance was apparently less, being outside the 95% 
confidence limits of the control values. In these cases, however, some of the animals that 
received the higher codeine doses died within 45 min, but after assessment for tail-flick 
latency (Table 7.11). Ephedrine or phenylpropanolamine 20 mg kg i led to high mortality 
rates (>75 %) for mice that received the higher codeine doses and were subsequently 
excluded. 
7.3.5. Effects of the sympathomimetics on the expression of opioid dependence 
The effects of ephedrine and phenylpropanolamine on the expression of morphine 
dependence are shown in Table 7.8. Ephedrine or phenylpropanolamine was given 1 h 10 
min before naloxone challenge. Most of the parameters were significantly suppressed in 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Likewise, prior treatment with phenylpropanolamine tended to suppress some of the 
withdrawal features. 
The effects of ephedrine and phenylpropanolamine on the expression of codeine 
dependence are shown in Table 7.9. Ephedrine or phenylpropanolamine was administered 
I 55 min before naloxone challenge. As was the case for morphine dependence, there was 
a reduction in the intensity of the withdrawal signs in the animals that received the 
I sympathomimetics prior to naloxone challenge. 
To offset the effects that the time-lag between the administration of the sympathomimetics 
and naloxone challenge may have on the effects of the former on the expression of opioid 
dependence some groups received ephedrine or phenylpropanolamine, 10 mg kg"^  
subcutaneously, 10 min before IP naloxone injection. The results are shown in Table 7.10. 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































TABLE 7.11. MORTALITY RATES IN THE INDUCTION AND EXPRESSION 
PHASES. 
I fa In the induction period. 
I Induction regimen^ n % mortality 
— 
I {il Morphine + : 
Ephedrine 5 mg kg"^ + 72 --
Ephedrine 10 mg kg"^ + 72 4.2 
Phenylpropanolamine 5 mg kg-1 100 ~ 
Phenylpropanolamine 10 mg kg"^ 100 6.0 
(ii Codeine +: 
Ephedrine 5 mg kg"^ + 120 26.7 
Phenylpropanolamine 5 mg kg"^ 90 --
Phenylpropanolamine 10 mg kg'^ 120 35.8 
(b In the expression phase^. 
Acute pretreatment n % mortality 
Salme 120 “ 
• 
Ephedrine 5 mg kg"^ 68 17.6 
Ephedrine 10 mg kg"^ 72 63.8 
Phenylpropanolamine 5 mg kg"^ 84 -
Phenylpropanolamine 10 mg kg"^ 78 32.1 
a There was no mortality in groups that received only opioids in the induction period, 
b Only values for codeine tolerant/dependent mice are shown, there was no mortality in 
the corresponding morphine groups. 
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7.4. DISCUSSION 
I Chronic pretreatment with ephedrine or phenylpropanolamine led to the attenuation of 
morphine and codeine antinociceptive activities. The development of tolerance to the 
opioids was apparently enhanced by concurrent administration of the sympathomimetics 
during the induction phase, whereas the opioid dependence that developed was not affected 
to a large extent. On the other hand, expression of opioid tolerance was apparently not 
affected by acute pretreatment with sympathomimetics, while the withdrawal signs were 
significantly suppressed. During the course of these interactions, there was high toxicity 
of the opioid-sympathomimetic combinations (Table 7.11). 
Both opioids and adrenergic agonists exhibit dose-dependent antinociceptive activity after 
intrathecal administration (Yaksh, 1985; Yaksh and Noueihed; 1985). These 
antinociceptive effects are, however, mediated through different mechanisms (Reddy et 
al., 1980). Systemically administered clonidine, an ofj-adrenergic agonist, shows potent 
I antinociception (Kawasaki et al., 1978). Paalzow (1978) reported that rats rendered 
tolerant to clonidine by repeated subcutaneous injections showed cross-tolerance to acute 
subcutaneous morphine. It was subsequently shown (McKeamey, 1985) that tolerance to 
the behavioral effects of clonidine developed after chronic administration of morphine. It 
has been shown in the previous chapter that in naive mice ephedrine and 
I 
phenylpropanolamine had no demonstrable antinociceptive effects of their own after 
intraperitoneal administration but significantly potentiated the antinociceptive effects of an 
acute opioid dose. As presented above, chronic pretreatment with the sympathomimetics 
led to attenuation of the antinociceptive effects of morphine and codeine. After repeated 
subcutaneous opioid injections, the sympathomimetics tended to lose their potentiating 
effects on opioid analgesia. From this perspective, cross-tolerance between opioids and 
these sympathomimetics probably occurs. The interactions between ephedrine 5 and 10 
mg kg-i or phenylpropanolamine 10 mg kg i with codeine (Table 7.7b) would suggest that 
even in tolerant mice the sympathomimetics potentiate codeine antinociception. This, 
116 
however, may be due to the high toxicity of these combinations, as already mentioned, 
or it may be that the level of codeine tolerance (tolerance index 2.8, Table 7.4b) after the 
induction regimen used is still too low. Though no deaths were observed in morphine 
tolerant/dependent mice pretreated with phenylpropanolamine 20 mg kg the possibility 
of higher toxicity could account for the apparent discrepancy of the results for this group 
too (Table 7.7a). 
When the sympathomimetics were given together with morphine in the induction phase, 
the combination led to development of enhanced tolerance. Data from the codeine-
sympathomimetic combinations are complicated by the fact that there was usually high 
toxicity observed, and whereas the surviving mice looked grossly normal, this may have 
contributed to the apparent discrepancies relative to those for morphine. It is noteworthy 
that the interactions of phenylpropanolamine 5 mg kg i and codeine during the induction 
period were free of any mortality and resulted in a significantly higher level of tolerance 
(Table 7.4b). 
These results may also be looked at in terms of the possible catecholamine level changes. 
It bears repetition that depletion of central catecholamine levels leads to attenuation of 
opioid analgesia (e.g. Sigg et al., 1958; Fennesy and Lee, 1970). Repeated administration 
of ephedrine or phenylpropanolamine leads to depletion of catecholamines from the tissues 
(Hoffman and Lefkowitz, 1991). After chronic administration of the sympathomimetics 
the catecholamine levels are lowered and subsequently administered opioids produce less 
profound antinociception. Following chronic administration of opioids, which may also 
lower catecholamine levels, an acute dose of ephedrine or phenylpropanolamine may not 









on the development of opioid dependence. The development of physical dependence may 
be mediated by mechanisms different from those for tolerance (Wiister et al., 1985). In 
the acute situation, there are independent mechanisms for adrenergic and opioid 
antinociception (Reddy et al., 1980). Monasky et al, (1990) have suggested that the 
clearance of opioids may not be affected by adrenergic agents. Concomitantly 
administered ephedrine or phenylpropanolamine may not, therefore, affect the access of 
the opioids to the opioid receptors, which would explain the apparent lack of effect on the 
development of dependence. 
The expression of physical dependence, on the other hand, has a large component of 
sympathomimetic activity. Clonidine has been shown to suppress some aspects of the 
opioid withdrawal syndrome (Tseng et al., 1975; Aghajanian, 1978; Gold et al., 1980; 
Hamburg and Tallman, 1981). It is postulated that this may be partly due to its actions 
on locus coeruleus neurons, by a direct action on Qf2-adrenoceptors (Lai and Fielding, 
1983). The apparent suppression of the withdrawal signs observed when ephedrine or 
phenylpropanolamine were administered could probably be due to their direct action on 
adrenoceptors, as proposed for clonidine (Lai and Fielding, 1983). 
One recurrent observation in this investigation (of the chronic interactions) was that of 
high lethal toxicity of opioid-sympathomimetic combinations. The regimens adopted for 
the induction of morphine or codeine tolerance and physical dependence were free of any 
fatalities on their own. Similarly, ephedrine or phenylpropanolamine (5 10 and 20 mg kg" 
1) given alone twice daily over three or four days led to no death of mice. Another 
sympathomimetic agent, cocaine, is known to potentiate the toxicity of morphine in mice 
and rats (Blumberg and Ikeda, 1978) a fact that is even reflected clinically (Finkle and 
McCloskey, 1977). The possibility of higher toxicity of opioid-sympathomimetic mixtures 




CHAPTER 8; THE ROLE OF ADRENOCEPTORS IN THE POTENTIATION OF 
OPIOID ANTINOCICEPTION BY EPHEDRINE AND PHENYLPROPANOLAMINE 
8.1. INTRODUCTION 
In the last two chapters it has been shown that in the acute setting ephedrine and 
phenylpropanolamine potentiate the antinociceptive activities of both morphine and 
codeine (Chapter 6); the chronic interactions between these opioids and the 
sympathomimetics suggest that the latter enhance the development of opioid tolerance 
without affecting the development of physical dependence; whereas in the expression 
phase tolerance is not affected but the withdrawal signs are significantly suppressed 
(chapter 7). Ephedrine and phenylpropanolamine both have a direct effect on a- and B-
adrenoceptors, as well as indirect effects through release of noradrenaline (Hoffman and 
Lefkowitz, 1991). As reviewed earlier on, both a- and B-adrenergic mechanisms could 
affect various aspects of opioid activity. In order to elucidate the adrenergic mechanisms 
involved in the observed modification of opioid activity above, the effects of various 
adrenoceptor blockers was investigated. In addition, the effects of clonidine, a specific a 
adrenoceptor agonist, on opioid antinociception were also tested to corroborate the 
findings obtained with the adrenoceptor blockers. 
V . 
8.2. METHODS 
8.2.1.Drugs: Morphine, codeine, ephedrine and phenylpropanolamine as above, in 
addition clonidine hydrochloride, propranolol hydrochloride and yohimbine hydrochloride 
(Sigma CO.) phentolamine (Ciba-Geigy); and prazosin hydrochloride (Pfizer Inc.) were 
used. The drugs were dissolved in physiological saline as described earlier on. Ephedrine, 
phenylpropanolamine and clonidine were administered intraperitoneally 10 min prior to 
the subcutaneous dose of opioid. The adrenoceptor blockers were administered 
subcutaneously 10 min prior to the sympathomimetics. Where the same route of 




The doses employed were: morphine 5 mg kg"^ and codeine 60 mg kg ] , being 
approximate to the respective ED^QS; ephedrine and phenylpropanolamine 10 mg kg"^, 
previously shown to potentiate opioid antinociception; propranolol, phentolamine, 
yohimbine and prazosin 6, 2, 4 and 2 mg kg'^, respectively. The doses of the 
adrenoceptor blockers were adapted from those of other workers and are considered to 
selectively block the respective receptors (Doherty and Hancock, 1983; Wong 1984; 
1986) while for clonidine preliminary screening was done and only the dose levels that 
had no effect on the tail-flick time were subsequently used. The conditions for the tail-
flick test were as described in Chapter 6. 
8.2.2. Statistical analysis 
The data for the mean tail-flick reaction time were analyzed and compared by means of 
the unpaired Student's t-test. 
8.3. RESULTS 
8.3.1. The effects of the various adrenoceptor antagonists on opioid antinociception. 
The effects of phentolamine, a non-selective a-adrenoceptor antagonist; propranolol, a 
non-selective B-adrenoceptor antagonist; yohimbine, a selective Q;2-acirenoceptor 
antagonist; and prazosin, a selective a^-adrenoceptor antagonist, on the antinociceptive 
activities of morphine and codeine are shown in Table 8.1. None of the antagonists 
affected the tail-flick reaction time (Table 8.1a). Similarly they had no effect on the 
antinociceptive action of morphine 5 mg kg] (Table 8.1b), and codeine 60 mg k g ] 
(Table 8.1c). 
8.3.2. The effects of phentolamine and propranolol on the potentiating effects of ephedrine 
and phenylpropanolamine on opioid antinociception 
The effects of phentolamine and propranolol on the potentiation of morphine or codeine 


































































































































































































































































































































































































































































































































































































































are shown in Table 8.2. As previously established, ephedrine and phenylpropanolamine 
had no effect on the tail-flick reaction time (Table 8.2a) but significantly enhanced the 
antinociceptive activities of morphine (Table 8.2b) and codeine (Table 8.2c). Pretreatment 
with phentolamine (2 mg kg-” subcutaneously 10 min before the administration of either 
ephedrine or phenylpropanolamine had no effect on the tail-flick reaction time (Table 
8.2a) but abolished the ability of the sympathomimetics to enhance morphine 
antinociception (Table 8.2b). The same was the case with codeine as the antinociceptive 
agent (Table 8.2c). 
Propranolol (6 mg kg ” subcutaneously, on the other hand,in combination with ephedrine 
or phenylpropanolamine had no apparent effect on the tail-flick reaction time and neither 
did it affect the ability of ephedrine and phenylpropanolamine to enhance opioid 
antinociception. 
8.3.3. The effects of yohimbine and prazosin on the potentiating effects of ephedrine and 
phenylpropanolamine on opioid antinociception 
The effects of yohimbine and prazosin on the modification of the antinociceptive activities 
of morphine and codeine by the sympathomimetics were also investigated. The results are 
shown in Table 8.3. Yohimbine (4 mg k g \ subcutaneously) in combination with either 
sympathomimetic had no effect on the tail-flick reaction time (Table 8.3a) but significantly 
abolished the enhancing effect of ephedrine and phenylpropanolamine on subcutaneous 
morphine and codeine antinociception. Prazosin (2 mg kg-\ subcutaneously), on the other 
hand, had no apparent effect on the tail-flick reaction time in combination with either 
sympathomimetic (Table 8.3a) and neither did it affect the potentiation of morphine or 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8.3.4. The effects of clonidine on opioid antinociception. 
In view of the findings that a2-adrenoceptor blockade abolished the potentiating effects 
of the sympathomimetics on opioid antinociception, the effects of clonidine, an Qf2-agonist, 
were investigated. Since clonidine is well known to have potent antinociceptive actions 
(e.g. Bentley et al., 1977), it was necessary to screen several dose levels, and only those 
established to have no effects on the tail-flick reaction time were subsequently used. The 
effects of clonidine on the tail-flick time are shown in Table 8.4a. Low doses of clonidine 
(25, 50, 100 and 200 ptg kg]) had no effect on, whereas 500 /ig k g ] prolonged, the tail-
flick reaction time. While having no significant effect on the tail-flick time, clonidine 200 
fxg kg'^ was apparently sedative to some test animals; for this reason this dose was also 
excluded from tests on opioid antinociception. 
The results of pretreatment with clonidine 25, 50 and 100 fig k g ] on morphine 
antinociception are shown in Table 8.4b. Clonidine dose-dependently potentiated morphine 
antinociception. 
The effects of clonidine pretreatment on codeine antinociception are shown in Table 8.4c. 
As was the case for morphine, clonidine potentiated codeine antinociception. This was not 










































































































































































































































































































































































































































































































































































































The above results have shown that the adrenoceptor antagonists used, viz: propranolol (6 
mg kg-i), phentolamine (2 mg kg ” prazosin (2 mg kg ” and yohimbine (4 mg kg-” had 
no antinociceptive activities on their own, and also had no effect on the antinociceptive 
responses to codeine (60 mg kg- subcutaneously) or morphine (5 mg kg 
subcutaneously). Propranolol, a non-selective B-adrenoceptor antagonist, had no apparent 
effect on the potentiation of opioid antinociception by ephedrine and phenylpropanolamine. 
The non-selective a-adrenoceptor antagonist, phentolamine, on the other hand, 
significantly abolished this effect of the sympathomimetics. This pointed to the possibility 
of a- rather than B- adrenoceptor involvement. Pretreatment with prazosin, a selective a^ 
adrenoceptor antagonist, was ineffective in blocking the enhancing effects of ephedrine 
and phenylpropanolamine on opioid antinociception, whereas yohimbine, a selective a r 
adrenoceptor antagonist, was effective. These results suggest that ephedrine and 
phenylpropanolamine potentiate the antinociceptive activities of codeine and morphine 
through an action on the a2-adrenoceptors. This is further supported by the findings that 
j low doses of clonidine, devoid of antinociceptive activity on their own, clearly enhanced 
opioid antinociception. 
I . 
Many reports have underlined a role of adrenergic mechanisms in various opioid actions. 
Morphine analgesia may be modified by alterations in the central adrenergic tone (Dewey 
et al. 1970; Fennessy and Lee, 1970). Destruction of the catecholaminergic neurons using 
the neurotoxin 6-hydroxy-dopamine reportedly leads to an attenuation of morphine self-
administration (Meade and Amit, 1974) as does inhibition of catecholamine synthesis 
(Davis and Smith, 1972, 1973; Pozuelo and Kerr, 1972; Glick et al., 1973). The intestinal 
transport inhibitory effect, which is a primarily peripheral action of opioids (Manara et 
al. 1986), is antagonized by yohimbine (Wong, 1984; 1986). Opioid-induced hypothermia 
was reportedly antagonised by af2-adrenoceptor antagonists (Lawrence and Livingston, 




antinociception is consistent with earlier reports that showed no effect by a-receptor 
blockade (Hylden and Wilcox, 1983; Reddy et al, 1980), or by B-blockade (Cowan and 
Macfarlane, 1975). 
The data suggest that ephedrine and phenylpropanolamine enhance opioid antinociception 
probably by an action on a2-adrenoceptors. Alpha2-adrenoceptors are often situated 
presynaptically and their activation is part of a negative feedback mechanism inhibiting 
further transmitter release (Holting and Starke, 1986). Considerable evidence suggests that 
opioid agonist action results in an inhibition of sympathetic transmission in various 
noradrenergically innervated tissues (Ledda and Mantelli, 1982; Andrade et al., 1983; 
Fuder and Rothacher, 1984). Activation of the bulbospinal catecholamine pathways exerts 
an inhibitory influence on the dorsal and ventral horn neurons of the cord (Phillis et al., 
1968; Engberg and Marshall, 1971). Both Q;2-agonists and opioids activate the bulbospinal 
noradrenergic pathways with similar effects (Yaksh, 1985), though through different 
i mechanisms (Reddy et al., 1980; Stevens et al., 1988). Furthermore, it has been shown j 
that there is a co-existence of Qj2-adrenoceptors and opioid-recognition sites on the same 
neurons (Surprenant and North, 1985; Aghajanian and Wang, 1986; Ramme et al, 1986). 
These receptors are apparently tightly coupled and seem to activate a common transducing 
mechanism (Matsui and Yamamoto, 1984; Aghajanian and Wang, 1986; Dunlap et ai 
1987). Based on studies on locus coeruleus neurones, there are indications that a j -
adrenoceptor and pc-opioid receptors are linked to the same K+-channels and both 
activate potassium conductance (Andrade and Aghajanian, 1985; North and William, 
1985). These similarities between the actions of opioids and a2-agonists may explain the 
potentiation of the analgesic effects of codeine and morphine by ephedrine and 
phenylpropanolamine, which is reinforced by the results obtained with clonidine 
pretreatment. 




shared in common by opioids and Q:2-adrenoceptor activation. For instance, at the level 
of the dorsal horn, the excitation of wide dynamic-range neurones by high-threshold 
afferents is selectively inhibited by opioids and a2-agonists (Duggan and North, 1984; 
Fleetwood-Walker et al., 1985; Monasky et al., 1990). Studies on single spinal neurons 
indicate that (spinal) opioids depress the slope of stimulus-response curve. This is 
comparable to the reduction in the stimulus-frequency response curve observed by 
activation of the bulbospinal pathways. The concurrent activation of two independent 
spinal mechanisms, each of which diminishes the gain of the measured system, may lead 
to a summation of the net effect (Kitahata et al., 1974; Gebhart et al., 1984; Monasky et 
al., 1990). Other possible common mechanisms include the reduction in the release of 
substance P from the small primary afferents (Gintzler and Scaliasi, 1982) and reduced 
post-synaptic excitation evoked in the dorsal horn (Go and Yaksh, 1987; Fleetwood-
Walker et al., 1985). 
j Clonidine effects on morphine antinociception were clearly dose-dependent whereas this 
was not so with codeine. This apparent difference could be due to the different time scales 
for the two tests (morphine experiments - tail-flick test done 40 min after clonidine, 
codeine experiments - test done 25 min after clonidine) governed by the peak effects of 
the respective opioids. It may be that at 25 min the effects of clonidine are greater than 
at 40 min. However, both time schedules were used in the saline controls with no 
apparent discrepancy. 
Ephedrine and phenylpropanolamine have direct actions on adrenoceptors, as well as 
indirect actions through release of catecholamines (Hoffman and Lefkowitz, 1991). Their 
actions are non-selective, since they act on both a- and B- adrenoceptors. In this chapter 
i 
it has been shown that their potentiating effect on opioid antinociception in mice, using 
144 
the spinally-mediated tail-flick reaction, is most probably an a2-adrenoceptor mediated 




more credence to this assumption. This supports the postulation, in the previous chapter, 
that the suppression of withdrawal signs by ephedrine and phenylpropanolamine could be 
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CHAPTER 9: EFFECTS OF EPHEDRINE AND PHENYLPROPANOLAMINE ON 
I 
^ ACUTE LETHAL TOXICITY OF MORPHINE AND CODEINE 
9.1. INTRODUCTION. 
Thus far it has been shown that ephedrine and phenylpropanolamine enhance the 
antinociceptive activities of morphine and codeine in naive mice (Chapter 6); enhance the 
development of opioid tolerance with no significant effect on that of dependence, while 
in the expression phase tolerance is unaffected but withdrawal signs are suppressed 
(Chapter 7). These effects may be through ofj-adrenoceptor activation (Chapter 8). During 
the course of chronic interaction studies, high toxicity was observed in tolerant/dependent 
mice that received both sympathomimetics and opioid (Chapter 7). Other agents with 
sympathomimetic activity, notably amphetamine and cocaine, are known to potentiate 
opioid toxicity in various species (Blumberg and Ikeda, 1978; Kreek, 1987; Johanson and 
Fischman, 1989). In man, higher morbidity and mortality results from the use of 
compound codeine preparations than from codeine per se (Tennant, 1983; Kreek, 1987). 
There have been anecdotal reports of deaths arising from cough mixture binges among 
Hong Kong youths (South China Morning Post, 28th, Feb. 1991). In this chapter the 
•j 
j effects of ephedrine and phenylpropanolamine on the acute lethal toxicity of codeine and 
I 
'I 
j morphine in naive mice are reported. 
I 
9.2. METHODS 
9.2.1. Morphine, codeine, ephedrine and phenylpropanolamine were used as in the 
previous chapters.The sympathomimetics were administered intraperitoneally 10 min 
before the subcutaneous dose of opioid, in line with earlier treatment schedules. 
9.2.2. Assessment of the lethal toxicity of morphine and codeine. 
Ephedrine and phenylpropanolamine were administered, IP, 10 min prior to the SC opioid 
dose. After receiving morphine or codeine the mice were placed in open boxes, 45 cm 
long, 45 cm wide and 32 cm deep, lined with fine wood shavings, and observed for 90 
131 
min. To minimize the effects of crowding (Blumberg and Ikeda, 1978; Woods and 
Winger, 1987), the mice were observed in groups of five at a time. All the experiments 
were performed in the same room, at ambient temperature, between 09.30 am and 12.30 
pm. The end point was the death of mice. Preliminary tests showed that most mortality 
occurred within 45 - 90 min, consequently 90 min was adopted as a cut-off time for all 
the studies. 
9.2.3. Statistical data analysis 
Morphine LD50 values and their 95% confidence limits were calculated using linear 
regression. The LD50 after the various pretreatments were considered significantly 
different from the control values if they fell outside the 95% confidence limits of latter, 
and also if the control LD50 lay outside the 95% confidence limits of the experimental 
LD50. Three logarithmically spaced doses and at least 20 mice per dose level were used 
to determine each LD50. 
i 
Codeine mortality values were compared using the Chi-squared test. The occurrence of 
mortality in experimental groups that otherwise had no associated mortality in the controls 
was considered significant. The level of significance for the Chi-squared test was P < 
0.05. 
9.3. RESULTS 
9.3.1. The effects of IP ephedrine and phenylpropanolamine on the lethal toxicity of SC 
codeine 
The effects of ephedrine and phenylpropanolamine on codeine lethality are presented in 
Table 9.1. Under these conditions, ephedrine and phenylpropanolamine (20, 40, 80 mg 
kg-i) had no mortality on their own. Codeine at 80 and 120 mg kg] also had no fatalities 




The effects of ephedrine and phenylpropanolamine on the lethal toxicity of 
morphine 
The effects of ephedrine and phenylpropanolamine on morphine LD50 are shown in Table 
9.2. At these experimental conditions, morphine had an LD50 of 267.8 (262.5 - 272.1) mg 
kg-i within 90 min. After pretreatment with ephedrine (20, 40, 80 mg kg-\ 
intraperitoneally), 10 min prior to the administration of morphine, the LD50 fell 
approximately 5-fold. The ephedrine doses used enhanced morphine lethality to the same 
extent. Phenylpropanolamine (20, 40 and 80 mg kg]) pretreatment also enhanced the 
lethal toxicity of morphine by 3- to 5-fold, in a dose-dependent manner. 
9.4. DISCUSSION 
These data show that a combination of ephedrine or phenylpropanolamine in moderately 
high doses (20, 40 80 mg kg- intraperitoneally) and (subcutaneous) morphine or codeine j . 
I is more lethal than either agent(s) alone. This is in line with the findings of potentiation 
of the acute antinociceptive effects of these opioids by the sympathomimetics (Chapter 6) 
and is also concordant with reports that showed potentiation of opioid analgesia and 
lethality by other sympatomimetics (Richards et al, 1975; Forrest et al, 1977; Blumberg 
and Ikeda, 1978). These data also support the observations of increased mortality due to 
a combination of the opioids and sympathomimetics, compared to the opioids only, in the 
chronic interactions (Chapter 7). 
The acute lethal toxicity of morphine and codeine in mice is largely stimulatory and 
convulsant (Blumberg and Ikeda, 1978; Szekely, 1982). Ephedrine and 




TABLE 9.1. EFFECTS OF EPHEDRINE AND PHENYLPROPANOLAMINE ON THE 
T/ETHAL TOXICITY OF CODEINE. 
Pretreatment Codeine dose No. of % Mortality 
mg kg-l, IP mg kg"S SC • mice 
Saline 20 --
Saline 10 80 20 --
(ml kg-l) 120 20 ~ 
160 20 10 
240 20 80 
Saline 20 --
Ephedrine 20 80 20 25^ 
120 20 80^ 
160 20 95^ 
240 20 100^ 
Saline 20 .—— 
80 20 30 
Ephedrine 40 12 0 2 0 80^ 
160 20 100^ 
240 20 100^ 
Saline 20 —— 
80 20 60^ 
Ephedrine 80 120 20 
• 160 20 100^ 
240 20 100^ 
Saline 20 --
80 20 —— 
Phenylpropanolamine 2 0 12 0 2 0 2 0^ 
160 20 75^ 
240 20 100^ 
Saline 20 --
80 20 10^ 
Phenylpropanolamine 40 120 2 0 55 
160 20 9 0^ 
240 20 100^ 
Saline 20 —— 
80 20 10^ 
Phenylpropanolamine 80 120 2 0 65^ 
160 20 100^ 
240 20 100^ 
——no mortality. 




TABLE 9>2. EFFECTS OF EPHEDRINE AND PHENYLPROPANOLAMINE ON THE 
LETHAL TOXICITY OF MORPHINE. 
Pretreatment No. of Morphine LD^Q mg kg"^ 
mg kg-1, IP mice (95% confidence limits) 
Saline 10 (ml kg]) 63 “ 267.8 (262.5 - 272.1) 
E p h e d r i n e 20 60 5 3 . 2 ( 4 6 . 4 - 6 1 . 4 ) ^ 
E p h e d r i n e 40 65 4 9 . 7 ( 4 9 . 3 - 5 0 . 2 ) ^ 
E p h e d r i n e 80 66 4 4 . 3 ( 3 9 . 4 - 4 9 . 7 ) ^ 
P h e n y l p r o p a n o l a m i n e 20 60 9 3 . 2 ( 8 9 . 7 - 9 6 . 8 ) ^ 
P h e n y l p r o p a n o l a m i n e 40 60 7 4 . 0 ( 6 7 . 9 - 8 0 . 6 ) ^ 
P h e n y l p r o p a n o l a m i n e 80 60 4 2 . 5 ( 4 0 . 2 - 4 4 . 9 ) ^ j 
i a s i g n i f i c a n t l y l o w e r t h a n t h e c o n t r o l v a l u e 
I . 
135 . 
to, though quantitatively less than, those of amphetamine (Dietz et al., 1985). In this 
study, the animals became hyperactive prior to developing fatal convulsions. There was 
» 
no qualitative behavioral difference between the sympathomimetic-pretreated mice and the 
controls, the former had more marked hyperactivity though. The greater lethality of the 
combination of the opioids with these sympathomimetics in mice may, therefore, be due 
to increased central stimulation toxicity. This mechanism of toxicity is different than that 
of opioids in man which is predominantly due to respiratory and general central nervous 
system depression. Nevertheless, in rats, in which opioid toxicity leads to general 
depression and catalepsy with or without convulsions — akin to the situation in man 
opioid toxicity is also increased by the sympathomimetics cocaine and amphetamine 
(Blumberg and Ikeda, 1978). This is the case in man too (Finkle and McCloskey, 1977). 
Apparently, regardless of the basic mechanisms involved, the toxicity of opioids is 
augmented by sympathomimetic agents, 
i • 
4 
Compound codeine preparations are gaining ground as substances of abuse (Tennant, 
1983; Kreek, 1987; Chan et, 1990; CRDA, 1990) often resulting in high morbidity and 
mortality. One explanation for such observations is the easier availability over the counter 
of the codeine compounds relative to codeine per se. The other possibility is that of the 
modification of codeine activity, including toxicity, in combination with other agents, for 
instance the sympathomimetics. Findings in this chapter suggest that sympathomimetic-
opioid combinations lead to an increase in lethality. It is possible, too, that these 
observations reflect a sum of (sub-lethal) toxicities of the opioids and sympathomimetics. 
During the chronic interactions, and in tolerant/dependent mice, the lethal toxicity of the 
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« 
opioids was higher in the groups receiving the combination than in those on the opioids 
only. This may suggest that tolerance to the toxic effects does not develop as fast as it 
does for antinociceptive effects. Ephedrine (half-life 4-11 h) and phenylpropanolamine 
(half-life 3-8 h) are slowly eliminated from the body, at least relative to the opioids. 
repeated doses of the sympathomimetics may conceivably lead to their accumulation in the 
body, which would then contribute to the overall toxicity. From a clinical perspective, a 
combination of opioid and sympathomimetic may be more reinforcing on account of the 
potentiation of the acute effects. Physical dependence develops at the normal rate, while 
the development of tolerance is enhanced; this may then require one to take larger 
amounts of the mixture to attain the original high and offset the pharmacogenic need. 
Unfortunately, as shown in this chapter, opioid toxicity is enhanced by sympathomimetics. 
From this point of view, the continued free availability of sympathomimetic-containing 
codeine compounds to the general public becomes questionable at the very best, 
t 
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CHAPTER 10; EFFECTS OF EPHEDRINE AND PHENYLPROPANOLAMINE ON 
THE PLASMA AND BRAIN DISPOSITION OF MORPHINE AND CODEINE » 
10.1. INTRODUCTION 
It is often said that pharmacology is divided into two categories, one dealing with what 
the drug does to the body (pharmacodynamics) and the other dealing with what the body 
does to the drug (pharmacokinetics). The previous four chapters have addressed how 
ephedrine and phenylpropanolamine influence the pharmacodynamics of morphine and 
codeine. The present chapter focuses on the possible influence of the sympathomimetics 
on the pharmacokinetics of the opioids. 
There are reports suggesting that ephedrine and phenylpropanolamine may alter the 
pharmacokinetic profiles of the xanthines caffeine and theophylline (Weinberger et al., 
1975; Lake et al., 1990). This is thought to be through metabolic impairment, and 
4 
i probably explains the high incidence of adverse effects when caffeine or theophylline and j 
ephedrine or phenylpropanolamine are co-administered in humans (Lake et al., 1990). 
i * 
Some workers have suggested that some histamine (Hi) receptor blockers, also common 
ingredients of cough and cold preparations, may facilitate opioid passage across the blood-
brain barrier (Leza et al., 1990). Others, however, found that co-administered ST-91, an 
a2-adrenoceptor agonist, had no effect on the clearance of intrathecal morphine (Monasky 
et al., 1990). 
The metabolic conversion of codeine through O-demethylation to morphine (Adler et al. 
1955) is a subject that is gaining much attention recently (Yue et al., 1989a; 1989b; 
i 




metabolite being responsible for the analgesic and addictive effects of codeine (Sjoqvist, 
1991). 
It has been shown that ephedrine and phenylpropanolamine modify opioid antinociception 
(Chapter 6); development of tolerance and expression of physical dependence (Chapter 7); 
and lethal toxicity (Chapter 9). Data presented in Chapter 8 suggest that the potentiation 
of morphine and codeine antinociception by ephedrine and phenylpropanolamine is most 
probably an Q;2-adrenoceptor mediated action. The work presented in this chapter is aimed 
at establishing whether or not the sympathomimetics alter the plasma and/or brain levels 
of codeine or morphine after single (analgesic) dose treatment. Evidence for the 
conversion of codeine to morphine was also sought. Indicative pharmacokinetic parameters 
(see Chapter 4) are presented as calculated from the concentration-time profiles. 
1 
In essence, the question addressed in this chapter is whether the observed modification of 
various opioid actions/effects so far established could be, at least in part, due to alterations 
in the disposition of codeine arid morphine. Male ICR mice were used as in the foregone 
chapters. 
10.2. MATERIALS AND METHODS 
10.2.1. Treatment protocol 
Mice were pretreated with IP ephedrine or phenylpropanolamine 10 mg kg'^ prior to SC 
morphine (8 mg kg"^) or codeine (60 mg kg]). The codeine dose used is approximate to 
the ED50 {vide supra) while for morphine the highest analgesic dose level was used. The 




plasma and brain levels, this limitation was not applicable in the case of codeine due to 
the high ED50. At these dose levels, the sympathomimetics potentiate the opioid 
(antinociceptive) effects, as shown earlier. 
10.2.2. Sample collection 
After the opioid dose, mice were sacrificed at 15 and 30 min, and at 1, 2, and 3 h under 
light ether anaesthesia by exsanguination and/or decapitation. Blood from 3 to 4 animals 
« 
was pooled in tubes with EDTA and centrifuged at 2000 g for 30 min at 8 T h e plasma 
was then separated and stored frozen at -20°C until assay. 
After decapitation the brain was rapidly removed as described by Wong (1976). Briefly, 
the skin of the head was reflected to expose the skull and an incision made along the 
sagittal suture from the foramen magnum towards the nostril. The parietal bones were 
. t hen separated using blunt forceps to expose the brain which was in turn gently removed 
with a spatula. The brain was then wrapped in aluminum foil, put into a chilled plastic 
bottle with cap (Wong, 1976) and also kept frozen at -20 C until assay. 
I ‘ 
I 
Prior to assay the brain was weighed and then homogenized in toto in 3 ml of 
physiological saline. Brain from morphine-treated animals were homogenized two at a 
time, while those from the codeine-treated ones were singly homogenized. The 
homogenate was centrifuged at 2000 g for 30 min at 8 C. All the supernatant was 
separated and immediately assayed for opioids. For standards a known amount of opioid 
and internal standard were added prior to homogenization. 
140 
J 
Only small volumes of blood (< 1 ml) could be obtained per mouse and so it was 
necessary to pool together several samples in order to obtain at least 1 ml of plasma for ‘ 
assay. Mouse brain weights ranged from 380 to 540 mg, combining 2 brains — as was 
the case for the morphine-treated mice gave about 1 g. Because all sample collections 
were end point procedures by themselves there were no follow up samples from any 
animal. 
10.2.3. Assay method 
Many analytical methods for morphine and its surrogates have been described over time. 
In general the most popular, sensitive (recent) ones have tended to involve reversed-phase 
ion-pair high performance liquid chromatography (HPLC) with ultra-violet (uv) and/or 
electrochemical detection (Tagliaro et al., 1989). These basic concepts were followed in 
this investigation and the assay method used was a modification of that described by 
Svensson et al. (1982) involving solid phase extraction using Sep-Pak™ C^g cartridges. 
10.2.3.1. Materials 
Methanol and acetonitrile (Mallinckrodt) were HPLC grade and used as received. Water 
was glass (double) distilled. Sodium dodecyl sulphate (Bio-Rad), Naloxone hydrochloride 
(Dupont), Sodium dihydrogen phosphate and ammonium sulphate (Merck) were all 
analytical grade reagents and used without further purification. Sep-Pak™ Cjg cartridges 
were from Waters (Waters, Millipore). 
I 
10.2.3.2. Sample preparation 
1 ml of plasma or all the supernatant of the brain homogenate were processed through 
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solid-phase extraction using Sep-Pak cartridges (Svensson et al., 1982). The samples were 
buffered with 3 ml of 0.5 M ammonium sulphate (adjusted to pH 9.3 with ammonium) 
and then passed through the cartridges. 
The cartridges were washed with 20 ml of 5 mM ammonium sulphate, (pH 9.3) followed 
by 0.5 ml of water. The drugs were then eluted using 3.0 ml of 15% (v/v) acetonitrile in 
10 mM phosphate buffer (adjusted to pH 2.1 using phosphoric acid) (Yue et al., 1989a). 
The eluent was then buffered with a further 3 ml of 0.5 M ammonium sulphate and 
treated through another cartridge as above. Aliquots (100 - 300 lA) of the final 3 ml of 
eluent were then injected into the HPLC system. 
A vacuum manifold (Visipress"^^, Supelco), was used and enabled samples to be processed 
in batches of 12 at a time. During the extraction the flow rate was manually adjusted to 
4 
about 2 ml min], except during washing when the flow rate was faster. 
The Sep-PakTM cartridges were re-used during the study. Before use, the cartridges were 
treated with 5 ml of methanol, 5 ml of 15% (v/v) acetonitrile in phosphate buffer (pH 2.1) 
and 5 ml of water. After use the cartridges were washed with 5 ml of methanol followed 
by 10 ml of 15 % (v/v) acetonitrile in phosphate buffer (pH 2.1) and then 5 ml of water. 
These would then be treated as for the new ones prior to re-use, as described above. In 
this way each cartridge was re-used 6 times (plasma samples) or 5 times (brain 
homogenate) without affecting the recovery of drugs or the quality of the chromatograms. 





10.2.3.3. Chromatographic apparatus and conditions 
• . 
The chromatographic apparatus consisted of a Model 6000 A pump (Waters); a Rheodyne 
7125 injector with a 500 fxl loop; a RP 8 precolumn (guard column) and a stainless steel" 
/x-Bondpak C^g reversed-phase column (Waters) with particle size 10 fxm. Detection was 
performed by an ultra-violet detector (Hitachi 220S Spectrophotometer) set at 210 nm for 
codeine; and a Bioanalytical Systems (West Lafayette, In) Model LC-4B amperometric 
detector for morphine. The latter had a glassy carbon working electrode with applied 
potential set at 1.2 V against a Ag/AgCl reference electrode. Signals from the 
electrochemical detector were recorded by a Linseis L 6512 recorder. 
The mobile phase consisted of methanol 45% in 10 mM phosphate buffer pH 2.1 (v/v) 
containing 1 mM sodium dodecyl sulphate. The mobile phase was filtered through a 0.22 
j ptm filter and simultaneously degassed under vacuum. The eluent was delivered at 1 ml 
mirfl except when the pressure rose too high the flow rate was reduced to 0.8 ml min"^. 
During the assay, the mobile phase was recycled. Under these conditions good separation 
of morphine, naloxone (internal standard) and codeine was achieved with respective 
retention times of 4.5, 5.5, and 6.7 min at flow rate 1 ml min"^ (Figure 10.1). 
10.2.3.4. Standard solutions 
Stock solutions of morphine and codeine 100 fxg ml ] in double distilled water were made 
and stored frozen at -20°C. Standard solutions — 5 fxg ml"^ for morphine and 10 /xg ml'^ 
for codeine were made and kept at 4°C during the course of use. Standard solutions . 




10.2.3.5. Standard curves / Calibration graphs 
I 
Calibration graphs of peak height ratios to concentration were linear over the ranges 0.1 -
5 fjLg ml-1 for plasma morphine, 0.5 -15 /xg ml"^  for plasma codeine, 0.1 - 5 /xg g"^ for 
brain morphine and 0.5 - 30 fxg g ] for brain codeine. 
Known amounts of morphine or codeine were added to plasma or brain, together with the 
internal standard and taken through the entire sample preparation procedure. The linearity 
« 
of the peak height ratios to concentration was tested by linear regression analysis. The 
calibrations are shown in Table 10.1. 
To test for recovery a known amount of morphine or codeine and internal standard were 
added to 3 ml of 15% (v/v) acetonitrile in phosphate buffer, pH 2.1, and the response 
compared to that for an equal amount that had been processed through the Sep-Pak 
cartridges. This was between 80 - 90% throughout the investigation. 
Intra-assay variations were tested by the response of a standard solution at the beginning 
and at the end of the assay. Between run fluctuations in sensitivity were similarly 
determined. Both were low, being 5 - 10%, and sometimes less than 5%. 
10.2.4. Kinetic and statistical calculations 
Both plasma and brain levels of morphine and codeine are presented as mean SEM for 
the various time points. Data for corresponding concentation-time points were analyzed 
and compared by the Student's t-test with the level of significance atP < 0.05 and where 
I indicated differences among the concentration-time curves were tested by analysis of 
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TABLE 10.1. CALIBRATIONS FOR MORPHINE AND CODEINE 
Concentration Peak height ratios 
(a) Plasma morphine: 
0 . 1 0 . 1 8 6 5 
. 0 . 2 5 0 . 2 7 8 6 
0.5 0.4162 
1 . 0 0 . 7 0 6 8 
2.5 1.3275 
5 . 0 2 . 3 685 
r 0.9985. 
(b) Plasma codeine: 
i 0.5 0.6053 
t 1.0 0.9125 




r = 0•9989. 
i • , 





•2 . 5 1.2873 
5.0 2.2816 
r = 0.9993. 
j (d) Brain codeine: 












variance (Bowman and Rand, 1980). Pharmacokinetic parameters were obtained from 
plasma concentration-time curves using a computer program (PKCAL; Shumaker, 1986). 
10.3. RESULTS 
’ 




i The plasma concentration-time profiles of morphine with or without sympathomimetic 
I 
pretreatment are presented in Table 10.2a. The values are comparably similar with no 
S significant differences among the various treatment groups, except for 
i I 
phenylpropanolamine + morphine at 2 h which is significantly lower than the 
corresponding value in the morphine only group (P < 0.05 t-test). Analysis of variance 
• for the time-concentration profiles, however, shows no difference (F-ratio less than unity). 
It is noteworthy that at 30 min, corresponding to the peak antinociceptive effects of 
morphine, the concentrations are the same. 
The plasma concentration-time profiles for codeine are shown in Table 10.2b. As is the 
case for mprphine, there are no significant differences between the codeine only group 
levels and those from the sympathomimetic pretreated ones. No significant amounts of 
either morphine or codeine were detected in the 3 h plasma samples. 
• ^ 
A summary of the pharmacokinetic parameters for plasma morphine and codeine 
calculated from the above table is given in Table 10.3. Codeine elimination half-life (ti/^), 
area under concentration-time curves (AUC), mean residence time (MRT), clearance (CI) 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































pretreatment. The parameters for morphine alone and ephedrine + morphine show marked 
similarity. Those for phenylpropanolamine + morphine are apparently different — lower 
elimination ty^, MRT and Vd and higher clearance; but the significance of such 
discrepancies is limited by the lack of difference in the original data (i.e. concentration-
I ‘ . 
time points). 
It is therefore apparent that neither phenylpropanolamine nor ephedrine had any effect on 
1 the plasma disposition of codeine; ephedrine did not affect the disposition of morphine, 
and while phenylpropanolamine had an apparent effect on morphine disposition this was 
not significant either. 
I 
10.3.2. Effects of ephedrine and phenylpropanolamine on brain opioid levels. 
Table 10.4a shows brain morphine levels between 15 min and 3 h. There are no 
discernable differences between the morphine only and sympathomimetic pretreated 
groups. 
Table 10.4b shows the brain codeine profiles between 15 min and 2 h. There was no 
difference between the codeine only group and the phenylpropanolamine + codeine 
concentration-time profiles, while that for ephedrine + codeine shows some disparity on 
account of the markedly lower terminal concentration (2 h). No significant amount of 
codeine was detectable in the brain at 3 h. 
A summary of the elimination ty^ and AUC for brain morphine and codeine are shown 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1 pretreatment. The elimination t,^  of morphine in ephedrine pretreated mice is apparently 
1 
1 longer, but may not be significantly so in view of the similarity of the original brain 
n , 
~ concentration-time data (Table 10.4a). Codeine parameters (Table 10.5b) show similar 
i« 
I elimination t^s, but a higher AUG with codeine alone relative to the sympathomimetic 
i pretreated groups. The significance of such findings is discussed below, 
i 
j 10.3.3. Plasma morphine levels after single dose of codeine 
•bp' 
B 
I Morphine was detected in significant amounts in plasma of mice that had received codeine 
1 
I 60 mg kg-1. At 15 min, only a trace was detectable and could not be quantified. The 
n findings for 30 min - 2 h are shown in Table 10.6. Comparison of corresponding time 
I 
points shows statistical significance for a number of time-points (ephedrine + codeine at 
j 30 min and 1 h; phenylpropanolamine + codeine at 1 h), but analysis of variance of the 
1 
three sets of data reveals no significant differences. The AUCs calculated are fairly 
disparate,though when expressed as a percentage of the corresponding AUG for codeine, 
, the differences narrow down (26.2 - 40%, Table 10.7). There was no quantifiable 
f morphine detected in the brain after single dose codeine, in all treatment groups, 
f 
] 10.3.4. Brain: plasma concentration ratios of morphine and codeine at time of peak effect 
The brain opioid concentrations (ng g"^ ) were expressed as a ratio of the corresponding 
plasma concentration (fxg ml'^ ) at 15 min for codeine and 30 min for morphine, the 
.. 
respective times for peak (antinociceptive) effects. The results are shown in Table 10.8. 
‘ The ratios were not significantly different with or without ephedrine or 
phenylpropanolamine for either morphine or codeine. That codeine crosses the blood-brain 
barrier more readily than does morphine is evident from the high brain to plasma 
153 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































I . . . 
i concentration ratios for codeine compared to the morphine ones, the shorter elimination 




• 10.4. DISCUSSION 
i ‘ 
The plasma concentration-time profiles for both morphine and codeine are apparently the 
I same regardless of pretreatment with ephedrine or phenylpropanolamine. A. summary of 
the plasma opioid pharmacokinetic piarameters suggests no significant alterations after 
sympathomimetic pretreatment. Morphine was found in significant amounts in plasma of 
mice that had received single dose codeine, but at 30 min and longer, after the peak effect 
of codeine (15 min). Curiously, no significant amounts of morphine were detectable in the 
i 
1 
j brain after single dose codeine. Brain concentration-time profiles of morphine and codeine 
were also not affected to a significant extent by sympathomimetic pretreatment. 




half-life of morphine, while apparently shortening that of codeine. However, taken in 
j conjunction with the fact that the differences in the values from which these parameters 
were obtained were not statistically significant the significance of this finding is 
diminished; at best the effect of ephedrine on brain opioid elimination half-life is 
equivocal. A comparison of brain to plasma concentration ratios showed that at the times 
corresponding to peak antinociceptive activity there were no significant differences after 
sympathomimetic pretreatments. These data, therefore, suggest that plasma and brain 
disposition of morphine and codeine in mice are not significantly affected by pretreatment 






J Ephedrine and phenylpropanolamine have been implicated in the impairment of 
J ‘ 
metabolism of other drugs, notably caffeine and theophylline (Weinberger et al., 1975; 
Lake et al., 1990), giving rise to higher plasma levels and a greater incidence of adverse 
'i • 
effects when they are co-administered. Some agents have been suggested to increase the 
I ‘ 
permeability of the blood-brain barrier to opioids, leading to greater potency of opioids 
I (Leza et al., 1990). This investigation provided no evidence that ephedrine or 
phenylpropanolamine increase the opioid levels in plasma or facilitate their penetration 
into the brain. 
/ 
The finding of measurable levels of morphine after single dose codeine was interesting for 
a number of reasons. Codeine is 0-demethylated to morphine (Adler et al., 1955) and is 
increasingly being considered as a pro-drug — that it may be morphine so formed that 
exerts its analgesic and addictive effects (Sjoqvist, 1991). After oral administration, with 
a first pass effect, this may occur early and to a greater extent (Rogers et al., 1982) so 
I 
as to be of clinical significance in the mediation of pain relief, but, even then, the extent 
j to which this is the case is unresolved (Findlay et al. 1978). Shah and Mason (1990) have 
suggested that demethylation occurs more rapidly in rats, with morphine detectable in a 
2 min post-dosing sample. In this investigation, however, quantifiable morphine levels 
were only notable at 30 min, a time when the antinociceptive effects of codeine have 
tapered off {vide supra). The peak effects of codeine occur at 15 min when morphine is 
I barely detectable. That morphine levels are negligibly low while codeine levels are high 
i \ i . 
at time of peak effect suggests that codeine may exert antinociceptive effects on its own. 
More so, there were no significant morphine levels detected in the brain following single 
dose codeine. These data are in line with those of other workers who have suggested that 
158 
I 
I the morphine metabolite may have only a minor analgesic influence after single dose 
-s • 
: codeine (Shah and Mason, 1990). It should be noted, however, that plasma and brain 
levels of morphine after single dose morphine were higher at 15 min than at 30 min, and 
I yet peak effects of morphine occur at 30 min. It appears there is no obvious relationship 
i . 
I between morphine levels in plasma or brain and peak effects. Nonetheless, ephedrine or 




i Single dose treatment with ephedrine or phenylpropanolamine apparently had no effect on the metabolism of codeine to morphine. The quantifiable levels still occurred at 30 min, 
‘ and though the concentration-time profiles show no consistent pattern for the various 
} 
j treatment regimens, there seem to be no major differences attributable to the 
sympathomimetics. It would seem that the sympathomimetics reduce the conversion of 
codeine to morphine (AUG 117.8 vis-a-vis 76.4 with ephedrine and 80.3 with 
i phenylpropanolamine, Table 10.7). When expressed as a percentage of the corresponding 
I 
I AUC of codeine, however, the differences are less apparent, varying from 40% to 26.6%. 
m 
I The significance of whatever discrepancies are observed becomes even more difficult to 
I 
appreciate in view of the large number of animals involved, each of which could have 
I handled codeine metabolism differently. In humans, AUCs of morphine relative to codeine 
I after single dose codeine have been noted to vary from 0.1% to 34.6% (Findlay et al., 
I 1978) and the values obtained in the present study in mice (26.2% to 40%) may well be 
f 
within the normal variations in this species. . 
‘ 
Brain levels of morphine and codeine were also not significantly affected by ephedrine and 





j • morphine/codeine content was measured and this cannot exclude the possibility that the 
sympathomimetics may affect opioid levels in discrete brain areas, especially in those 
involved in the processing of nociceptive information. 
'I 
.S “ i 
I This investigation was constrained by the fact that sample collections were end-point 
i 
I' procedures by themselves. Consequently, a more frequent schedule was not adopted, and 
H 
‘ there were no follow up samples from any single mouse. Samples were pooled, and so 
the results are representative mean values from groups of 60 - 80 mice. Whereas mean 
values of the concentrations at various time points were used, these were then treated as 
single points for purposes of pharmacokinetic computation, without the benefit of error 
•1 ‘ 
j being incorporated and the pharmacokinetic parameters so obtained, therefore, have only 
an indicative value. Inter-individual variations in drug handling is a well-known 
phenomenon in all species (Sjoqvist and Von Bar, 1973). These limitations 
notwithstanding, it was possible to find fairly consistent results, suggesting that ephedrine i •j 
\ and phenylpropanolamine had no significant effect on the pharmacokinetics of morphine 
and codeine in mice after single dose treatment. 
-i 
In the foregone chapters it was noted that the time of peak antinociceptive effects of the 
opioids was un-altered by sympathomimetic pretreatment in both naive and opioid 
1 tolerant/dependent mice. Coupled with the data in this chapter, there is strong indication 
that the observed potentiation of acute opioid antinociception and lethal toxicity by 
ephedrine and phenylpropanolamine may not be due to pharmacokinetic interactions. 
In conclusion, it has been shown that ephedrine and phenylpropanolamine have no 
I \ 
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, apparent effect on plasma and brain disposition of morphine and codeine in mice after 
\ 
1 single dose treatment. The modification of opioid activity reported earlier on may be due 
i • 
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I CHAPTER 11: EFFECTS OF EPHEDRINE AND PHENYLPROPANOLAMINE ON 
I 
THE 24 H URINARY EXCRETION OF CODEINE. MORPHTNE AND THEIR * 
‘% 
METABOLITES; AND THE DISPOSITION OF CODEINE AND MORPHINE AT 
J 
, STEADY STATE. 
I 
11.1. INTRODUCTION 
J The major metabolic pathways for codeine and morphine as suggested by Adler et al. 
: (1955) are shown in Figure 11.1 . Both drugs are extensively metabolized by hepatic 
biotransformation. After oral administration some metabolism may occur in the intestine 
prior to absorption. The kidney is the main route of excretion, with a small fraction being 
excreted in the bile leading to enterohepatic circulation (Dahlstrom and Paalzow, 1977; 
I 
I 
j Iwamoto and Klaassen, 1977). 
-
Codeine is 0-demethylated to form morphine (M) N-demethylated to form norcodeine 
(NC), and conjugated to form glucuronides and sulphates of both codeine and its 
k 
I metabolites. Morphine is demethylated to form normorphine (NM) or conjugated at the 
i 
6-0- or 3-0-position to give morphine-6-glucuronide (M6G) and morphine-3-glucuronide 
1 
5 • 
(M3G) respectively. Other (minor) metabolites include NM-glucuronide, M-3,6-
diglucuronide, morphine ethereal sulphate and NM-diglucuronide (Yeh et al. 1977). Since 
I 
morphine is a metabolite of codeine, all the metabolites of morphine apply to codeine as 
well. It has been reported that morphine may undergo 0-methylation back to codeine in 
man (Boerner and Abbott, 1973). Clinically available codeine is largely manufactured by 
such a step from naturally occurring morphine (Jaffe and Martin, 1991). 
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FIGURE 11 .1 MAJOR METABOLIC PATHWAYS FOR MORPHINE AND CODEINE. 
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1 
j disposition of these agents in mice has received relatively little attention. The time course 
of morphine and codeine at "steady state", the metabolites of both opioids and their 
relative concentrations in urine, plasma and brain were investigated. The results are 
discussed from the perspective of the possible effects of ephedrine and 




11.2.1. The 24 h urinary excretion of codeine, momhine and their metabolites. 
Mice were weighed, pretreated with ephedrine or phenylpropanolamine 10 mg kg-\ IP, 
followed by SC codeine 60 mg kg! or morphine 8 mg kg !, as appropriate, and then 
J placed in Nalgene™ metabolic cages (Nalge, Sybron Corp., Rochester, N.Y., USA). 
I Urine was collected for 24 h after which the volume was measured and an aliquot (1 - 2 
ml) stored frozen at -20 C until assay. Only two metabolic cages were available for this 
study. The treatment schedules were the same as for the interactions reported in Chapter 
10 (10.2.1). 
I- • 
I 11.2.2. Disposition of morphine and codeine at steady state. 
j Mice were treated for two days, twice daily, using the dosage regimens outlined in 
I -
Chapter 7 (Tables 7.1 and 7.2) for the induction of opioid tolerance/dependence. On the 
third day the animals received the relevant opioid in a single dose of 120 mg kg] (this 
j 
would be the dose given were the induction regimen to continue), and then sacrificed at 
15 and 30 min, and at 1, 2, 3 and 4 h to obtain brain and blood samples (see 10.2.2). To 
minimize mortality associated with higher sympathomimetic pretreatment doses only 5 mg 
164 
• kg-1 of either agent was employed in all the relevant treatments, including that on day 3. 
For the purposes of this investigation two days prior treatment with opioids was 
» 
considered a sufficient time course leading to steady state concentrations. 
•I 
i 
11.2.3. Assay method. 
, The chromatographic conditions were essentially the same as outlined in Chapter 10 but f 
the mobile phase was altered to 35% methanol (v/v), containing 2 mM sodium dodecyl 
sulphate and 2% tetrahydrofuran (v/v) (Merck, Damstadt, Germany) in phosphate buffer 
(pH 2.1) in order to achieve better separation of morphine, codeine and their metabolites. 
Pure standards were only commercially available for M3G, M6G, NM and NC. 
i , 
Standard curves were constructed for the various biological samples, i.e. urine, plasma 
and brain and showed consistent linearity (Figures 11.2-11.15, at the end of this chapter)• 
Plasma and brain samples were processed as described in Chapter 10. Urine samples were 
j similarly treated but only 0.5 ml of urine was assayed in each case. 
•i 
I 
11.2.4. Data analysis. 
11.2.4.1. Urine data: The proportions of codeine, morphine and their metabolites excreted 
in the urine over 24 h are expressed as percentages of the given dose. The results are 
presented as mean % SEM. Comparisons between corresponding data points were made 
by the unpaired Student's t-test. 
Indicative metabolic ratios (MR) were calculated as percentage dose excreted unchanged 





Codeine 0-demethylation = Codeine 
M + M3G + M6G + NM 
Codeine N-demethylation = Codeine 
NC + NM 
Morphine N-demethylation = Morphine 
NM 
Morphine glucuronidation = Morphine 
M3G + M6G 
Since no codeine glucuronide standards were available, codeine glucuronidation MR was 
not obtained. 
11.2.4.2. Plasma and brain data: Data obtained from plasma and brain samples were 
i 
analyzed and compared as outlined in Chapter 10. 
11.3. RESULTS 
11.3.1. Effects of ephedrine and phenylpropanolamine on urinary excretion of morphine 
and codeine. 
11.3.1.1. Morphine: Morphine, NM, M6G and M3G were recovered from the urine. The 
results are shown in Table 11.1. Total amount recovered ranged between 40 - 60% of the 
administered dose, with no significant differences on account of ephedrine or 
phenylpropanolamine pretreatment. The mean amount excreted as unchanged morphine 





groups M3G was the major metabolite of morphine, with M6G and NM being less 
abundant. Mean % M3G is significantly lower in the phenylpropanolamine pretreated » 
group relative to the unpretreated group. 
4 -
Table 11.3a presents these results as percentage of the total recovered drug material and 
’ shows wide discrepancies among the different groups. However, indicative glucuronidation 
metabolic ratios (MRs) (0.38 0.06, 0.48 0.04 and 0.23 0.16 for the morphine 
alone, phenylpropanolamine + morphine and ephedrine + morphine groups respectively, 
Table 11.1) show no significant difference in this metabolic pathway. The fraction 
excreted as NM ranged between 1 - 7% of the administered dose and also showed no 
I 
I statistically significant difference between the morphine only group and the 
sympathomimetic-pretreated ones (Table 11.1). 
i 11.3.2.2. Codeine: Codeine, NC, M, M3G and M6G were recovered from the urine of 
j 
I codeine treated mice. The results are shown in Table 11.2. Total mean recovery of 
j 
> » j 
j codeine and its metabolites ranged between 30 - 40% of the administered dose. Recovery 
I 
of drug related material was apparently less in the phenylpropanolamine + codeine group 
relative to the codeine only one (P < 0.05; t-test) while the corresponding value for the 
ephedrine + codeine group is not significantly different. For all treatment groups the 
amount of codeine excreted unchanged was between 10 - 15%, NC was the major 
metabolite recovered (7 - 12%) followed by M3G (6 - 9%). For all these parameters there 
i 
are no statistically significant differences between the codeine only group and those 
I 
I 
pretreated with either sympathomimetic. Table 11.3b shows the percentage contribution 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































I morphine (Table 11.3a), there is concordance of the results in all treatment groups, 
i 
The indicative metabolic ratios for 0-demethylation are 0.77 0.29 0.85 0.32 and 
I 0.93 0.21 for codeine alone, phenylpropanolamine + codeine and ephedrine + codeine 
i _ 
i respectively (Table 11.2). There are no discernible differences among the treatment groups 
I with respect to O-demethylation. N-demethylation indicative MRs are 0.93 0.17, 0.96 
I 
• 0.38 and 1.28 0.26 for codeine alone, phenylpropanolamine + codeine and 
. 
4' 
ephedrine + codeine respectively (Table 11.2), again suggesting that this metabolic 
pathway was not significantly affected by sympathomimetic pretreatment. 
The sum total of the findings on urinary excretion studies is that sympathomimetic 
pretreatment had no significant effect. 
j 11.3.2. Effects of ephedrine and phenylpropanolamine on plasma levels of codeine, 
morphine and their metabolites at steady state. ‘ 
11.3.2.1. Morphine: Only morphine and M3G were detected in significant amounts in the 
plasma. The results are shown in Table 11.4. There were no significant amounts of 
morphine or M3G detected in samples from animals that received no morphine on the test 
day. For both morphine and M3G the concentration-time profiles show marked overlap, 
with no statistically significant differences (ANOVA, see Chapter 10). The maximum 
levels of M3G were obtained at 30 min in all groups. By 4 h no measurable levels of 
morphine were detected in plasma. Indicative pharmacokinetic parameters for plasma 
morphine and M3G are shown in Table 11.5. The values shown all appear to be within 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































_ — — „ 
I mice that had received codeine. The profiles are shown in Table 11.6. NC and M3G were 
I the major metabolites detected with levels of morphine being much lower. Analysis of the 
^ respective sets of data reveals no statistically significant differences, with overlapping 
I -
I concentration-time profiles. 
- • % 
M 
I -
a Table 11.7 shows the pharmacokinetic parameters for plasma codeine and its metabolites. 
I 
There are marked similarities among the values for codeine. The values for NC and M3G 
show no apparent consistency. For NC, the codeine only group shows higher area under 
i 
I the plasma concentration-time curve (AUC) and longer elimination half life than in the 
sympathomimetic pretreated groups. For M3G control half life and AUC fall in between 
J » 
those for the pretreated groups. Such findings are, however, of limited interpretative value 
without the benefit of error, as explained in Chapter 10. 
i a 
i . 
i 11.3.3. Effects of ephedrine and phenylpropanolamine on brain disposition of morphine 
and codeine at steady state. 
11.3.3.1. Morphine: Only morphine and M3G were detected in the brain of mice that had 
received morphine. The results are shown in Table 11.8. The brain levels (fig g"^) of 
1 
M3G were much lower than the corresponding plasma levels (/xg ml"^) (about 35-fold less 
at peak plasma concentration). There are no statistically significant differences among the 
three sets of data. 
. 
-
I Indicative pharmacokinetic parameters for brain morphine and M3G are shown in Table 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































same, while AUG for the morphine only group falls in between the ones for the 




I - . 
I 
I 11.3.3.2. Codeine: Only codeine and NC were detected in measurable amounts in the 
I brain of mice that had received codeine. The results are presented in Table 11.10. As was 
j 
f the case for morphine, the concentration-time profiles overlap with no statistically / 
f 
significant differences among the three treatment groups. The brain levels of NC were 
relatively lower than the corresponding plasma levels, but by only 2-fold at time of peak 
plasma concentration. 
Table 11.11. shows the brain pharmacokinetics of codeine and NC. Codeine AUG is 
essentially similar for all the three groups, while the half life is apparently lower though 
the range (36.7 - 48 min) is too narrow to be of significance. The AUG for NC is similar 
for all groups, but the elimination half life for the ephedrine pretreated group is about 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































I llA. DISCUSSION 
i 
The data presented (11.3.1) throw some light on the metabolism of codeine and morphine 
^ » 
in mice. Only a small fraction of either agent (< 15%) was excreted unchanged after 
parenteral administration. The major metabolite for morphine was found to be M3G, while 
i 
for codeine, NC and M3G were the major metabolites recovered (Table 11.3). Whereas 
A 
I the values in Table 11.3a suggest an effect of the sympathomimetics on morphine 
I 
metabolism, when expressed in terms of the administered dose (Table 11.1) these 
• J 
\ 
differences are diminished. Given the wide, normal variations in drug metabolism alluded 
to in the previous chapter, and considering the large standard deviations of the results, it 
is difficult to attribute the observed discrepancies entirely to the sympathomimetics. About 
50% of the administered morphine dose was recovered from the 24 h urine as drug related 
material, while for codeine this was between 30 - 40%. It should be borne in mind that 
as there was no authentic compound, codeine-6-glucuronide (C6G) levels were not 
j determined, and yet this is considered the major metabolite of codeine. The fraction 
I 
excreted could have been higher. 
Plasma and brain profiles for morphine and codeine were essentially similar with or 
without pretreatment with ephedrine or phenylpropanolamine. For morphine treated groups 
only morphine and M3G were detectable in significant amounts in both plasma and brain, 
unlike the urine samples which contained significant amounts of M6G and NM as well. 
This apparent discrepancy may be explained in terms of the lower levels of the latter two 
relative to those for morphine and M3G. In addition, the kidney is capable of forming 
morphine glucuronides (Dollery, 1991) so it is conceivable that plasma/brain samples may 
fail to show M6G and yet it turns up in the urine having been thus formed. 
. 183 
« 
I Brain levels of M3G were much less than in plasma after morphine treatment, and \ 
undetectable in brain following codeine treatment. A major function of drug metabolism 
.:’r . 
is the formation of highly water soluble (and less lipophilic) metabolites that are easier to 
i • 
eliminate via the urine. M3G is apparently very hydrophillic and poorly penetrates the 
I . 
blood-brain barrier. Morphine was not detected in brain after codeine treatment (similar 
•A 




A diligent search for codeine and NC in urine, plasma and brain samples from animals 
that received morphine revealed none. Unlike the earlier-cited report (Boemer and Abbott, 
1973), the present study found no evidence to suggest 0-methylation of morphine to 
codeine. 
j Interestingly, except for Table 11.3a, all the data show no clear cut effect of the 
sympathomimetics on opioid disposition (the limitations of the data in Table 11.3a have 
been stated above). This despite definite pharmacodynamic modifications (Chapters 6 7 
8 and 9). More so, the data for the interactions at steady state are markedly similar to 
those for single dose interactions (Chapter 10) except for morphine clearance which is 
apparently higher for the single dose study (Tables 10.2 and 11.5). Whereas the possible 
cause for this difference is not apparent, it is noteworthy that all the treatment groups are 
similarly affected. Furthermore, a direct comparison of the results for the two treatment 
groups is limited by the fact that it was not possible to study both single dose and steady 
state kinetics in the same animal(s). 
184 
0 
Though treatment with opioids, with or without sympathomimetics, was for only two days 
I before the (plasma and brain) samples were obtained, this is a justified regimen 
I considering that it was effective for the induction of opioid tolerance/dependence. The 
I main question was, after all, what happened during the chronic interactions and, if 
I anything, whether that could explain the apparent differences previously noted. Within the 
• constrains of the present study there is no suggestion that opioid disposition is affected by 
I ephedrine or phenylpropanolamine pretreatment. 
The values obtained for the fraction excreted unchanged for both agents (< 15%) and the 
major metabolic profiles generally agree with those often cited on the basis of human 
‘ 
studies (e.g. Dollery, 1991). Whereas the picture for codeine metabolism could not be 
fully elucidated due to lack of C6G standards, the data presented also fit in with the 
general trend. This observation is important inasmuch as it suggests that opioid 
\ metabolism in the mouse is akin to that in man, and so dispositional studies in the former 
j may have a high predictive value on the situation obtaining in the human. The mouse 
J « 
I model is apparently a good enough model for pharmacokinetic studies as well, 
j 
It is currently thought that codeine O-demethylation cosegregates with polymorphic 
debrisoquine hydroxylation with both inter-individual and inter-ethnic variation (Yue et 
al., 1989b; Sjoqvist, 1991). Due to the small number of animals used in the experiments 
presented in this chapter this possibility was not explored. It is worthwhile to note that the 
animals used were all the same strain. Keeping in mind the possibility of inter-individual 
variations in the metabolism of these drugs reinforces the lack of significant differences 
that could be attributable to sympathomimetic pretreatment. 
. 185 
« 
In conclusion, the major urinary metabolites of codeine and morphine as presented suggest 
I 
I that ephedrine or phenylpropanolamine pretreatment has no effect on the profiles. The 
» 
4 . 
plasma and brain profiles of codeine and morphine were not significantly affected by 
• sympathomimetic pretreatment either. These data further support those for single dose 
I 
studies (Chapter 10) that ephedrine and phenylpropanolamine have no effect on the 
•K 
"I 
I disposition of codeine and morphine in mice. The concordance of the data obtained in this 
f ‘ 
.•ft 
study with those for studies in man suggests that the mouse may be as good a model for 
1 
•j . 
(opioid) pharmacokinetic studies as it is for pharmacodynamic ones. The observed 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































12.1. Summary of the conclusions, 
i 1. Ephedrine and phenylpropanolamine potentiated the antinociceptive activities of 
morphine and codeine in mice. Since both analgesia and the mood-elevating effects of 
opioids are mediated via pc-receptors it can be postulated that a sympathomimetic-opioid 
preparation is more reinforcing than opioid alone, and therefore more liable to be 
abused. This may partly explain the high abuse rate of cough and cold mixtures 
containing opioids and sympathomimetics. 
2. Ephedrine and phenylpropanolamine had no effect on the development of physical 
dependence but suppressed the withdrawal signs. The development of opioid tolerance 
was apparently enhanced, while expression of tolerance was not markedly affected by 
the sympathomimetics. Assuming a similar situation obtains in man a drug abuser would 
j 
require larger amounts of the mixture, to achieve the original "high" sooner than would 
be the case if only the equivalent amount of the opioid were being taken. This could 
j be another explanation for the high abuse rate of such cold and cough preparations. 
3. The effects of ephedrine and phenylpropanolamine on opioid antinociception are due 
to a2-adrenoceptor activation. This is most probably the same mechanism at play in the 
attenuation of the withdrawal signs by these sympathomimetics. 
4. The lethal toxicity of morphine and codeine was potentiated by the sympathomimetics 
in acute or chronic interactions, and also in opioid tolerant/dependent animals. 
Tolerance to the toxic effects of the opioids apparently develops at a slower rate than 
• 214 
‘ J 
that to the analgesic (and probably reinforcing) effects. Such observations may partly 
I explain the high morbidity and mortality resulting from the mixtures, and the possibility 
of high toxicity of such combinations needs to be borne in mind. 
5. Ephedrine and phenylpropanolamine had no apparent effect on the disposition of 
codeine and morphine in single dose and chronic interaction studies. The observed 
I 
I effects of the sympathomimetics on opioid activity are largely pharmacodynamic. 
• 
6. This study has shown that ephedrine and phenylpropanolamine modify the effects of 
codeine and morphine. Throughout the investigation the effects of ephedrine and 
phenylpropanolamine were remarkably similar. Save for a few discrepancies, results 
from codeine- and morphine-treated groups were equally comparable. To the best of 
j my knowledge this is the first study to investigate interactions of these agents in such 
1 . 
i detail. Coupled with anecdotal reports of high morbidity and mortality from codeine 
j compounds, these findings, at the very least, underline the need to restrict the 
t 
1 • 
I availability of opioid-sympathomimetic-containing preparations. 
12.2. Prospects for further studies. 
1. Self-administration studies would be required to investigate the possibility of increased 
reinforcing ability of the mixtures compared with either opioid alone. This has only 
been postulated on the basis of the antinociceptive potentiation. 
-
2. The possible involvement of catecholamine level changes would be another line of 
study worth following up on. The basis for such changes has been presented. 
• 215 
3. Since this study started from observations of high abuse of the mixtures, it would be 
I 
necessary to extend the study of these interactions directly in humans. There is a need 
* 
to identify and follow up chronic abusers of cough and cold medicines. A community 
based study would help establish the patterns and problems faced by these abusers. 
4. The observation that ephedrine and phenylpropanolamine potentiate opioid 
antinociception opens up the possibility that a combination of either sympathomimetic 
with codeine or morphine may be more effective in pain management than the opioid(s) 
alone. K would be desirable to investigate this hypothesis, which could lead to use of 
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Abstract—The effects of ephedrine and phenylpropanolamine on the 
antinociceptive activities of morphine and codeine were investigated. 
Both morphine and codeine exhibited dose-dependent antinocicep-
tive activities in the tail flick test. Ephredrine (5, 10 and 20 mg/kg) 
and phenylpropanolamine (5, 10 and 20 mg/kg) showed no antino-
ciceptive effect when administered alone. The antinociceptive effects 
of morphine were enhanced in mice pretreated with ephedrine 
or phenylpropanolamine. Similarly, codeine antinociception was 
increased in mice pretreated with ephedrine or phenylpropanol-
amine. In all cases, the ED50 values and single dose comparisons 
were shifted in the same direction. These effects on the antinocicep-
tive potencies of morphine and codeine were found to be dose-
dependent, being statistically significant at the higher dose levels of 
ephedrine and phenylpropanolamine used in the present study. 
Introduction 
Ephedrine and phenylpropanolamine (PPA) are commonly used in com-
bination with opiates in "cold remedies" or "cough mixtures". Both 
ephedrine and PPA are known to have biochemical central nervous system 
(CNS) effects qualitatively similar to, though quantitatively less than, 
amphetamine (Dietz et al•’ 1985). There is accumulating evidence for the 
involvement of brain catecholamines in various actions of the opiates 
(Kuriyama, 1982; Lai and Fielding, 1983; Szekely, 1982). Amphetamine, 
cocaine and other CNS stimulants have been reported to potentiate the 
analgesic effect of morphine (Szekely, 1982). Previous reports (Dewey et al, 
1970) showed that ephedrine had no effect on morphine antinociception. 
5 
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We are not aware of any report on the interactions between PPA and the 
opiates. In view of the recent observation in Hong Kong (Chan et al 
1990) of increasing abuse of proprietary formulations of "cough remedies" 
containing ephedrine and codeine, the present study was undertaken to 
investigate the effects of ephedrine and PPA on the antinociceptive effect of 
both morphine and codeine in mice. 
Methods 
Animals 
Male ICR mice, weighing 30-35 g, were used. The animals were allowed 
free access to standard laboratory diet and tap water, and were kept under 
artificial lighting for 12 hr each day (6a.m.-6 p.m.). Each mouse was used 
only once. 
Antinociceptive assay 
A modification of the tail flick assay of D'Amour and Smith (1941) was 
1 used. Adjustments were made such that mice not showing a tail flick reac-
I tion within 10 sec were considered to exhibit 100 % analgesia. Prior to the 
i treatment, the mice were screened and those showing no response within 
5 sec were excluded from the study. Saline controls were used for each 
treatment regime, taking into account the likely day to day fluctuations in 
antinociceptive response. The percentage analgesia per group was 
calculated as: 
Test group mean - Saline control mean < / 
10 - Saline control mean 
The peak effects of morphine and codeine in this assay occurred 30 min 
and 15 min after s.c. administration, respectively. Pretreatment with PPA 
and ephedrine was given i.p. 10 min before the relevant opiate drug. 
Preliminary studies showed no difference when pretreatment was given 10 
20 or 30 min earlier, the 10 min interval was chosen for convenience. 
Control animals received saline injections at the corresponding times. 
Drugs 
Morphine sulphate and codeine phosphate (Macfarlan Smith Ltd., 
Edinburgh, U.K.), phenylpropanolamine hydrochloride (Sigma, St. Louis, 
MO, U.S.A.) and ephedrine hydrochloride (May & Baker, Essex, U.K.) 
were used. All doses refer to the weight of the salts used. The drugs were 
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dissolved in a physiological saline solution at such concentrations that the 
required doses were given in a volume of 10 ml/kg, s.c. or i.p. as applicable 
Statistical analysis 
Dose-response curves, ED50 values and their 95% confidence limits were 
calculated using linear regression analysis. The curves were tested for 
parallelism using the parallel line assay method (Colquhoun, 1971). The 
ED 50 value of morphine and codeine, after the various pretreatments, was 
considered significantly different from the control value if it fell outside the 
95 /o confidence limits of the latter, and also if the control ED5 laid out-
side the 95% confidence limits of the experimental ED50. At least 40 mice 
were used to determine each ED 50. Data for single dose comparisons were 
analyzed and compared by means of the unpaired (2-tailed) Student's 
-test. 
Results 
Effects of ephedrine and phenylpropanolamine on the tail flick response in 
mice 
When given alone, ephedrine and phenylpropanolamine had no 
antinociceptive effects in the doses used in the present study. The mean 
response times of mice injected with these drugs were not significantly 
different from those of the saline control animals (Table I). 
TABLE I 
I Effects of i.p. ephedrine and phenylpropanolamine (PPA) on the tail flick response in mice 
Tail flick reaction time (sec) 
Drug No. of mice (mean S.E.M.) 
Saline 10 ml/kg 43 3.07 0.15 
PPA 5 mg/kg 14 2.79 0.23 
PPA 10 mg/kg 15 3.25 0.31 
PPA 20 mg/kg 14 . 3.06 0.32 
Ephedrine 5 mg/kg 20 3.20 0.21 
Ephedrine 10 mg/kg 20 3.34 0.23 
Ephedrine 20 mg/kg 14 2.71 0.28 
Effects of PPA and ephedrine on the antinociceptive activities of morphine 
and codeine 
The effects of a single dose of PPA and ephedrine on the antinociceptive 
effects of a single dose of morphine and codeine are shown in Table II. 
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TABLE I I 
Effects of ephedrine and phenylpropanolamine (PPA) on the antinociceptive effects 
of morphine and codeine 
Tail flick time 
No. of (sec)(') Percentage 
Pretreatment Treatment mice (mean S.E.M.) analgesia 
Saline Morphine 5 mg/kg 74 6.91 ±0.19 54.3 
Ephedrine 10 mg/kg Morphine 5 mg/kg 40 7.81 0.30(2) 67.6 
PPA lOmgAg Morphine 5 mg/kg 34 7.90 ±0.30 (2) 68.9 
Saline Codeine 60 mg/kg 94 6.45 0.10 47.5 
Ephedrine lOmglcg Codeine 60 mg/kg 61 7.34 0.27 (2) 60.6 
PPA 10 mg/kg Codeine 60 mg/kg 34 7.24 0.30 (2) 59.1 
(‘)Tail nick response of nonpretreated saline control mice was 3.24 0.08 (n = 136). 
(2) P<0.05 compared with the corresponding saline-pretreated group. 
J TABLE III 
Effects of varying closes of ephedrine and phenylpropanolamine (PPA) 
on the antinociceptive effects of morphine and codeine 
Tail nick time 
(sec) (I) Percentage 
Pretreatment No. of mice (mean S.E.M.) analgesia 
A. Treatment with morphine 5 mg/kg’ s.c. 
Saline 57 6.87 0.30 53.7 
Ephedrine 5 mg/kg 34 7.03 0.34 56.0 
Ephedrine 10 mg/kg 34 7.66 0.30(2) 65.3 
Ephedrine 20 mg/kg 34 8.05 0.34 (2) 71.1 
PPA 5 mg/kg 24 7.33 0.43 60.4 
PPA 10 mg/kg 24 8.25 0.37 (2) 74.1 
PPA 20 mg/kg 24 7.93 0.36(2) 69.4 
B. Treatment with codeine 60 mg/kg, s.c. 
Saline 45 6.86 ±0.31 53.5 
Ephedrine 5 mg/kg 36 7.93 0.32(2) 69.5 
Ephedrine 10 mg/kg 35 8.24 0.30(2) 73.9 
Ephedrine 20 mg/kg 36 8.93 0.29(2) 84.1 
PPA 5 mg/kg 23 7.38 0.50 61.2 
PPA 10 mg/kg 23 7.84 0.45(2) 67.9 
PPA 20 mg/kg 23 8.04 0.49 (2) 71.0 
(1) Tail flick response of nonpretreated saline mice was 3.25 0.08 (n = 108). 
(2) P < 0.05 compared with the corresponding saline-pretreated group. 
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Ephedrine and PPA, at a dose of lOmg/kg, i.p. given 10 min beforehand, 
significantly potentiated the antinociceptive effects of morphine 5 mg/kg 
and codeine 60 mg/kg. These doses of morphine and codeine were 
approximately the ED5 values of the respective drug in naive animals (see 
Table IV). 
The effects of varying doses of ephedrine and PPA on the antinociceptive 
effects of a single dose of morphine and codeine were studied and the 
results are shown in Table III. Ephedrine dose-dependently potentiated the 
antinociceptive activity of a dose of 5 mg/kg morphine. In the case of PPA 
with morphine, the dose-response relationship was not as obvious as in the 
case of morphine with ephedrine. As for the antinociceptive effect of 
codeine, both ephedrine and PPA dose-dependently enhanced the 
antinociceptive activities of codeine. 
Apart from the effect on the single-dose antinociceptive effects of codeine 
and morphine, the effects of ephedrine and PPA on the ED50 values of 
these two opiate drugs were also studied. The results are shown in 
Table IV. The ED50 value of s.c. morphine in saline-pretreated animals was 
determined to be 4.74 mg/kg. Ephedrine and PPA both caused a parallel 
shift of the dose-response curves of morphine to the left. Ephedrine dose-
I dependently enhanced the antinociceptive effect of morphine and the ED50 
TABLE I V 
Effects of i.p. ephedrine and phenylpropanolamine (PPA) on the ED^q values 
of morphine and codeine 
ED50 (95 /o confidence limits) 
Pretreatment (mglcg, s.c.) 
A. Morphine as the antinociceptive agent 
Saline 4.74 (4.58-4.90) 
Ephedrine 5 mg/kg 3.47 (3.45-3.50)(‘) 
Ephedrine 10 mg/kg 2.59 (2.44-2.76)(') 
Ephedrine 20 mg/kg 2.04 (1.86-2.24)(') 
PPA 5mg/kg 3.55 (3.27-3.85)(') 
PPA 10 mg/kg 2.34 (2.10-2.60)(') 
PPA 20 mg/kg 2.61 (2.26-3.01)(') 
B. Codeine as the antinociceptive agent 
Saline 56.43 (54.35-58.59) 
Ephedrine 5 mg/kg 33.71 (31.43-36.16)(') 
Ephedrine 10 mg/kg 21.72 (21.33-22.12)(') 
Ephedrine 20 mg/kg 17.87 (15.61-20.47)(') 
PPA 5 mg/kg 26.76 (23.96-29.89)(') 
PPA 10 mg/kg. 26.64 (25.52-27.80)(') 
PPA 20 mg/kg 16.20 (14.80-17.74)(') 
(1) Values significantly different from the corresponding saline control values. 
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values in these pretreated groups were significantly different from the 
saline-pretreated control animals. PPA also enhanced the antinociceptive 
effect of morphine though the dose-response relationship was not as clear-
cut as for ephedrine. The ED50 of morphine in animals pretreated with 
PPA, 10 mg/kg, was not different from those pretreated with PPA, 
20 mg/kg. Both ephedrine and PPA also caused a parallel shift of the dose-
response curves of codeine. Ephedrine dose-dependently potentiated the 
antinociceptive activity of codeine, as shown by significant decreases in the 
ED 50 values in those groups pretreated with ephedrine. Though pretreat-
ment with PPA, 5 mg/kg and 10 mg/kg, enhanced the antinociceptive 
activity of codeine, there was no significant difference in the ED 50 values of 
these two groups. When the pretreatment dose of PPA was increased to 
20 mg/kg, there was a further enhancement of codeine's antinociceptive 
activity, as shown by a further decrease in the ED 50 value. 
Discussion 
In the present study we have found that ephedrine and phenyl-
I propanolamine (PPA), at the doses studied, possess no apparent antino-
I ciceptive activity as measured by the tail flick test. However, these two 
I drugs potentiate the antinociceptive activities of both morphine and 
codeine. Such findings are at variance with those reported by Dewey et al 
(1970) who only used one dose level of ephedrine, but are in line with the 
general observations based on other sympathomimetics as reviewed by 
Szekely (1982). 
Ephedrine and PPA both have a direct action on the adrenoceptors, 
as well as an indirect action through the release of noradrenaline 
(Weiner, 1985). Administration of morphine and other opioid peptides has 
been shown to increase both plasma and brain levels of catecholamines 
(Rethy et al” 1971; Smith et al:’ 1972; Van Loon et al.’ 1981; Appel and 
Van Loon, 1986). In addition, opioids have been demonstrated to increase 
the central sympathetic outflow to the adrenal medulla and peripheral 
sympathetic nerve endings (Van Loon et al, 1981; Pfeiffer et al, 1983; 
Feldberg and Wei, 1986). It has previously been suggested that increasing 
the central adrenergic tone potentiates morphine analgesia, whereas deple-
tion of the catecholamines attenuates morphine analgesia (Dewey et al.’ 
1970; Fennessy and Lee, 1970). 
On the other hand, in vitro studies show that administration of opioid 
agonists results in an inhibition of sympathetic transmission in various 
tissues (Ledda and Mantelli, 1982; Fuder and Rothacher, 1984). Further-
more, there has been demonstrated a co-existence of aj-adrenoceptors and 
opioid recognition sites on the same neurones, and these receptors appear 
to be tightly coupled and seem to activate . common transmission 
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mechanisms (Unnerstall et al.’ 1981; Ramme et al, 1986; Surprenant and 
North, 1985; Aghajanian and Wang, 1986; Jackischi et al, 1986). All these 
studies demonstrate the interaction between the noradrenergic system and 
pioids. Our findings further support the suggestion that the opioid action 
is linked to the release of catecholamines. 
In the present study, the shifts in the dose-response curves were parallel 
in all cases, suggesting that the basic mechanism of the antinociceptive 
effect of the opioids was not altered by pretreatment with sympatho-
mimetics. Despite various pretreatments with sympathomimetics, the peak 
antinociceptive effects of codeine and morphine still occurred at 15 min and 
30 min, respectively, indicating that pharmacokinetic changes are unlikely 
to be responsible for the observed enhancement of opioid antinociceptive 
activities. 
The low addictive (and abuse) potential of codeine vis-a-vis morphine is 
a well-documented fact, so much that in most countries codeine-containing 
preparations are available over the counter, without prescription. Despite 
the widespread use of codeine (and other opioids) in combination with 
sympathomimetic agents, investigation of their interactions has received 
j relatively little attention. The finding by Chan et al (1990) of the high 
1 abuse rate of proprietary cough mixtures containing codeine and 
I ephedrine, partly inspired the present study. These preliminary findings 
that ephedrine and PPA potentiate the acute antinociceptive effects of 
codeine and morphine, may be a clue to the high abuse rate. It is possible 
that the mixture is more reinforcing than codeine alone, and, consequently, 
more liable to be abused. Tentatively, we have demonstrated that the abuse 
of proprietary mixtures of codeine and ephedrine may have a pharmaco-
logical basis. 
Further work is in progress to elucidate the mechanism of these inter-
actions and to explore the effects of these sympathomimetics on the 
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Effects of Sympathomimetic Agents on Opiate Analgesia Tolerance 
and Dependence in Mice 
Yoswa M. Dambisya, Chak-Lam Wong and Kelvin Chan 
Department of Pharmacology, Faculty of Medicine, The Chinese University of Hong Kong 
SUMMARY 
The effects of chronic pretreatment with ephedrine and phenylpropanolamine (PPA) on the antinociceptive activities of morphine and co-
deine, as well as their effects on the induction and expression of tolerance to, and dependence on morphine and codeine in mice are reported. 
Chronic pretreatment with ephedrine or PPA attenuated the antinociceptive effects of subsequently administered morphine or codeine. When 
administered during the induction phase, sympathomimetics enhanced opiate tolerance with little or no effect on the development of physical 
dependence. Given in the expression phase, ephedrine and PPA did not significantly affect tolerance, whereas there was significant suppression 
of withdrawal signs. The possible implications of these results are discussed. 
Key words: Opiate antinociception - Tolerance - Dependence - Ephedrine - Phenylpropanolamine - Withdrawal signs 
INTRODUCTION diet and tap water, and were kept under artificial light 
Ephedrine and phenylpropanolamine (PPA) are for 12 h each day (0600-1800 h). Each mouse was used 
widely used, often in combination with opiates, in ‘cold only once, 
and ‘cough’ mixtures. These mixtures are freely 
available over the counter in most countries. Whereas Drugs 
the low addictive, and abuse, potential of codeine vis- Morphine sulphate (Macfarlan Smith Ltd.), codeine 
a-vis morphine is a well-known fact, recent observa- phosphate (Macfarlan Smith Ltd.), phenylpropanol-
tions indicate a tendency towards increasing non- amine hydrochloride (Sigma), ephedrine hydrochloride 
medical use of codeine-containing preparations (15). (May & Baker) and naloxone hydrochloride (Dupont) 
The high abuse of ephedrine-codeine-containing cold were used. All doses refer to the weight of the salts 
preparations in Hong Kong has recently been reported used. Drugs were dissolved in physiological saline solu-
(3). The current study was undertaken in an attempt tion at such concentrations that requisite doses were 
to elucidate the interactions between these commonly given in a volume of 10 ml/kg subcutaneously (s.c.) 
used sympathomimetics and opiates, which may explain or intraperitoneally (i.p.) as applicable, 
the increased abuse phenomenon observed. In our 
earlier report (4) we showed that ephedrine and PPA Antinociceptive assay 
potentiated the acute antinociceptive effects of both The tail-flick method of D'Armour and Smith (5) 
morphine and codeine in mice. We now report on their was used with modifications, screening and calculations 
interactions after chronic treatment. as described in detail elsewhere (4). 
MATERIALS AND METHODS Chronic pretreatment with ephedrine or PPA 
A fixed dose of the sympathomimetic agent was ad-
Animals ministered i.p. twice a day for 3 days to investigate the 
Male ICR mice weighing between 30-35 g were used. effects on the antinociceptive activity of morphine, and 
Animals were allowed free access to standard laboratory i.p. twice daily for 4 days for the effects on codeine 
0379-0355/91/$5.00 + $2.00 
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antinociception. Assessment was done on the 4th day Dependence was assessed by the occurrence of 
for morphine and 5th day for codeine. Treatment withdrawal signs following a naloxone challenge (13, 
schedules were in line with those adopted for the in- 28). Naloxone was administered i.p. 45 min after the 
duction of morphine or codeine tolerance and acute codeine dose and 1 h after the acute morphine 
dependence. dose. Animals were labelled and weighed shortly before 
injection of naloxone and then reweighed 3 h later. 
Induction of morphine tolerance and dependence Following administration of naloxone mice were 
A three-day graded dose regimen was used for the observed for 15 min on an elevated platform (42 cm 
induction of morphine tolerance and dependence. The long, 28 cm wide and 60 cm high) for the occurrence 
treatment schedule consisted of twice daily s.c. doses of wet-dog shakes (WDS) and withdrawal jumping, 
given at 30 mg/kg (a.m.) and 45 mg/kg (p.m.) on day Mice were observed in groups of 7 or 8 and thereafter 
1 60 mg/kg and 90 mg/kg on day 2; and 120 mg/kg kept in well-ventilated cages without access to food and 
b.i.d. (a.m. and p.m.) on day 3. Animals were then water for the remaining 3 h. Percentage weight loss per 
assessed for both tolerance and dependence, as de- animal was obtained from the equation: 
scribed by Way et al. (27), on the 4th day. 
Original weight - weight 3 h later 
Induction of codeine tolerance and dependence Original weight 
A four-day treatment schedule was adopted to in-
duce codeine tolerance and dependence. Subcutaneous To assess the intensity of WDS a cut-off point of 
doses of codeine were given twice daily at 75. 100, 120 5 WDS per animal in 15 min was used. Preliminary 
and 150 mg/kg on day 1 , 2 , 3 and 4’ respectively. Mice observations had indicated that those mice having 5 or 
were then assessed on the 5th day for both tolerance more WDS tended to have them incessantly. The in-
and dependence, as for morphine. tensity of WDS was calculated as: 
Effects of sympathomimetics on the induction of mor- Group mean 
phine or codeine tolerance and dependence 
A fixed dose of ephedrine or PPA was given i.p. 
before the appropriate s c . doses ofmorphine f o r assessment of jumping only those animals that 
Z cod throughout the induction penod. Mice were jumped off the platform were considered positive for 
= a s s e s s e d for tolemnce and dependence as for tho^ this sign. Mice were returned to the platform after each 
that received only opiates during the induction penod. and a cut-off point of 3 jumps per animal in 15 
I,-- , - . . min was used as those that had 3 or more jumps would 
Effects of sympathomimetics on the expression of mor- u^^au, ^^ , i ‘ .‘ . . . 
. . . r ^ , J hardly stay on the platform. Intensity of jumping was 
phine or codeine tolerance and dependence calculated as. 
Only mice receiving no sympathomimetics during the 
induction phase were used for this purpose. An acute ^ 
dose of ephedrine or PPA was given i.p. 10 min before x 100 
the acute opiate dose during assessment for tolerance ^ 
and dependence. A few groups were given sym- _ , . . , , . 
pathomimetics shortly before naloxone challenge to off- analysis, the overall magnitude of the 
set the effects of the time-lag (see below). withdrawal syndrome was considered on the basis of 
all 3 parameters (20). 
Assessment of opiate tolerance and dependence 
Animals were assessed for both tolerance and Statistical analysis 
dependence (27). Tolerance was assessed as the loss of Dose-response curves, ED50 values and their 95% 
the antinociceptive effects of the opiates, using the tail- confidence limits were calculated using linear regres-
flick test (5) and was manifested by a shift of the dose- sion. A value was considered significantly different 
response curves to the right and an accentuation of the from the control value if it fell outside the 95% con-
ED50 values (8,12). The tolerance index was calculated fidence limits of the latter, and also if the control ED50 
the ratio of ED value in tolerant mice: ED50 value lay outside the 95% confidence limits of the compared 
in naive mice (17, 27). value. Three logarithmically-spaced dose levels, utiliz-
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Sympathomimetics and opiate analgesia, tolerance and dependence 241 
ing at least 42 mice, were used to determine each E D 5 0 . TABLE 1 . Effects of chronic ephedrine or P P A pretrealmeni on an-
Data o n the intensity o f W D S and jumping, and those linociceptive activities of morphine and codeine 
o n weight loss were compared using the unpaired ‘ “ 
(2-tailed) Student's t test. In all comparisons the level Morphine 
of s ignif icance w a s P < 0 . 0 5 . Pretreatment dose Morphine EDso mg/kg 
(mg/kg. b.i.d.x3 days) (95% confidence limits) 
RESULTS None 4.7 (4.5-4.9) 
Saline 10 ml/kg 5.2 (4.9-5.4) 
Fnhedrine 5 13.7 (12.6-14.9)' 
Effects of chronic ephedrine or P P A pretreatment on ^^ .. 9 2 (8.4 lo.o) 
the antinociceptive activities of morphine and codeine ” 20 13.2 (i 1.9-14.6)' 
Following chronic pretreatment with sympatho- PPA 5 9.0 (8.5-9.6)-
mimetics the antinociceptive effects of morphine and ; ^ 
codeine were significantly attenuated (Table 1). ” 
Pretreatment with saline for 3 or 4 days did not affect Codeine 
t he ant inocicept ive e f fec t s o f m o r p h i n e a n d codeine , pretreatment dose Codeine e d „ mg/kg 
respectively. N o withdrawal signs were observed in this (mg/kg, b.i.d. x 4 days) (95% confidence limits) 
group of mice. None - 56.4 (54.3-58.9) 
Saline 10 ml/kg 54.4 (49.7-60.4) 
Effects of ephedrine or PPA on the induction of opiate Ephedrine 5 137.6 (i 19.2-158.8)-
tolerance ” 0 128.4 (ii6.4-i4i.7) 
A three-day graded course o f morphine led to the ” 20 6 (99.4-mW 
development of tolerance with a tolerance index of 4.7. „ ,q 103.3 (94.9-i06.0)° 
Concurrent administration o f ephedrine or P P A (5, 10 ’ 20 100.5 (93.2-108.4)" 
m g / k g ) during the induction phase resulted in • “ 
significantly h igher to le rance (Table 2a). W h e n saline Values significantly different from corresponding control values. 
TABLE 2. Effects of ephedrine or PPA on induction of tolerance lo morphine and codeine 
Drug concomitantly adm. Dose of Opiate ED„ (mg/kg) Tolerance 
during induction phase sympathomimetic (95Vo conf. limits) 
(a) Morphine tolerance 
( i .p .x3 days) 
None (naive mice) 4.7 (4.5-4.9) \ 
None (morphine only) 22.2 (20.9-23.6) 4.7 
Saline (+ morphine) 10 tnl/kg 21.7 (20.9-22.7) 4.3 
Ephedrine ” 5 mg/kg 43.5 (37.5-50.5) 9.3 
” ” 10 mg/kg 42.1 (40.2-44.0) 9.0" 
PPA ” 5 mg/kg 49.7 (42.2-58.4) 10.6 
” ” 0 mg/kg 43.8 (40.9-46.9) 9.3. 
(b) Codeine tolerance 
(i.p. b.i.d.x4 days) 
None (naive mice) 56.4 (54.3-58.9) 1 
None (codeine only) 156.8 (156.8-160.9) 2.8 
Saline ( +codeine) 10 mi/kg 164.5 (158.2-171.8) 2.9 
Ephedrine ” 5 mg/kg 184.9 (165.5-206.6) 3.3 
PPA ” 5 mg/kg 248.5 (245.5-251.5) 4.4* 
” ” 10 mg/kg 180.7 (163.2-200.2) ^ 
•Values significantly higher than morphine only group. ^Values significantly higher than codeine only group. 
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was given during the induction period, subsequent and codeine tolerance and dependence. The results were 
tolerance was not affected. Concurrent administration similar to controls and are not shown, 
of ephedrine or PPA 20 mg/kg over the induction 
period was invariably fatal. Effects of ephedrine or PPA on the induction of mor-
A four-day graded course of codeine led to the phine and codeine dependence 
development of codeine tolerance, with a tolerance in- Results of the effects of sympathomimetics on the 
dex of 2.8. Concurrent administration of saline dur- development of morphine dependence are shown in 
ing this period did not affect the development of Table 3. A three-day course of morphine led to the 
tolerance (Table 2b). Ephedrine 5 mg/kg over the in- development of morphine dependence, as seen from the 
duction period produced a higher level of tolerance, but withdrawal signs. Concurrent administration of either 
this was not significantly different from that of the sympathomimetic during the induction phase apparent-
codeine-saline group. Higher ephedrine dose levels (10, ly had little or no effect on the development of 
20 mg/kg) during the induction phase were invariably dependence. The loss of weight was significantly lower 
fatal. PPA 5 mg/kg concurrently administered during at the highest dose level of naloxone (10 mg/kg) in all 
the induction of codeine tolerance led to a significant- test groups, but other withdrawal signs were essential-
ly higher level of tolerance. PPA 10 mg/kg apparently ly the same, except for the ephedrine 5 mg/kg group 
had no effect on the development of tolerance; this at naloxone 5 mg/kg, which exhibited significantly less 
group, however, had high mortality rates over the four- intense WDS. Concurrent administration of saline dur-
day treatment period. Concurrent administration of ing the induction phase did not affect the development 
PPA 20 mg/kg was invariably fatal. A smaller dose of morphine dependence, and the same was the case 
level of ephedrine or PPA (2.5 mg/kg), which showed for the lower ephedrine or PPA dose level (2.5 mg/kg). 
no effect on acute interactions, was concurrently ad- The results of the effects of ephedrine or PPA on 
ministered in the induction phase for both morphine the induction of codeine dependence are shown in Table 
TABLE 3. Effects of ephedrine/PPA on induction of morphine dependence 
Cone. adm. drug in 
induction period No. of Naloxone Vo Weight loss Wet-dog shakes Jumping 
(+ morphine) mice (i.p. mg/kg) Mean ± SEM Mean ± SEM (%) Mean ± SEM (%) 
16 Saline 5.4± 0.8 0.44 ±0.18 8.8 0 0.0 
. . . . , 16 2.5 6.2±0.6 3.56±0.38 71.3 0.31 0.21 10.4 
Morphine only j 6.8 0.6 4.56 0.20 91.3 .19 0.33 39.6 
16 10 9.9±0.5 4.88 ±0.23 97.5 1.44 ±0.36 47.9 
14 Saline 5.4±0.6 0.57 ±0.27 11.4 0 0.0 
Ephedrine S mg/kg 5 2.5 7.1 ±0.6 3.00± 0.39 60.0 0.07 ± 0.07 2.2 
b.i.d.x3 days 15 5 7.0±0.6 3.53±0.43' 70.7 0.67 ±0.27 22.2 
15 10 7.0 0.6 4.20 ±0.33 84.0 0.80 ±0.30 26.7 
14 Saline 4.1 ±0.7 0.57 0.25 11.4 0 0.0 
Ephedrine 10 mg/kg 16 2.5 4.8±0.6 4.38 0.31 87.5 0.38±0.26 12.5 
b.i.d.x3 days 16 5 6.5±0.7 4.56± 0.18 91.3 1.06 ±0.31 35.4 
16 10 7.5±0.6 4.50 ±0.35 90.0 1.19±0.32 39.6 
21 Saline 3.2 ±0.4- 0.48 ±0.18 9.5 0 0.0 
PPA 5 mg/kg 25 2.5 6.4±0.6 3.28±0.35 65.6 0.28±0.17 9.3 
b.i.d.x3 days 25 5 5.1 ±0.5 4.56± 0.15 91.2 0.44 ±0.19 14.7 
25 10 6.7 ±0.4- 4.48 ± 0.15 89.6 0.96 ±0.25 32.0 
17 Saline 4.6 ±0.5 0.53 ±0.19 10.6 0 0.0 
PPA 10 mg/kg 20 2.5 7.3 ±0.5 3.60 ±0.36 72.0 0.5 ±0.25 16.7 
b.i.d.x3 days 22 5 8.1 ±0.7 4.50± 0.21 90.0 0.77 ±0.25 25.8 
21 10 7.4 ±0.5- 4.24 ±0.37 84.8 1.38± 0.30 46.0 
•Values significantly lower than corresponding values in morphine only group. 
• 2 6 0 
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TABLE 4. Effects of ephedritte/PPA on induction of codeine dependence 
Cone. adm. drug in 
the induction period. No. of Naloxone % Weight loss Wet-dog shakes jumping 
(+ codeine) mice (i.p. mg/kg) Mean±SEM Mean±SEM (%) Mean±SEM (%) 
23 Saline 4.56 ± 0.50 0.26 ±0.09 5.2 0 0 0 
Codeine only 2.5 6.03 ± 0.24 2.21 ±0.27 45.5 0 0 0 
30 5 6.40 ±0.39 4.00 ±0.24 80.0 0.13 ±0.08 44 
10 6.76 ±0.43 4.55 ± 0.31 91.0 0.29 ±0.12 9*7 
17 Saline 4.53 ± 0.62 0.47 ±0.23 n .g 0 0 0 
Ephedrine 5 mg/kg 20 2.5 4.65 ±0.4- 2.85±0.36 57 0 0 O O 
b.i.d.x4 days 20 5 4.84 ±0.5_ 3.55±0.42 71.0 0 0 0 
20 10 5.74 ±0.59 3.85 ± 0.39- 77.0 0.25 ±0.14 8.3 
16 Saline 3.63 ±0.5 0.31 ±0.18 6.3 0 0 0 
PPA 5 mg/kg 18 2.5 4.80±0.59- 3.44 0.44» 68.9 0 0 0 
b.rd.x4days 18 5 5.60± 0.66 4.22 0.33 84.4 0.11 0.11 
18 10 6.40 ± 0.67 4.50 ±0.25 90.0 0.39 ±0.20 13.0 
Saline 4.40 ±0.52 0.36±0.17 7.1 0 0 0 
PPA 10 mg/kg 14 2.5 5.09±0.52- 2.14 0.48 42.1 0 o O 
b.i.d.x4days 4 5 5.28 ± 0.80 2.64 ±0.51- 52.9 0.14 ±0.14 4 8 
JO 5.90 0.62 3.07 ±0.49- 61.4 0.21 ±0.16 7.1 
•Significantly lower than corresponding values in codeine only group. 
^Significantly higher than corresponding values in codeine only group. 
j 4. A four-day course of codeine led to detectable 10 min before acute codeine in the assessment of co-
dependence. When ephedrine 5 mg/kg was given dur- deine tolerance had no effect. However, at 10 mg/kg 
n t^he induction period subsequent withdrawal signs of either agent, the degree of tolerance was apparently 
indicated less weight loss at naloxone dose levels 2.5 less, being outside the 95% confidence limits of the con-
and 5 mg/kg, with less intense WDS at naloxone 10 trol value. In the latter cases, though, some of the 
mg/kg. With PPA 5 mg/kg, the weight loss was less animals that received the higher codeine dose levels died 
at naloxone dose level 2.5 mg/kg, whereas the intensi- within 45 min. but after the assessment for tail-flick 
ty of WDS was higher in the same group. Concurrent latency. Ephedrine or PPA 20 mg/kg led to high mor-
administration of PPA 10 mg/kg during the induction tality rates (>75%) for mice that received the higher 
phase led to less weight loss at naloxone dose 2.5 mg/kg codeine doses and were subsequently excluded, 
and less intense WDS at naloxone dose levels 5 and 10 
mg/kg. The combination of codeine with sym- Effects of sympathomimetics on the expression of 
pathomimetics was associated with high mortality rates opiate dependence 
during the induction period. The effects of ephedrine or PPA on the expression 
Taking all withdrawal features into consideration of morphine dependence are shown in Table 6 
2^0), sympathomimetics did not significantly affect the Ephedrine or PPA was given 1 h 10 min before nalox-
development of opiate dependence. one challenge. Most parameters were significantly sup-
‘ , . . pressed in the groups that received ephedrine injection 
Mfects of ephednne or PPA on the expression of opiate compared to those assessed without it. Likewise, prior 
tolerance treatment with PPA tended to suppress some of the 
Results of the administration of ephedrine or PPA withdrawal signs. 
miji before the acute opiate dose during assessment The effects of ephedrine or PPA on the expression 
for tolerance are shown in Table 5. Morphine tolerance of codeine dependence are shown in Table 7. As was 
w? not significantly affected by acute pretreatment the case for morphine d encfence, there was a reduc-
with sympathomimetics at the doses used (Table 5a). tion in the intensity of withdrawal signs in mice that 
Acute pretreatment with ephedrine or PPA 5 mg/kg received sympathomimetics (55 min) prior to naloxone. 
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TABLE 5. Effects of ephedrine or PPA on the expression of morphine and codeine tolerance 
ED50 mg/kg 
Acute pretreatment (95% conf. limits) 
(a) Morphine tolerance 
None 22.2 (20.9-23.6) 
Ephedrine 5 mg/kg 24.1 (23.4-25.2) 
” 10 mg/kg 25.4 (19.4-33.1) 
” 20 mg/kg 23.1 (22.4-23.8) 
PPA 5 mg/kg 24.8 (23.5-26.1) 
” 10 mg/kg 20.8 (20.3-21.4) 
” 20 mg/kg 19.5 (18.3-20.7) 
(b) Codeine tolerance 
None 56.8 
(152.8-160.9) 
Ephedrine 5 mg/kg 129.4 
(108.9-153.9) 
, 10 mg/kg 125.5 
(110.7-142.3)' 
PPA 5 mg/kg 174.3 
(144.3-210.6) 
“ 1 0 mg/kg 139.7 
(130.6-151.2)-
•Values significantly lower than in no pretreatment controls. 
To offset the effects that the time-lag between ad- and adrenergic agonists exhibit dose-dependent an-
j ministration of sympathomimetics and naloxone tinociceptive activity after intrathecal administration 
j challenge may have on the effects of the former on the (31, 32). These antinociceptive effects are, however, 
expression of opiate dependence, some groups received m e d i a t e d t h r o u g h d i f f e r e n t m e c h a n i s m s (23) . 
ephedrine or P P A 10 m g / k g s .c . 10 min before nalox- Systemically administered clonidine, an a2-adrenergic 
one. The results are shown in Table 8. Clearly, acute agonist, shows potent antinociception (14). Paalzow 
pretreatment with sympathomimetics significantly sup- (21) reported that rats rendered tolerant to clonidine 
pressed withdrawal signs. by repeated s.c. injections showed cross-tolerance to 
acute s.c. morphine. It was subsequently shown (18) 
DISCUSSION that tolerance to the behavioral effects of clonidine 
In this study chronic pretreatment with ephedrine or developed after chronic administration of morphine. 
PPA led to the attenuation of morphine and codeine Our earlier findings (4) showed that in naive mice 
analgesic activities. The development of tolerance to ephedrine and PPA had no demonstrable antinocicep-
opiates was apparently enhanced by concomitant ad- tive effects of their own after i.p. administration, but 
ministration of sympathomimetics during the induction significantly potentiated the antinociceptive effects of 
phase, whereas the opiate dependence that developed an acute opiate dose. In this report, chronic pretreat-
was not affected to a large extent. On the other hand, ment with sympathomimetics led to an attenuation of 
the expression of opiate tolerance was apparently not the antinociceptive effects of morphine and codeine, 
affected by acute pretreatment with sympathomimetics, After repeated s.c. opiate injections, sympathomimetics 
while withdrawal signs were significantly suppressed. tended to lose their potentiating effects on opiate 
During the course of these interactions toxicity of analgesia. From this perspective, cross-tolerance be-
opiates tended to be enhanced. tween opiates and sympathomimetics probably occurs. 
Adrenergic mechanisms have always been implicated Interactions between ephedrine or PPA 10 mg/kg and 
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TABLE 7. Effects of ephedrine/PPA on expression of codeine dependence 
No. of Naloxone % Weight loss Wet-doe shakes , • 
Acutep .ice i.p. mg/kg) Mean.SEM M s^d/Mg 
Saline 4.56 ± 0.5 0.26 ±0.09 T l 0 ^ 
None 29 2.5 6.03 ± 0.24 2.21 ±0.27 45.5 0 q q 
f , 6.40 0.39 4.00 0.24 80.0 0.13 0.08 4 4 
31 10 6J6±0.43 4.55 0.31 91.0 0.29±0.12 9 7 
Saline 3.21 ±0.68 0.40 ±0.22 8.0 0 0 0 
Ephedrine 5 mg/kg 2.5 4.83±0.57 2.20± 0.47 44 0 0 nn 
; 5 4.48 ± 0.52- 2.70 ± 0.67- 54.0 0 n'o 
” 10 6.11 ±0.77 2.80 0.59- 56.0 0.50 0.32 ,67 
18 Saline 4.82±0.51 0.36 ± 0.20 7 2 0 0 0 
PPA 5 mg/kg I I 2.5 5.77±0.67 .08±0.47 21.6 0.08 ±0.08 2 7 
I I 5 5.97 ±0.46 .75±0.60" 35.0 0 0 0 
22 10 5.15±0.51 2.00±0.52« 40.0 0 OO 
14 Saline 2.70 ±0.45° 0.50 ± 0.27 10.0 0 0 0 
PPA 10 mg/kg 14 2.5 2.80±0.42 3.00± 0.60 60.0 0 n'n 
5 4.13 ±0.61 2.91 ±0.48 58.2 0 on 
10 10 4.50 0.70^ 3.50 0.68 70.0 0.13 0.13 42 
•Values significantly less than in corresponding codeine only group. 
TABLE 6. The effects of ephedrine/PPA on the expression of morphine dependence 
No. of Naloxone % Weight loss Wet-dog shakes 
Acute pretreatment mice (i.p. mg/kg) Mean.SEM Mean^SE^^ (.o) Me , S T _ 
If Saline 5.40± 0.8 0.44 ±0.18 8.8 0 0 0 
None ^ 2.5 6.20±0.6 3.56 0.38 71.3 0.31 0.21 ,04 
\ 0.6 4.56^0.20 91.3 1.19±0.33 39 6 
J 6 0 9.90 0.5 4.88 0.23 97.5 1.44^0.36 47 9 
i II SajM^r 4.41 0.33 0.41 ±0.17 8.2 0 no 
Ephedrine 5 mg/kg = 2.5 6.29±0.56 2.31 ±0.38- 46.2 0.12±0 12 4 0 
26 3.62±0.37" 72.3 0.12 0.12 4.0 
f 10 7.42^0.51- 3.69±0.34- 73.8 0.69^0.21' 23 1 
f Saline 2.70±0.4« 0.38 ±0.13 7.1 0 0 0 
Ephedrine 10 mg/kg 25 2.5 3.30±0.3° 0.88±0.29- 17 4 0 0 0 
25 0.4 1.80±0.34" 36.5 0.24^0.14 77 
10 6.90 0.4 1. 0.38 37.4 0.28 0.15 91 
Sahne 3.70±0.5 0.43 ± 0.20 8.6 0 0 0 
Ephedrine 20 mg/kg 5 2.5 4.40±0.4" 3.20± 0.54 64.0 0 40 ± 0 24 13 3 
5 ,0 = 3 " .51 62.7 0.27 0:21. 8:9 
15 10 6.40=t0.46« 3.71:t0.52- 74.3 0.43 ±0.25' 91 
II Saline 3.46 ±0.57- 0.39±0.21 7.7 0 0 0 
PPA 5 mg/kg ^ 2.5 3.54 0.52 .93 0.45. 38.6 0.14 0.09 4 8 
^51 3.39'±0.47- 67.7 0.46 0.24 15.3 
‘ 10 6.24^0.46- 3.39^0.57- 67.7 .16 0.34 38 5 
\1 Sahne 3.57 ±0.63 0.33 ±0.19 6.7 0 0 0 
PPA 10 mg/kg 2.5 5.80±0.68 2.58± 0.63 51.6 0.25 ±0.25 8 3 
6.90 0.68 3.17 0.58 63.4 0.62^ 0.29 20:7 
, 10 7.21 ±0.58' 3.92±0.51- 78.4 0.83 ± 0.39 27.9 
Sahne 3.59 ±0.39- 0.38 ±0.21 7.6 0 0 0 
PPA 20 mg/kg ^ 2.5 4.07±0.49" 1.43±0.37- 28.6 0 0 0 
, , 5.75±0.56 2.71 ±0.57- 54.2 0.43 ±0.23" 14 3 
5.51 ±0.52- 3.00^:0.49' 60.0 0.43 ±0.23' 14.3 
•Values significantly lower than in corresponding morphine only group. 
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TABLE 8. Effects of ephedrine/PPA on expression of morphine/codeine dependence (symp. adm. 10 min before naloxone) 
Treatment No. of Naloxone % Weight loss Wet-dog shakes Jumping 
(s c.) mice (i.p. mg/kg) Mean ±SEM Mean ±SEM (%) Mean ± SEM («7o) 
(a) Morphine dependence 
15 Saline 3.62 ±0.4- 0.21 ±0.18 4.2 0 0.0 
Ephedrine 10 mg/kg 2.5 4.02 ±0.6" 0.72±0.4- 14.4 0 0.0 
15 5 4.90 ±0.8- 1.42 ±0.32" 28.4 0 0.0 
15 10 6.10 ±0.5- 1.69 ±0.42" 33.8 0.38 ±0.21- M.I 
15 Saline 4.10 ±0.52" 0.32 ± 0.23 6.4 0 0.0 
PPA 10 mg/kg 16 2.5 4.29±0.42'' 1.10±0.52" 22.0 0 0 
16 5 5.20 ±0.7° 1.25 ± 0.6- 25.0 0 0.0 
16 10 7.10±0.8° 1.92 ±0.75- 38.4 0.43 ±0.32" 8.6 
(b) Codeine dependence 
14 Saline 3.10±0.5* 0.28 ±0.12 5.8 0 00 
Ephedrine 10 mg/kg 2.5 3.90±0.46» 0.92±0.63' 18.4 0 0.0 
17 5 5.10±0.56* 0.96*0.52" 19.2 0 0.0 
17 10 4.90 ±0.72* 1.38 ±0.44" 27.6 0 0.0 
16 Saline 2.62 ±0.52' 0.41 ±0.16 8.2 0 0.0 
PPA 10 mg/kg 18 2.5 3.46±0.38» 1.12±0.6* 22.4 0 0.0 
8 5 4.25 ±0.41* 0.98 ±0.46* 19.6 0 0.0 
>8 10 5.20 ±0.48* 1.30 0.44» 26.0 0 0.0 
•Significantly less than corresponding controls (see Table 3). 
'Significantly less than corresponding controls (see Table 4). 
mice sympathomimetics potentiate codeine antinocicep- are lowered and subsequently administered opiates pro-
tion. This, however, may be due to the high toxicity duce less profound antinociception. After chronic ad-
of these combinations, as already mentioned, or it may ministration of opiates, which may also lower 
be that the level of codeine tolerance (tolerance index catecholamine levels, an acute dose of the sym-
2.8, Table 2b) after the induction regimen used is still pathomimetic may not significantly elevate the 
too low. catecholamines to affect the reduced sensitivity to 
When sympathomimetics were given together with opiates in the tolerant state, 
morphine in the induction phase, the combination led In the induction phase sympathomimetics had little 
to the development of enhanced tolerance. Data from or no apparent effect on the development of opiate 
the codeine-sympathomimetic combinations are com- dependence. The development of physical dependence 
plicated by the fact that there was usually high toxicity may be mediated by mechanisms different from those 
observed, and whereas the surviving mice appeared for tolerance (30). In the acute situation there are in-
grossly normal, this may have contributed to the ap- dependent mechanisms for adrenergic and opiate an-
parent discrepancies relative to those for morphine. It tinociception (23). It has recently been shown that the 
is noteworthy that interactions of PPA 5 mg/kg + co- clearance of opiates may not be affected by adrenergic 
deine during the induction period were free of any mor- agents (19). Concomitantly administered ephedrine or 
tality and resulted in a significantly higher level of PPA may not, therefore, affect the access of opiates 
tolerance (Table 2b). These results may also be inter- to opioid receptors, which would explain the apparent 
preted in terms of the possible catecholamine level lack of effect on the development of dependence, 
changes. Depletion of central catecholamine levels leads The expression of physical dependence, on the other 
to attenuation of opiate analgesia (7’ 25). Repeated ad- hand, has a large component of sympathetic activity, 
ministration of ephedrine or PPA leads to depletion Clonidine has been shown to suppress some aspects of 
of catecholamines from tissues (29). After chronic ad- the opiate withdrawal syndrome (1’ 10’ 11’ 26). It is 
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the locus coeruleus n e u r o n s , by a direct action on consumption of cough and cold remedies in Hong Kong youths. 
of2-adrenoceptors (16). Bo th ephedrine and P P A have Neurosci Lett 1990, Suppi. 40 si8. 
indirect as well as direct e f f e c t s o n adrenoceptors (29) 4. Dambisya, Y.M.’ Wong, C.L., Chan. K. The effects of ephedrine 
The apparent suppression o f withdrawal signs observed ond Phenylpropanolamine on the antinociceptive effects ofmor-
when these sympathomimet ics were administered could tn. — e in mice. Arch mt Pharmacodyn 1990.308 
p robab ly be d u e t o their d i rec t act ion o n adrenocep- 5. D'Armour, F.E.. Smith, D.L. A method for determining loss 
tors, as proposed for clonidine (16). of pain sensation. J Pharmacol Exp Ther 1941’ 72: 74-9. 
O n e recurrent obse rva t ion in this s tudy was that of Engberg, I., Marshall, K.C. Mechanism of noradrenaline hyper-
high lethal toxicity of op ia te - sympa thomimet ic com- ~ 9 7 1 . ^ 
birjations. T h e regimens a d o p t e d for induct ion of mor- 1. Fennessy. M.R., Lee. J.R. Modification ofmorphine analgesia 
phine or codeine to lerance a n d dependence were free by drugs affecting adrenergic and tryptaminergic mechanisms. 
of any fatali t ies on their o w n . Similarly, ephedrine or Pharm Pharmacol 1970, 22 930-5. 
P P A (5, 10. 20 mg /kg ) given alone b. i .d. over 3 or 4 & ernandes M.. Kluwe. S.. Coper. H. The development of 
UA j / .if . . T I tolerance lo morphine in the rat. Psychophartnacology 1977,54: 
days led to no deaths in mice. Another sym- 197-201. ^ 
pathomimetic agent, cocaine, is known to potentiate 9. Finkie, B.s., McCioskey, K.L. The forensic toxicology ofco-
toxicity of morphine (2), a fact that is even clinically caine. in: Cocaine. Petersen, R.C.. Stillman, R.C. (Eds.). Natl 
reflected (9). Since codeine-sympathomimet ic mixtures Drug Abuse Rockviiie. MD. USA 1977. Research 
DRUGHS of abuse, t he possibility .0. D.R., H O. 
f higher toxicity of the combina t ion compared to either ficacy of clonidine in opiate withdrawal: A study of thirty pa-
ingredients should be b o r n e in mind , m o r e so in the “ents. Drug Alcohol Depend 1980, 6: 201-8. 
setting of non-medical use of drugs, since the doses can- ‘ ‘ Hamburg, M., Tallman, J.F. Chronic morphine administration 
not be control led increases the apparent number of Ui-adrenergic receptors in rat 
, , . ‘ . . brain. Nature 1981, 291: 493-5. 
In conclusion, we have extended our previous study 12. Kalant, H., LeBIanc. A.E., Cibblings, R.J. Tolerance ,0, and 
(4), m which we noted that in the acute setting a com- dependence on, some non-opiate psychotropic drugs. Pharmacol 
bination of codeine with a sympathomimet ic may make Rev 971’ 23 35-91. 
the mixture m o r e reinforcing, and therefore more liable Kameii, c . , Ueki. S. Naloxone-induced abstinence syndromes 
trt hp nhiicpH Frr^m tUic „ ‘ ^"orphine treated mice. Jpn J Pharmacol 1974, 24: 655-7. 
. . . . • i c p u i L u w o u l u a p p e a r i n a i 1 4 . K a w a s a k i , K . , T a k e s u e , H . , M a t s u h i t a , A • Modulation of spinal 
m situations where sympa thomime t i c agents are reflex activities in acute spinal rats and a-adrenergk agonist 
chronically co-adminis tered with opiates , tolerance to clonidine. Jpn j Pharmacol 1978, 28: 165-9. 
opiates develops faster, whereas the rate of dependence Kreek, M.R. Multiple drug abuse patterns and medical conse-
development remains unaltered. A drug abuser would Psycj^o^ari^aco ogy: The Third Generation of Pro-
. , ^ gress. Meltzer. H.Y. (Ed.). Raven Press: New York 1987 
require larger amounts sooner than would be the case 1597-I604. ’ 
if only the opiate (equivalent amoun t ) were being taken, J6. Lai, H.. Fielding. S. Clonidine in the treatment of narcotic ad-
tO achieve the original ‘h igh , . This would then expose diction. Trends Pharmacol Sci 1983. 4: 70-1. 
the individual to the greater toxicity of the combina- Martin’ W.R., Sloan, J.W. Neuropharmacology and 
t i o n o f t h a o c " t c ^ f a « : o » . ‘ . neurochemistry of subjective effects, analgesia, tolerance and 
Some of these aspects o f Opiate-SympathomimetlC dependence produced by narcotic analgesics. In: Drug Addic-
mteractions are still under investigation. tion, Vol. 1. Martin, W.R. (Ed.). Springer-Verlag: Berlin 1977 
43-158. ‘ 
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Abst rac t . E p h e d r i n e a n d p h e n y l p r o p a n o l a m i n e ( P P A ) have been pa r t i cu la r ly interested in the a b u s e of cold a n d 
(10 mg/kg) pretreatment intraperitoneally (IP) poten- cough "remedies" which contain codeine and ephedrine 
t iated the an t inoc icep t ive effects of s u b c u t a n e o u s (SC) ( C h a n et al. 1990). T h e low addict ive a n d abuse po ten t i a l 
morphine (5 mg/kg) and codeine (60 mg/kg) in mice of codeine vis-a-vis morphine is well known, and no 
using the tail-flick method. Prior administration of pro- doubt forms the basis for the free availability of codeine-
pranolol (6 mg/kg, SC) 10 min before the sym- containing preparations. On the assumption that the 
pathomimetics had no effect on this action. Phen- high degree of abuse could be due to altered activity of 
tolamine (2 mg/kg, SC), on the other hand, abolished the codeine (and other opioids) in the presence of sym-
enhancing effects of ephedrine and PPA on opioid pathomimetics, the current study was undertaken. We 
antinociception. Prazosin (2 mg/kg, SC) pretreatment have previously reported that in t^ je :cute set n 
did not significantly affect the potentiation of opioid rine and phenylpropanolamine (PPA) potentiate the 
antinociception by ephedrine and PPA, while yohimbine antinociceptive activities of both morphine and codeine 
(4 mg/kg, SC) effLtively antagonised this enhancing ef- (Dambisya et al. 1990): Studies on the chronic mterac-
fect. None of he adrenoceptor antagonists had any effect tions between these opioids and the sympathomimetics 
on the tail-flick reac t ion t ime o n the i r own in the doses suggest t h a t t he I f e ^ h a n ^ h e of 
used, and neither did they affect opioid antinociceptive tolerance without affecting the development of physical 
resp ses. It is c o n c l u d e d fhat e p h e d r i n e and PPA poten- dependence; whereas m the expression phase tolerance 
tiate the antinociceptive effects ofmorphine and codeine, is not affected but the withdrawa ' = = 
_ probably through an action on a.adrenoceptors. 
Key words: O p i o i d an t inoc i cep t ion - A d r e n o c e p t o r an- so far been largely speculative. This r e p o r t is an attempt 
tagonists — Sympathomimetics - Potentiation - a,- to interpret these interactions m terms of adrenoceptor 
Adrenoceptors activation. 
Materials and methods 
Many studies have implicated adrenergic mechanisms in 
various opio id ac t ions (Fennesy and Lee 1970; Shiomi Animals. Male ICR mice weighing 30-35 g were used. The animals 
and Takagi 1974 Aghajanian 1978 W o n g 1984 Van were allowed free access to standard laboratory diet ^nd tap water 
der L a a n 1985). I t is b e c o m i n g increasingly evident t h a t and were kept under artificial light for 12 h each day (0600-1800 
activation o f the bulbospinal noradrenergic pathways hours). Each mouse was used only once. 
may be one of the common actions by which both Drugs. Morphine sulphate and codeine phosphate (Macfarlan 
opioids and adrenergic agonists mediate their antinoci- smith Ltd) ephedrine hydrochloride (May and Baker) phenyl-
ceptive activities (Yaksh 1985 Monasky et al. 1990) propanolamine hydrochloride, propranolol hydrochloride and yo-
thoueh apparently through different sites o f action himbine hydrochloride (Sigma Co.) phentolamine (Ciba-Geigy); 
/ p ^ H H v .^t q I 1QRO • Stevens et al 1988 Manv codeine- and prazosin hydrochloride (Pfizer Inc.) were used. The drugs were (Reddy et al. 198U Mevens et al. M a n y c o a e m e dissolved in physiological saline solution at such concentrations 
containing preparations are freely available over the ^at the requisite doses were given in a volume of 10 ml/kg, sub-
counter in most countries and the increasing non-medical cutaneously (SC) or intraperitoneally (IP) as applicable. The doses 
use of such preparations has been cited (Kreek 1987). We refer to the weight of the salts used. 
* Present address: School of Pharmacy, Portsmouth Polytechnic, Antinociceptive assay. The tail-flick method of D Armour and 
Portsmouth POl 2DT, UK Smith (1941) was used, with modifications, screening and calcula-
Offprint requests to: Y.M. Dambisya tions as described in detail elsewhere (Dambisya et al. 1990). The 
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mice were screened prior to the treatment and those showing no Effects of phentolamine and propranolol on the 
response within 5 s were excluded from the study. During the test potentiating effects of ephedrine and PPA on opioid 
those showing no tail-flick reaction within 10 s were considered to antinociception 
exhibit 100% analgesia. The percentage analgesia was calculated as: 
test group mean-saline control mean The effects of phentolamine and propranolol on the 
10-saline control mean 100 potentiation of morphine or codeine antinociception by 
ephedrine and PPA were investigated and the results are 
As in our earlier reports, the peak effects of codeine and mor- shown in Table 2. As previously established, ephedrine 
phine occurred at 15 min and 30 min, respectively, after SC ad- and PPA (10 mg/kg) had no effect on the tail-flick reac-
ministration. Ephedrine and PPA were administered IP 10 min tion time (Table 2a), but significantly enhanced the 
SC^O rtf^th " * ac tinocice ^viti. ^ f^phinef mg/kg) (Table 
received saline injections at the corresponding times. Where the 2b) and codeine (60 mg/kg) (Table 2c). Pretreatment with 
same route of administration was employed for subsequent treat- phentolamine (2 mg/kg) 10 min SC before the ad-
ments, different sites were used. ministration of either ephedrine or PPA had no effect on 
the tail-flick reaction time (Table 2a), but abolished the 
Statistical analysis The data for the mean tail-flick reaction time ability of the sympathomimetics to enhance morphine 
were analyzed and compared by means of the unpaired Student s antinociception (Table 2b). The same was the case with 
codeine as the antinociceptive agent (Table 2c). 
Propranolol (6 mg/kg) SC, on the other hand, in 
combination with ephedrine or PPA had no apparent 
Results effect on the tail-flick reaction time and neither did it 
affect the ability of ephedrine and PPA to enhance opioid 
Effects of the various adrenoceptor antagonists antinociception. 
on opioid antinociception 
The effects of phentolamine, a non-selective a- Effects of yohimbine and prazosin on the potentiating 
adrenoceptor antagonist; propranolol, a non-selective effects of ephedrine and PPA on opioid antinociception 
p-adrenoceptor antagonist; yohimbine, a selective 0.2-
adrenoceptor antagonist; and prazosin, a selective oti- The effects of yohimbine and prazosin on the modifica-
adrenoceptor antagonist, on the antinociceptive activi- tion of the antinociceptive activities of morphine and 
ties of morphine and codeine are shown in Table 1. None codeine by the sympathomimetics were also investigated, 
of the antagonists affected the tail-flick reaction time The results are shown in Table 3. Yohimbine (4 mg/kg, 
(Table la). Similarly, they had no effect on the antinoci- SC) in combination with either sympathomimetic had no 
ceptive action of morphine (5 mg/kg) (Table lb), and effect on the tail-flick reaction time (Table 3a), but signifi-
codeine (60 mg/kg) (Table Ic). cantly abolished the enhancing effect of ephedrine and 
PPA (10 mg/kg, IP) on SC morphine (5 mg/kg) and 
codeine (60 mg/kg) antinociception. Prazosin (2 mg/kg, 
. . j SC), on the other hand, had no apparent effect on the 
Table 1. Effects of various adrenoceptor antagonists on opioid tail-flick reaction time in combination with either sym-
antmociception pathomimetic (Table 3a), and neither did it affect the 
Pretreatment (SC) No. of Tail-flick time % anal- potentiation of morphine or codeine antinociception by 
mice (mean SEM) gesia either sympathomimetic. 
(a) Saline 10 ml/kg 
Saline control 38 3.06 0.17 - Discussion 
Phentolamine (2 mg/kg) 26 3.18 0.16 -
Propranolol (6 mg/kg) 21 3.24 0.21 - The present study has shown that the adrenoceptor an-
= 2 r/mgl) Is 3 36^0 20 a^gonists used, viz: propranolol (6 mg/kg) 
' ’ (2 mg/kg), prazosin (2 mg/kg), and yohimbine (4 mg/kg) 
(b) Morphine 5 mg/kg had no antinociceptive activities on their own, and also 
Saline 19 6.43 ±0.54 48.6 had no effect on the antinociceptive responses to codeine 
Phentolamine (2 mg/kg) 22 6.47 0.53 49,1 (60 mg/kg, SC) or morphine (5 mg/kg, SC). The doses of 
Propranolol (6 mg/kg) 18 6.65 0.57 51.7 morphine (5 mg/kg) and codeine (60 mg/kg) used were 
= kg) j i l U P-iously found to be oxi e 
® ED50 values; while ephedrine and PPA at 10 mg/kg IP 
(cj Codeine 60 mg/kg have been demonstrated to significantly enhance opioid 
Saline 29 6.80 0.51 53.9 antinociception (Dambisya et al. 1990). The doses of the 
Phentolamine (2 mg/kg) 28 6.87 ±0.48 54.9 adrenoceptor antagonists were adopted from those used 
Propranolol (6 mg/kg) 23 6.56 0.57 50.4 by other workers and are considered to selectively block 
Yohimbine (4mg/kg) 18 6.62±0.55 51.6 he respective receptors (Doherty and Hancock 1983; 
Prazosin (2 mg/kg) 26 6.35 0.55 47.7 ^ ^ ^ g 1984, 1986) Propranolol, a p-adrenoceptor an_ 
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Table 2. Effects of phentolamine and propranolol on sympathomimetic potentiation of opioid antinociception 
Pretreatment No. of mice Tail-flick time % analgesia 
(mean SEM) 
(a) Saline 10 mllkg, SC 
Saline control 41 3.08 0.15 -
Ephedrine (10 mg/kg) 18 3.42 0.32 -
PPA (10 mg/kg) 17 3.12 0.22 -
Phentolamine (2 mg/kg) + PPA (10 mg/kg) 16 3.12 0.21 -
Phentolamine (2 mg/kg) + ephedrine (10 mg/kg) 15 3.09 0.17 -
Propranolol (6 mg/kg) + PPA (10 mg/kg) 15 2.98 0.22 — 
Propranolol (6 mg/kg) + ephedrine (10 mg/kg) 16 3.04±0.16 -
(b) Morphine 5 mg/kg 
Saline (10 ml/kg) 19 6.43 ±0.54 48.6 
Ephedrine (10 mg/kg) 21 8.44 0.54a 77.5 
PPA (10 mg/kg) 19 7.88 0.41a 69.4 
Phentolamine (2 mg/kg) + ephedrine (10 mg/kg) 21 6.86 0.54b 54.6 
Phentolamine (2 mg/kg) + PPA (10 mg/kg) 19 6.48 0.54 49.1 
Propranolol (6 mg/kg) + ephedrine (10 mg/kg) 22 8.13 ± 0.52a 73.0 
Propranolol (6 mg/kg) + PPA (10 mg/kg) 23 7.84 0.52a 68.8 
(c) Codeine 60 mg/kg 
Saline (10 ml/kg) 29 6.80 0.51 53.9 
Ephedrine (10mg/kg) 19 8.24±0.49« 74.6 
PPA (10 mg/kg) 19 8.35 0.48a 76.2 
Phentolamine (2 mg/kg) + ephedrine (10 mg/kg) 20 6.78 0.54b 53.5 
Phentolamine (2 mg/kg) + PPA (10 mg/kg) 22 6.73 0.50b 52.7 
Propranolol (6 mg/kg) + ephedrine (10 mg/kg) 20 8.38 0.45a 76.6 
Propranolol (6 mg/kg) + PPA (10 mg/kg) 22 8.45 0.45a 77.6 
a P<0 .05 compared to the corresponding controls 
b <0.05 compared to the corresponding groups without phentolamine 
Table 3. Effects of yohimbine and prazosin on the potentiating effects of ephedrine and PPA on opioid antinociception 
Pretreatment No. of mice Tail-flick time % analgesia 
(mean SEM) 
I (a) Saline 10 ml/kg 
i Saline control 47 3.02 0.16 -
Yohimbine (4 mg/kg) 18 3.36 0.20 -
Prazosin (2 mg/kg) 18 3.31 ±0.30 — 
Yohimbine + ephedrine (10 mg/kg) 19 3.03 0.18 -
Prazosin + ephedrine (10 mg/kg) 17 2.87 0.28 -
Prazosin + PPA (10 mg/kg) 16 3.12±0.11 — 
Yohimbine + PPA (10mg/kg) 18 3.01±0.16 — 
I (b) Morphine 5 mgjkg 
Yohimbine (4 mg/kg) + ephedrine (10 mg/kg) 18 6.36 0.54a 47.9 
Yohimbine (4 mg/kg) + PPA (10 mg/kg) 23 6.19 0.47« 45.4 
Prazosin (2 mg/kg) + ephedrine (10 mg/kg) 20 8.23 74.6 
Prazosin (2 mg/kg) + PPA (10 mg/kg) 20 8.33 0.53b 76.1 
(c) Codeine 60 mg/kg 
Prazosin (2 mg/kg) + ephedrine (10 mg/kg) 19 8.01 ± 0.59b 71.5 
Prazosin (2 mg/kg) + PPA (10 mg/kg) 20 8.19 0.54b 74.1 
Yohimbine (4 mg/kg) + ephedrine (10 mg/kg) 21 6.29 ±0.47" 46.8 
Yohimbine (4 mg/kg) + PPA (10 mg/kg) 19 6.23 0.67« 46.0 
a P<0 .05 compared to the corresponding without yohimbine (Table 2) 
b <0.05 compared to the corresponding control values (Table 2) 
tagonist, had no apparent effect on the potentiation of sympathomimetics. This pointed to the possibility of a-
opioid antinociception by ephedrine and PPA. The non- rather than p-adrenoceptor involvement. Pretreatment 
selective a-adrenoceptor antagonist, phentolamine, on with prazosin, a selective ai-adrenoceptor antagonist, 
the other hand, significantly abolished this effect of the was ineffective in blocking the enhancing effects of 
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ephedrine and PPA on opioid antinociception, whereas response curve. This is comparable to the reduction in 
yohimbine, a selective ota-adrenoceptor antagonist , was the stimulus-frequency response curve observed by ac-
effective. These results suggest that ephedrine and PPA tivation of the bulbospinal pathways. The concurrent 
potentiate the antinociceptive activities of codeine and activation of two independent spinal mechanisms, each 
morphine through an action on the a2-adrenoceptors. of which diminishes the gain of the measured system, 
Many reports have underlined a role of adrenergic may lead to a summation of the net effect (Kitahata et 
mechanisms in various opioid actions. Morphine anal- al. 1974; Gebhart et al. 1984; Monasky et al. 1990). 
gesia may be modified by alterations in the central Other possible common mechanisms include the reduc-
adrenergic tone (Dewey et al. 1970; Fennesy and Lee tion in the release of substance P from the small primary 
1970). Destruction of the catecholaminergic neurons us- afferents (Gintzler and Scaliasi 1982) and reduced post-
ing the neurotoxin 6-hydroxydopamine reportedly leads synaptic excitation evoked in the dorsal horn (Fletwood-
to an attenuation of morphine self-administration Walker et al. 1985; Go and Yaksh 1987). 
(Meade and Amit 1974), as does inhibition of catechola- Ephedrine and PPA have direct actions on the 
mine synthesis (Davis and Smith 1972, 1973; Pozuelo adrenoceptors, as well as indirect actions through release 
and Kerr 1972; Glick et al. 1973). The intestinal trans- of catecholamines (Weiner 1985). Their actions are non-
port inhibitory effect, which is a primarily peripheral selective, since they act on both a- and P-adrenoceptors. 
action of opioids (Manara et al. 1986), is antagonised by In this report we have shown that their potentiating effect 
yohimbine (Wong 1984 1986). Opioid-induced hypo- on opioid antinociception in mice, using the spinally-
thermia was reportedly antagonised by a2-adrenoceptor mediated tail-flick reaction, is most probably an ct:-
antagonists (Lawrence and Livingston 1981). Our finding adrenoceptor mediated one. Whether it is a direct action 
that the adrenoceptor antagonists had no effect on opioid of these sympathomimetics, an indirect one through 
antinociception is consistent with earlier reports that catecholamine release, or both is still under investigation, 
showed no effect by a-receptor blockade (Reddy et al. 
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EPHEDRINE AND PHENYLPROPANOLAMINE POTENTIATE THE LETHAL TOXICITY 
OF MORPHINE AND CODEINE IN NAIVE MICE 
YM Dambisya, K Chan, CL Wong* 
Department of Pharmacology, focufty of Medicine, The Chinese University of Hong Kong, Shatin, NT., Hong Kong 
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Abstract • The effects of ephedrine and phenylpropanolamine (PPA) on the acute lethal 
tojdcity of morphine and codeine In naive mice are reported. Moderate doses (20, 40, 80 mg 
kg-i, I.p.) of ephedrine or PPA led to no mortality on their own. Morphine had an LD q^ of 
267.8 (262.5-272.1) mg kg* after subcutaneous (s.c.) administration. On pretreatment with 
ephedrine, the LD q^ of morphine decreased approximately 5-fold while It decreased by between 
3 to 5 times on pretreatment with PPA. The lethal toxicity of codeine was similarly enhanced 
by pretreatment with these sympathomimetics, in a clearly dose-dependent manner. The data 
suggest that these sympathomimetics enhance opioid toxicity. The possible clinical implications 
of these findings are discussed. 
Key words Opioids, Sympathomiomctics, Lethal Toxicity, Potentiation. 
Introduction 
Drug abuse remains a world-wide problem compounds than from codeine per se (1, 6). 
despite efforts to stem it. Ephedrine and The current report is aimed at establishing 
phenylpropanolamine (PPA) are common the effects of ephedrine and PPA on the acute 
Ingredients of cough and cold 'remedies', often lethal toxicity of codeine and morphine in 
in combination with opioids. Morphine and naive mice, thereby extending our earlier 
codeine are widely used analgesics and are studies, 
subject to tight control in most countries. In 
contrast, various codeine-containing prepa-
rations (codeine compounds) are not subject Methods 
to such stringent control (1). There has been 
observed a high tendency towards abuse of Animals: Male JCR mice, 4 - 5 weeks 
such preparations containing codeine and old, weighing 30 - 35 9, were used The 
ephedrine (2). A study was undertaken in an animals were allowed free access to standard 
attempt to elucidate the possible modification laboratory diet and tap water, and were kept 
of opioid action that may occur in the under artificial light for 12 hours (6.00 am to 
presence of sympa-thomimetics. We have 6.00 pm) each day. Each animal was used 
previously established that ephedrine and PPA only once. 
enhance the antinociceptive activities of Drugs: Morphine sulphate and codeine 
morphine and codeine In naive mice (3); and phosphate (Macfarlan Smith Ltd) ephedrine 
enhance the development of opioid tolerance hydrochloride (May and Baker) and phenyl-
with no significant effect on that of propanolamine hydrochloride (Sigma Co. Ltd) 
dependence (4). It was observed that opioid were used. The drugs were dissolved in 
toxicity was enhanced by these sympatho- physiological saline solution at such concen-
mimetics in tolerant/dependent mice (4). Other trations that requisite doses were administered 
agents with sympathomimetic activity, notably in a volume of 10 ml kg-i subcutaneously (s.c.) 
amphetamine and cocaine, are known to or intraperitoneally (i.p.) as applicable. The 
potentiate opioid toxicity in various species doses refer to the weight of the salts used. 
(5, 6, 7). In man, higher morbidity and The controls received saline injections at the 
mortality results from the use of codeine corresponding times. In line with our previ-
.'Current Address School Of Pharmacj/, Portsmouth Polytechnic, Portsmouth POl 2DT, England 
Correspondence Dr YM Dambisya 
272 
256 Sifmpathomlmetics And Opioid Toxfcfty 
ous treatment protocols (3,4) the sympatho- time. All the exoeriments were r^ ric^ m^ oA in 
jnimep e 10 min be. . the same rc^r^f rr^^nlTmg^rUn 
? n ^ t i . r M ^ ween 09.30 h and 12.30 h. The end point 
U t h a l Toxicity of M j p h l n c and was the death of mice. There were no 
C 1” in^^n n^? I T ^ qualitatalivc behavioral differences between the 
administer^ 10 min prior to ^e 6pioM dose. sym- pathomimetic-pretreated mice and the 
After receMng morphine or ^ e i n e ^ e mice controls, the former had more marked 
were J^ a " n ^ ( 4 ? : ?^  I 5 • h^ractivity though. Preliminary tests showed 
cm ^de and 32 cm deep lined with fine that most mortality occurred i^thin 45 - 90 
wood shavings) and ob^rved for 90 min. To min. consequently 90 min was adopt^ a s ^ 
minimize the effects of crowding (5,8), the cutoff t i ^ h r Z L s L Z 
mice were observed in groups of five at a 
Table 1. The Effects Of Ephedrine And PPA On The Lethal Toxicity Of Cbdeine. 
Pretreatment Codeine D o « N o of mice % Mortality 
(mgkgMp.) (mgkg», sc.) ^ 
Saline 2 0 
80 20 
Saline 10 ml kg» 1 2 0 2 0 ^ 
160 20 10 
240 20 80 
Saline 2 0 . . 
80 20 25« 
Ephedrine 2 0 1 2 0 2 0 go* 
160 2 0 9 5 . 
2 4 0 2 0 100-
Saline 2 0 
80 20 30' 
Ephedrine 4 0 120 2 0 80* 
160 20 100' 
240 20 
Saline 2 0 ~ 
20 60-
Ephedrine 8 0 120 2 0 ioo> 
160 20 100' 
240 20 100-
Saline 2 0 -
80 20 .. 
PPA 2 0 120 2 0 20-
160 20 
2 4 0 2 0 100" 
Saline 2 0 -
80 20 10-
PPA 4 0 1 2 0 2 0 5 5 . 
160 20 90« 
240 20 100-
Saline 2 0 -
80 20 10. 
PPA 8 0 1 2 0 2 0 65-
160 20 ioo« 
2 4 0 2 0 100-
•signicficantly higher than the corresponding control value. 
— n o mortality. 
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Statlstl^l Anatysls: Morphine LD ephedrine doses used, the enhanced lethality' 
values and their 95% confidence limits were was not clearly dose dependent 
c^|cdat $ using linear regression. The LD^ PPA (20, 40. 80 mg I.p.) pretreatment 
after the var ous pretreatments were also enhanced the lethal toxicity of morphine 
considered significantly different from the ly from 3-fold to 6-fold, in a dose-dependent 
control values if they fell outside the 95% manner. . 
confidence limits of latter, and .also if the 
control LDgo lay outside the 95% confidence 
limits of the experimental LD^ .^ Three Discussion 
logarithmically spaced doses, and at least 20 
mice per dose level, were used to determine These data show that ephedrine and PPA 
each LD50. in moderately high doses (20, 40, 80 mg kg 
Codeine mortality values were compared * P ) enhance the acute lethal toxicity of 
using the Chi-squared test. The occurrence ^ ^ morphine and codeine in naive mice, 
of mortality in experimental groups that in line with our earlier findings of the 
otherwise had no associated mortality in the potentiation of the acute antinociceptive effects 
controls was considered significant. The level of these opioids by the sympathomimetics ’ 
of significance for the chi-squared test was and Is also concordant with previous reports 
p < 0 .05. that showed potentiation of opioid analgesia 
and lethality by other sympathomimetics 
(5, 9, 10). The current report further supports 
Results our earlier observations of increased mortality 
, , , _ due to a combination of the opioids and 
Effects on Lethal Toxicity of Codeine: sympathomimetics, compared to the opioids 
The effects of ephedrine and PPA on codeine only, in the chronic interactions (4) 
lethality are presented in Table 1. Under these The acute lethal toxicity of morphine and 
conditions, ephedrine and PPA (20, 40, 8 0 codeine in mice is largely stimulatory and 
mg kg\ I.p.) had no mortality on their own. convulsant (5, 11). Ephedrine and PPA have 
Codeine at 80. and 120 mg kg^ also had central nervous system (CNS) stimulant effects 
no fatalities on its own The sympatho- qualitatively similar to, though quantitatively 
mimetics clearly enhanced the lethal toxicity less than, those of amphetamine (12) The 
of c ^ e i n e in a dose-dependent manner, augmented opioid toxicity in combination with 
Effects on Lethal Toxicity of Mor- these sympathomimetics may therefore be due 
pWne: The effects of ephedrine and PPA to increased central stimulation toxicity. This 
on morphine LD^q are shown in Table 2. mechanism of toxicity is different than that of 
Under our expert- mental conditions, mor- opioids in man which is predominantly due 
phine had an LD^^of 267 .8 (262.5 - 272.1) to. respiratory and general CNS depression 
mg kg » within 9 0 min. After pretreatment Nevertheless, in rats, in which opioid toxicity 
with ephedrine (20’ 40, 80 mg kg\ i p.), 10 leads'to general depression and catalepsy with 
rjMn prior to the administration of morphine, or without convulsions - akin to the situation 
the L D j q fell approximately 5-fold At the in man - opioid toxicity is also increased by 
Table 2 The Effects Of Ephedrine And PPA On The Lethal Toxicity of Morphine. 
Pretreatment (i.p.) No of Morphine I D (95% Confidence Limits) 
mgkg^  sc. 
, 63 267.8 (262.5-272.1) 
60 63.2 (46.4 • 61.4, 
Ephedrine 40 mg kg 65 49.7 (49.3 • 50.2, 
Ephedrine 80 mg kg» 66 44 3 (39.4 - 49.7)" 
K Smsj^ s: 60 93.2 (89.7-96.8 
PPA 40 mg kg 60 74.0 (67.9.80.6)-
PPA80rngkg» 60 42.5 (40.2-44.9)» 
•significantly bwer than the control value. 
•. 2 7 4 
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the sympathomimetics cocaine and amp- References 
hetamine (5). This is also the case in man ‘ - ^ ^^  ,, 
(13). Apparently, regardless of the basic . JSTlH ^ i ^ J T ^ T i s ^ 
mechanisms involved, the toxicity of opioids regulations. New England J mal of MecSTs!^ 
is augmented by sympa-thomimelic agents. 308 288. 
C^eine compounds are gaining ground as 2. Chan K, Lai B, Chu SM. A pilot study on the 
substances of abuse (1, 2, 6), often resulting dependent consumption of cough and cold remedies 
In high morbidity and mortality. O n e S i ^ n f c f ^ ' * 1990; 
expj Ij^ n for such observations Is the^sier 3. Dambisya YM Wong CL, Chan K. Effects of 
availability over the counter of the codeine ephedrine and phenylpropanolamine on the 
compounds relative to codeine per $e. The antinociceptive effects of morphine and codeinc In 
other possibility is that of the modification of mice. Archives Internationales dc Parmacodynamie 
c o d e i n e activity, including toxicity, • in ^ 
combination with other agentts, for instance ‘ = ^ ^ K . Effects of 
.. . .. ^ ‘ sympathomimetic agents on opiate analgesia, toler-
the sympathomimetics.. ance and dependence in micc. Methods and Findings 
In our ongoing study on the interactions In Experimental and Clinical Pharmacology 1991 
between the opioids, morphine and codeine, 13 (5), in press. 
and the sympathomimetics, ephedrine and 5. Blumberg H, Ikeda C. Naltrexone, morphine and 
in mice, a num^r of pertinent find^gs 
have c o m e up. The symp|ithomimetics 206 303-10. 
enhance the acute effects of the opioids, 6. Kreek MR. Multiple dojg abuse patterns and medical 
including antinociception (3) and toxicity as consequences. In Meltzer HT ed. Psycho-
shown in this report. The sympathomimetics pharmacology. The Third Generation of Progress, 
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